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Mycophenolate mofetil (MMF) is widely used to minimise acute rejection following solid organ 
transplantation as it inhibits inosine monophosphate dehydrogenase (IMPDH) and thereby 
reduces lymphocyte activation. The effects of MMF and azathioprine on renal allograft outcome 
were examined by analysis of the national transplant database held at National Health Service 
(NHS) Blood and Transplant, Stoke Gifford, Bristol, UK. In a paired kidney analysis, MMF treated 
patients had a 3 year death censored graft survival of 91% (n=217) contrasts to 97% (n=231) in 
azathioprine treated patients (p=0.07) with an increased acute rejection rate in the first year 
after transplantation (44 v 31%, n=105 v 74, p<0.01). In a further study, 13% (n=71) of patients 
were found to be taking less than 1 g of MMF which was associated with a 3-fold increased risk 
of graft failure and inferior graft function up to 36 months.  
 
One strategy to improve graft outcome would entail targeting MMF dose according to pre-
transplant IMPDH activity, which is known to display wide variability between patients, in order 
to maximize efficacy and minimize toxicity. Therefore, it was decided to measure pre-transplant 
IMPDH activity and to investigate associations with renal allograft outcome and MMF dose 
tolerated after transplantation. IMPDH activity was measured by detection of generated XMP by 
a validated HPLC method in the peripheral mononuclear cells of 55 patients waiting for renal 
transplantation and was found to exhibit a 4-fold variation of IMPDH activity. Black males had 
significantly increased IMPDH activity contrasts to Black females (p=0.01). Within the first year 
of transplantation, 71% (n=12) patients required a reduction in MMF dose. There was no 
association between pre-transplant IMPDH activity and MMF dose achieved at 1 year or MMF 




It was proposed that the inter-individual variability of IMPDH activity may be associated with 
genetic polymorphisms and therefore sequencing of the exons of IMPDH I and II was 
undertaken. Two novel single nucleotide polymorphisms (SNPs), Leu244Leu and Ala285Thr, 
were identified in the IMPDH I gene. Patients with these variants did not exhibit differential 
IMPDH activity.  
  
Genotyping for established intronic SNPs was undertaken in our patient cohort as well as a 
random sample of 1040 recipients from the Collaborative Transplant Study DNA bank based at 
the University of Heidelberg, Germany. The presence of these SNPs did not increase the risk of 
rejection or affect graft function or MMF dose tolerated at 1 year after transplantation and 
there was no association between pre-transplant IMPDH activity, 5 year graft and patient 
survival and genotype.  
  
In our study, MMF treatment did not result in improved renal allograft outcomes in comparison 
to azathioprine therapy. Furthermore, we suggest that measurement of pre-transplant IMPDH 
activity or genotyping of the IMPDH enzymes is unlikely to assist in optimizing MMF dose and 




List of Figures 
 
Figure 1 De novo and salvage pathways of purine biosynthesis showing the central position of 
inosine monophosphate  ............................................................................................................... 26 
Figure 2 Conversion of IMP to AMP and XMP  .............................................................................. 27 
Figure 3 Mechanism of the IMPDH reaction  ................................................................................ 31 
Figure 4 Human type II IMPDH tetramer with bound dinucleotide analogue SAD (circled, red) and 
substrate analogue 6-Cl-IMP (circled, green)  ............................................................................... 35 
Figure 5 Ribbon diagram of human IMPDH II showing the overall βα barrel fold and secondary 
structure topology ......................................................................................................................... 36 
Figure 6 Amino acid sequence of IMPDH II demonstrating the residues involved in each domain
 ....................................................................................................................................................... 37 
Figure 7 Figure to demonstrate IMPDH residues interacting with XMP and MPA  ...................... 38 
Figure 8 The metabolism of MPA .................................................................................................. 49 
Figure 9 Univariate Kaplan-Meier for death censored graft survival for paired kidney analysis .. 69 
Figure 10 Graft function for paired kidney analysis ...................................................................... 71 
Figure 11 Chromatogram of nucleotide mix at pH 4, FR 0.6 mL/min and 9 mmol/L tetra-n butyl 
ammonium hydrogen sulphate ................................................................................................... 109 
Figure 12 Chromatogram of nucleotide mix at pH 5, FR 0.6 mL/min and 9 mmol/L tetra-n butyl 
ammonium hydrogen sulphate ................................................................................................... 110 
Figure 13 Chromatogram of nucleotide mix at pH 5.5, FR 0.6 mL/min and 9 mmol/L tetra-n butyl 
ammonium hydrogen sulphate ................................................................................................... 111 
Figure 14 Chromatogram of nucleotide mix at pH 4, FR 1 mL/min and 9 mmol/L tetra-n butyl 
ammonium hydrogen sulphate ................................................................................................... 112 
Figure 15 Chromatogram of nucleotide mix at pH 4, FR 0.6 mL/min and 7 mmol/L tetra-n butyl 
ammonium hydrogen sulphate ................................................................................................... 113 
Figure 16 Chromatogram of nucleotide mix under standard conditions with absorbance 
measured under different λ (230-270 nm) ................................................................................. 114 
18 
 
Figure 17 Chromatogram of patient sample at pH 4, FR 0.6 mL/min and 9 mmol/L tetra-n butyl 
ammonium hydrogen sulphate (A). The chromatogram has been focused on the XMP peak (B)
 ..................................................................................................................................................... 116 
Figure 18 Chromatogram of patient sample at pH 5, FR 0.6 mL/min and 9 mmol/L tetra-n butyl 
ammonium hydrogen sulphate ................................................................................................... 117 
Figure 19 Chromatogram of patient sample at pH 4, FR 1 mL/min and 9 mmol/L tetra-n butyl 
ammonium hydrogen sulphate ................................................................................................... 118 
Figure 20 Chromatogram of patient sample at pH 4, FR 0.6 mL/min and 7 mmol/L tetra-n butyl 
ammonium hydrogen sulphate ................................................................................................... 119 
Figure 21 Chromatogram of patient sample under standard conditions with absorbance 
measured under different λ (230-270 nm) ................................................................................. 120 
Figure 22 Chromatograms for exogenous XMP 120 µmol/L (A1) and patient sample (B1), under 
standard conditions, with the XMP peak then scanned at all  to provide a spectra (A2 and B2)
 ..................................................................................................................................................... 122 
Figure 23 Chromatogram of patient sample (A), after addition of exogenous XMP 15 μmol/ L (B) 
and with both traces overlaid (C) ................................................................................................ 123 
Figure 24 Chromatogram of patient samples incubated with substrate buffer without NAD ... 124 
Figure 25 Chromatograms of patient samples incubated with substrate buffer without IMP ... 125 
Figure 26 Chromatogram of patient sample incubated with substrate 11 μmol/L MPA ............ 126 
Figure 27 An example of a calibration curve ............................................................................... 127 
Figure 28 Chromatogram of water substituting the patient cell lysate in enzyme assay ........... 129 
Figure 29 Chromatogram of water substituting the substrate buffer in enzyme assay ............. 130 
Figure 30 Linearity between XMP formation and incubation time ............................................. 131 
Figure 31  Linearity between assay response and sample dilution ............................................. 132 
Figure 32 Chromatogram of patient cell lysate ........................................................................... 135 
Figure 33 Calibration curve derived from incubation with substrate of 8 different exogenous 
XMP concentrations .................................................................................................................... 136 
Figure 34 Linearity of the relationship between IMPDH protein and XMP peak area ................ 140 
Figure 35 An example of the chromatogram derived from LLC PK1 cells .................................... 141 
19 
 
Figure 36 An example of the chromatogram derived from HEK-293 cells .................................. 142 
Figure 37 An example of the chromatogram derived from HK-2 cells ........................................ 142 
Figure 38 An example of the chromatogram derived from Jurkat cells ...................................... 143 
Figure 39 Chromatogram of the same patient sample using Beckman (A) and Jasco (B) HPLC 
systems ........................................................................................................................................ 160 
Figure 40 IMPDH activity variation between patients ................................................................ 163 
Figure 41 Western blot obtained with patient cell lysates probed with antibodies raised against 
IMPDH I and IMPDH II ................................................................................................................. 166 
Figure 42 IMPDH activity measured by enzyme assay to compare with results obtained by 
densitometry of the western blot in figure 36 ............................................................................ 167 
Figure 43 Sequence of IMPDH I P1 (A), P2 (B) and P3 (C) promoters  ........................................ 183 
Figure 44 Sequence of IMPDH II promoter  ................................................................................ 184 
Figure 45 IMPDH I gene products with annealing temperature of 56 °C (exons 1-14) ............... 196 
Figure 46 IMPDH I gene products with annealing temperature of 56 °C and 60 °C (exon 3) ..... 196 
Figure 47 IMPDH I gene products with annealing temperature of 60 °C and 65 °C (exon 5 and 12)
 ..................................................................................................................................................... 197 
Figure 48 IMPDH I gene products with annealing temperature of 65 °C (exon 12) .................... 197 
Figure 49 IMPDH I and II gene products with annealing temperature of 56 °C and 57 °C (exons 1, 
IMPDH I and exons 19 and 20, IMPDH II) .................................................................................... 198 
Figure 50 IMPDH I gene products with annealing temperature of 56 °C (exons 1 and 3) .......... 198 
Figure 51 IMPDH I gene products with annealing temperature of 56 °C and 57 °C (exon 1) ..... 199 
Figure 52 IMPDH I gene products with annealing temperature of 56 °C (exon 1) ...................... 199 
Figure 53 IMPDH I gene products with annealing temperature of 53 °C and 56 °C (exons 3 and 
14) ................................................................................................................................................ 200 
Figure 54 PCR amplification of IMPDH II gene ............................................................................ 200 
Figure 55 SNP C to T (G to A on coding strand) in exon 8 of patient 171 .................................... 201 
Figure 56 SNP G to C in exon 7 of patients 123 (homozygote CC), 139 (heterozygote GG), 145 
(heterozygote GC) and 199 (heterozygote GC) ........................................................................... 201 
20 
 
Figure 57 Allelic discrimination plot for IMPDH I variant (rs2278293)........................................ 221 
Figure 58 Death censored graft survival of the genotype groups associated with IMPDH I variant 
(rs2278293) ................................................................................................................................. 222 
Figure 59 Cumulative rates of rejection over the first year according to genotype group of 
IMPDH I variant (rs2278293) ....................................................................................................... 222 
Figure 60 Allelic discrimination plot for IMPDH I variant (rs2278294)........................................ 225 
Figure 61 Death censored graft survival of the genotype groups associated with IMPDH I variant 
(rs2278294) ................................................................................................................................. 226 
Figure 62 Cumulative rates of rejection over the first year according to genotype group of 
IMPDH I variant (rs2278294) ....................................................................................................... 226 
Figure 63 Allelic discrimination plot for IMPDH II variant (rs11706052) .................................... 229 
Figure 64 Death censored graft survival of the genotype groups associated with IMPDH II variant 
(rs11706052) ............................................................................................................................... 230 
Figure 65 Cumulative rates of rejection over the first year according to genotype group of 





List of Tables 
 
Table 1 Distribution of IMPDH activity in rat tissue  ..................................................................... 29 
Table 2 Inhibition constants for IMPDH I and II ............................................................................ 30 
Table 3 Sequence homology of IMPDH from different species compared to homo sapiens ....... 32 
Table 4 Table of drugs affecting MPA exposure along with suggested mechanism ..................... 51 
Table 5 Clinical variables affecting MPA exposure along with suggested mechanism  ................ 52 
Table 6 Demographic and clinical variables for paired kidney analysis ........................................ 68 
Table 7 Multivariate risk estimates for end point of overall graft loss for paired kidney analysis 70 
Table 8 Demographic and clinical variables for MMF and azathioprine (Aza) treated patients. .. 75 
Table 9 Overall comparison between MMF and azathioprine treated patients ........................... 77 
Table 10 Multivariate risk estimates for end point of overall graft loss after 1 year for MMF and 
Azathioprine treated patients n=1129 .......................................................................................... 79 
Table 11 Multivariate risk estimates for end point of overall graft loss after 1 year for MMF and 
azathioprine treated patients n=1129 after including the effects of acute rejection................... 80 
Table 12 Graft function for MMF and azathioprine (Aza) treated patients .................................. 82 
Table 13 Acute rejection rates for MMF and azathioprine (Aza) treated patients ....................... 84 
Table 14 Relationship between ethnicity, gender and MMF dose at 12 months in patients 
receiving ciclosporin ...................................................................................................................... 86 
Table 15 Relationship between ethnicity, gender and MMF dose at 12 months in patients 
receiving tacrolimus ...................................................................................................................... 87 
Table 16 Methods for measuring IMPDH activity ......................................................................... 99 
Table 17 Comparison of HPLC assays for determination of XMP in mononuclear cell lysates (223)
 ..................................................................................................................................................... 100 
Table 18 Summary of the calibration curves run ........................................................................ 128 
Table 19 IMPDH enzyme assay completed on 5 separate occasions for 3 different patients with 
each HPLC sample run 5 times .................................................................................................... 133 
22 
 
Table 20 %CV of XMP determination from 2 blood samples taken at the same time from 9 
healthy volunteers ....................................................................................................................... 134 
Table 21  % Recovery compared to calibration curves derived from exogenous XMP ............... 137 
Table 22 Stability of patient samples and exogenous XMP ........................................................ 138 
Table 23 Comparison of %CV achieved for the IMPDH activity assay and XMP detection ......... 144 
Table 24 Summary of recent developments in HPLC methodology to detect XMP.................... 147 
Table 25 Published work describing the inhibition of IMPDH activity by MMF .......................... 151 
Table 26 Comparison of XMP concentrations obtained by processing samples on Jasco and 
Beckman HPLC apparatus ............................................................................................................ 159 
Table 27 Demographic variables associated with healthy volunteers and corresponding IMPDH 
activity ......................................................................................................................................... 161 
Table 28 Baseline demographic and clinical variables and IMPDH activity ................................ 164 
Table 29 Intra-individual variability of IMPDH activity ................................................................ 165 
Table 30 Relationship between post-transplant events and pre-transplant IMPDH activity ..... 170 
Table 31 Relationship between eGFR and pre-transplant IMPDH activity ................................. 171 
Table 32 Relationship between MMF dose at 1 year and eGFR ................................................. 171 
Table 33 Relationship between MMF dose at 1 year and gender and ethnicity ........................ 171 
Table 34 Post-transplant IMPDH activity and acute rejection .................................................... 175 
Table 35 Comparison of exon and intron sizes for IMPDH I and II genes ................................... 179 
Table 36 Clinical correlations and locations of the single nucleotide polymorphisms identified in 
the exons of IMPDH I and II ......................................................................................................... 187 
Table 37 Primers used for PCR amplification for IMPDH I gene .................................................. 191 
Table 38 Primers used for PCR amplification for IMPDH II gene ................................................. 192 
Table 39 All primers tested in order to amplify IMPDH I ............................................................ 194 
Table 40 All primers tested in order to amplify IMPDH II ........................................................... 195 
Table 41 SNPs identified in IMPDH I ............................................................................................ 201 
Table 42 Mean IMPDH activity in genotype group for Leu244Leu variant of IMPDH I ............... 202 
23 
 
Table 43 SNPs in the IMPDH I and II genes.................................................................................. 214 
Table 44 Hardy Weinberg equilibrium ........................................................................................ 214 
Table 45 Characteristics of study population for IMPDH I variant (rs2278293) ......................... 220 
Table 46 Hazard ratios of multivariate Cox regression ............................................................... 221 
Table 47 Characteristics of study population for IMPDH I variant (rs2278294) ......................... 224 
Table 48 Characteristics of study population for IMPDH II variant (rs11706052) ...................... 228 
Table 49 Relationship between IMPDH I and II SNPs and baseline variables and post-transplant 




















1 INTRODUCTION  
1.1 Purine Synthesis and Inosine Monophosphate Dehydrogenase 
 
The two major routes for purine synthesis are the de novo and salvage pathways (Figure 1). In 
the salvage pathway, purine bases are formed after degradation of deoxyribonucleic acid (DNA) 
and ribonucleic acid (RNA). In both pathways, 5-phosphoribosyl-1-pyrophosphate (PRPP) is 
required to form the ribonucleotide monophosphate intermediate which is then converted to 
the corresponding deoxyribonucleotide diphosphate and finally forms the triphosphate 
substrate for DNA polymerase. During de novo purine synthesis, inosine monophosphate (IMP) 
is the central branch point as it can either be converted to adenosine monophosphate (AMP) by 
adenylosuccinate synthetase and adenylosuccinate lyase or to guanosine monophosphate 
(GMP) (Figure 2). Inosine monophosphate dehydrogenase (IMPDH) catalyzes the formation of 
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Figure 1 De novo and salvage pathways of purine biosynthesis showing the central position of 
inosine monophosphate (1)  
1PPRP-5-phosphoribosyl-1-pyrophosphate. 2GTP-guanosine triphosphate. 3ATP-adenosine 
triphosphate. 4HGPRTase- hypoxanthine-guanine phosphoribosyltransferase. 5GMP-guanosine 
monophosphate. 6IMP-inosine monophosphate. 7AMP-adenosine monophosphate. 8IMPDH- 
inosine monophosphate dehydrogenase. 9GMP- guanosine monophosphate. In the de novo 
pathway, IMP can either be converted to GMP or to AMP depending on cellular concentrations 





Figure 2 Conversion of IMP to AMP and XMP (1) 
1IMP-inosine monophosphate dehydrogenase. 2AMP-adenosine monophosphate 
dehydrogenase. 3GMP-guanosine monophosphate dehydrogenase. IMP is converted to the 
intermediate adenylosuccinate and then to AMP. The reactions are catalyzed by 
adenylosuccinate synthetase and adenylosuccinate lyase respectively. Alternatively IMP can be 
converted to XMP by IMPDH before forming GMP by the actions of guanosine synthetase. 
      
1 
        
2 




The rate limiting step in both pathways is the synthesis of PRPP by PRPP synthetase which is 
inhibited by AMP and GMP. Additionally, regulation in the de novo pathway is by PRPP 
amidotransferase, which is inhibited by adenosine trisphosphate (ATP), adenosine diphosphate 
(ADP) and AMP at one inhibitory site and guanosine trisphosphate (GTP), guanosine 
diphosphate (GDP) and GMP at another, and at the branch point whereby IMP is converted to 
AMP and GMP. The accumulation of excess ATP leads to accelerated synthesis of GMP, and 
excess GTP leads to accelerated synthesis of AMP. Therefore, IMPDH is necessary not only for 
synthesis of guanine nucleotides but is also involved in maintaining adequate adenine 
nucleotide pools. In the salvage pathway, adenosine phosphoribosyltransferase and 
hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) control the breakdown of purine 
bases to the corresponding ribonucleotide phosphates. (1) 
 
Studies of children diagnosed with inborn errors of metabolism have suggested that both 
pathways are not functional in all cell types. Children with severe combined immunodeficiency 
disease have an inherited adenosine deaminase deficiency and were found to have reduced 
thymus derived (T) and bone marrow derived (B) lymphocyte concentrations but normal range 
of neutrophils, erythrocytes, platelets and normal brain function (2). In contrast, children with 
Lesch-Nyhan syndrome and deficiency of HGPRTase had usual numbers and functions of T and B 
lymphocytes but clinically experienced mental deficiency and were prone to self-mutilation (3). 
These findings suggest that lymphocytes are dependent on the de novo pathway of purine 
synthesis whilst brain cells require the salvage pathway. Most other cell types including 
fibroblasts, smooth muscle cells, endothelial and intestinal epithelial cells are able to utilize both 
pathways. Furthermore IMPDH concentrations are higher in the thymus and spleen compared to 
other rapidly dividing tissues including bone marrow and testis, reflecting the importance of 
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IMPDH to proliferating lymphocytes (Table 1) (4). Hence inhibition of IMPDH is likely to 
selectively inhibit T and B lymphocyte proliferation without significantly affecting other cells.  
 
Tissue IMPDH μU/ mg Relative Amount 
Thymus 347 15.5 
Spleen 264 11.8 
Testis 181 8.1 
Ovary 159 7.1 
Bone Marrow 127 5.7 
Lung 111 5.0 
Adipose Tissue 78 3.5 
Brain 73 3.3 
Intestine 67 3.0 
Liver 46 2.0 
Kidney 44 2.0 
Heart 44 2.0 
Peripheral Leukocytes 23 1.0 
Skeletal Muscle 22 1.0 
 
Table 1 Distribution of IMPDH activity in rat tissue (5) 
 
 
1.2 Type I and II Isoforms of IMPDH 
 
The two isoforms of human IMPDH were discovered after two complementary deoxyribonucleic 
acid (cDNA) clones with the same size open reading frame of 1542 base pair (bp) were isolated 
from a human spleen cDNA library. The isoforms consist of 514 amino acids with 84% sequence 
identity and are coded by two distinct genes located at 7q31.3-q32 and 3p21.2-p24.2 
respectively (6). The two proteins have similar catalytic activities and substrate affinities but 
differing inhibitor rate constants (Ki) (Table 2) (7). Despite the sequence homology, the two 
isoforms are not mutually redundant. Homozygous deletion of the type II gene leads to 
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embryonic lethality at day nine of gestation in mice, indicating that the type I isoform cannot 
substitute for the activity of the type II isoform during embryonic development (8). Deletion of 
the type I gene appears to have a milder phenotype with reduced T cell activation in response to 
anti-cluster of differentiation (CD) 3 and anti-CD28 antibodies (9). 
 
  Ki XMP / μM Ki NADH / μM Ki MPA / μM 
Isoform Type I 80 102 0.033 
 Type II 89 93 0.007 
 Ratio (I/II) 0.9 1.1 4.8 
Kinetic vs Substrate IMP Competitive Noncompetitive Noncompetitive 
 NAD Mixed Mixed Noncompetitive 
 


















Figure 3 Mechanism of the IMPDH reaction (10) 
Firstly IMP interacts with the cysteine residue (Cys 331) in the active site of IMPDH to a covalent 
intermediate (E-IMP). Then the hydride transfer to the nicotinamide ring of NAD occurs to form 
NADH. NADH dissociates and hydration at the 2-position of IMP to form the tetrahedral 
intermediate (E-XMP) takes place. The hydrolysis of E-XMP is rate limiting and generates XMP 
and free enzyme. 
 
 
IMPDH catalyses the rate limited step in the synthesis of guanine nucleotides which is the NAD 
dependent oxidation of IMP to XMP (Figure 3). An ordered bi-bi reaction mechanism for IMPDH 
activity has been proposed (11). Firstly nucleophilic attack of an active site cysteine (Cys 331) at 
the 2-position of IMP to form a covalent intermediate (E-IMP) occurs and then hydride transfer 
to the nicotinamide ring of NAD to form the reduced form of NAD (NADH). NADH dissociates 
and followed by hydration by a water moiety at the 2-position of IMP to form the tetrahedral 
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intermediate (E-XMP). The hydrolysis of E-XMP is rate limiting and generates XMP and free 
enzyme. However more recently it has been suggested that a random binding of substrates 
occurs followed by an ordered release of products (10, 12). Furthermore it has been shown that 
IMPDH activity is dependent on monovalent cations and it is suggested that this is a potassium 
ion (13-14). 
 
1.4 Characterization of IMPDH Protein 
 
IMPDH is a ubiquitous enzyme found in species from bacteria and yeast to mammals and it 
appears that there is a high degree of sequence conservation between several IMPDH protein 
sequences from different species including human IMPDH I and II as summarized in table 3.  
 





514 Pan troglodytes IMPDH II 608 100 
  Canis familiaris IMPDH II 538 99 
  Mus musculus IMPDH II 514 98 
  Saccharomyces cerevisiae IMPDHII 523 61 





  Escherichia coli IMPDH 488 37 
  Streptococcus pyogenes IMPDH 493 36 
  Toxoplasma gondii IMPDH 371 54 
Homo sapiens 
IMPDH I 
514 Canis familiaris IMPDH I 611 91 
  Mus musculus IMPDH I 514 98 
  Saccharomyces cerevisiae IMPDHI 524 59 
 
Table 3 Sequence homology of IMPDH from different species compared to homo sapiens 
(www.ebi.ac.uk/Tools/ClustalW2/index.html) 
IMPDH I and II proteins display a high degree of sequence conservation in different species 




Human IMPDH II exists as a tetramer composed of 56 kDa monomers, each containing 514 
amino acids (7). Eight crystal structures are available for IMPDH which include human IMPDH II, 
golden hamster, Streptococcus pyogenes, Tritrichomonas foetus, Borrelia Burgdorferi, 
Thermotoga Maritima, Pyrococcus horikoshii OT3 and Cryptosporidium parvum which have all 
shown highly conserved three dimensional structures (13, 15-18). Each monomer consists of 
two domains, a major catalytic domain and a smaller flanking domain (13). The 394-residue 
catalytic domain forms an eight-stranded parallel α/β barrel core with attached N- and C-
terminal sections. The active site is formed by loops between the strands of the barrel and thus 
is bound by one face of the barrel, as well as an 18-residue loop (residues 325–342) and 54-
residue flap (residues 398–451) inserted on the barrel face (15). The 120-residue flanking 
domain (residues 113–232) lies adjacent to the catalytic domain, inserted between the α2 helix 
and β3 sheet of the barrel. The function of the flanking domain in IMPDH is unknown as it is not 
required for activity (13) but contains two copies of a cystathionine β-synthase-like domain. This 
subdomain is highly conserved and can bind nucleic acids with nanomolar affinity but its 
function has yet to be elucidated although it is suggested that, at least in Escherichia Coli (E. 
Coli), it may coordinate the activities of the enzymes of purine nucleotide metabolism to 
maintain ATP and GTP pool sizes (19-21).  
 
Colby et al. determined the 3-dimensional structure of a ternary complex between the human 
type II isoform of IMPDH and the substrate and cofactor analogues 6-Cl-IMP and selenazole-4-
carboxamide adenine dinucleotide (SAD), which provides insight into the mechanism of cofactor 
binding as the SAD group occupies the site identified as the putative nicotinamide binding 
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pocket, which extends from the active site to the monomer-monomer interface (Figures 4-6) 
(15). The adenosine end of the dinucleotide analogue is bound in a cleft between α3 helix-β3 
sheet junction of one monomer and the βC- βD sheet junction of the adjacent monomer. 
Stacking of the NAD nicotinamide ring against the IMP base in this way favourably positions the 
nicotinamide ring for hydride transfer. In this orientation, the nicotinamide ring would lie in the 
anti-conformation relative to the ribose sugar. The hydride transfer is thought to occur to the B-
side of the nicotinamide ring, consistent with the fact that IMPDH is a B-side specific enzyme. 
Among the residues interacting with the NAD are Thr 252, Gln 469, and the Ser 275 and Ser 276 
which appear to be strictly or functionally conserved in eukaryotic IMPDH sequences (15).  
However, three of the four residues interacting with NAD in human type II IMPDH are not 
conserved between the human type I and type II isoforms as Thr 45, Phe 282 and His 253 in the 
type II isoform are replaced by Ile 45, Tyr 282, and Arg 253 in the type I isoform (6). 
 
A pair of β-strands comprising residues 400–450 forms an active site flap that potentially 
stabilizes binding of substrate (13). In this complex, the majority of the flap residues are 
disordered apart from the residues found adjacent to the adenine end of the dinucleotide. 
These are well ordered and comprise a 10-residue turn and a 5-residue section of β-sheet which 
make contact with the adenosine end of the dinucleotide. These contacts continue the series of 
interactions with IMP formed by the proximal part of the flap and suggest that the entire flap 
serves to stabilize both substrate and dinucleotide binding (13, 15). Protein–ligand interactions 
at the adenine end of SAD, which are likely to be preserved in NAD binding as well, include 
interactions with residues Gln 469, Ala 46 and Thr 45 from adjacent monomers in the tetrameric 







Figure 4 Human type II IMPDH tetramer with bound dinucleotide analogue SAD (circled, red) 
and substrate analogue 6-Cl-IMP (circled, green) (15) 
The dinucleotide binds at the monomer–monomer interface (dotted lines). The catalytic β-barrel 
















Figure 5 Ribbon diagram of human IMPDH II showing the overall βα barrel fold and secondary 
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Active Site Loop 
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Figure 6 Amino acid sequence of IMPDH II demonstrating the residues involved in each 
domain 
 
6-Cl-IMP is the halogenated analogue of IMP and it binds to the active site residue Cys 331 but it 
probably shifts the active site loop from the location observed in complexes with IMP. The active 
site flap forms one side of the IMP binding site with residues Tyr 411, Met 414, Gly 415 and Gln 
441 directly interacting with IMP. The opposite surface of the IMP binding site includes H bonds 
to Ser 68, Asp 364 and residues Ser 329, Gly 366, Gly 387 and Ser 388. Asp 364 anchors the 
ribose ring of IMP, the carboxylate binding in bidentate fashion to the 2’ and 3’ hydroxyls of the 
sugar and is thus essential for binding of the nucleotide. Gly 362 resides at the bottom of the 
IMP pocket, providing a tight β turn leading to Cys 331 (15). Kinetic experiments have suggested 
that although IMP can bind the enzyme in the absence of a potassium ion, this ion is required 
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probably to organize protein conformation around the active site helping to position Cys 331 for 
catalysis and may also stabilize the tetrameric form of IMPDH (13).  
 
MPA inhibits IMPDH by acting as a replacement for the nicotinamide portion of NAD. In addition 
the phenolic hydroxyl group of MPA forms hydrogen bonds to Thr 333 and Gln 441 and replaces 
the catalytic water molecule that attacks the 2-position of IMP (13). Figure 7 shows the 










1.5 Immunosuppressive Drugs and Renal Transplantation 
 
The first successful kidney transplantation was performed in 1954 between identical twins at the 
Peter Bent Brigham Hospital in Boston, United States of America (USA) (22). Graft survival 
between non-identical donor-recipient pairs, during this time, was limited by hyperacute as well 
as acute rejection. The choice of immunosuppressive agents initially consisted of total body 
irradiation and corticosteroid therapy (23-24). By 1962, azathioprine in combination with 
corticosteroids was being used to prevent and treat acute rejection to improve graft survival 
(25-26). The next major development was the use of polyclonal anti-lymphocyte and anti-
thymocyte globulins along with a monoclonal anti-T lymphocyte antibody known as OKT3 to 
prevent acute rejection (27-28). Ciclosporin was first used in clinical trials in 1978 in Cambridge, 
United Kingdom (UK), at Addenbrooke’s Hospital (29-32). Further studies established the 
benefits and complications associated with ciclosporin treatment in solid organ transplantation 
and ciclosporin in combination with corticosteroids, azathioprine and antibody therapy became 
the mainstay of treatment in the 1980s. Tacrolimus or FK506, another calcineurin inhibitor, has 
been used as an alternative to ciclosporin since 1989. It was observed that azathioprine was 
associated with side effects which included anaemia, leukopenia and thrombocytopenia as well 
as an increased incidence of opportunistic infections and skin malignancies. Therefore the 
development of a more specific, better tolerated anti-proliferative agent was desired. 
 
Since the late 1990s, a new generation of induction agents, the interleukin 2 receptor 
antagonists have led to a further reduction in acute rejection without substantially increasing 




1.6 IMPDH and Renal Transplantation 
  
Increased IMPDH activity was first discovered in rat hepatomas and appeared to correlate with 
the growth rate of individual hepatomas (5). Subsequently, increased IMPDH expression and 
activity was found in a variety of tumour cell lines including mitogen activated peripheral 
lymphocytes and solid brain and ovarian tumours, leukaemic and sarcoma cells (34). The 
increased IMPDH expression in these tumours and cell lines was attributed to enhanced type II 
activity (35). IMPDH I is constitutively expressed to maintain a basal concentration of guanine 
ribonucleotides (35) while the type II isoform is induced upon proliferation and expression is 
decreased  with cell differentiation (36). Therefore in resting lymphocytes IMPDH I is 
predominately expressed and following stimulation with phytohaemagglutinin (T lymphocytes) 
or transformation by Epstein-Barr virus (B lymphocytes) IMPDH II is strongly expressed (36). 
However, later studies have challenged this paradigm by suggesting that both isoforms have 
increased expression upon T lymphocyte stimulation (37). 
 
IMPDH is required for purine synthesis and hence inhibitors of IMPDH result in the cessation of 
cell replication and have been shown to induce cellular differentiation in leukaemic, breast 
tumour and melanoma cell lines (37-40). Following solid organ transplantation, recipient T 
lymphocytes become activated as a consequence of the presence of foreign tissue and this may 
lead to acute rejection. Inhibitors of IMPDH will specifically inhibit T cell proliferation as 
lymphocytes are dependent on the de novo synthesis of purines and hence should reduce the 
occurrence of rejection following transplantation. This fact has been exploited in the commercial 
development of inhibitors of IMPDH which include mycophenolate mofetil (MMF), mizoribine, 
ribavirin, tiazofurin and merimepodib.  
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1.7 IMPDH Inhibitors 
 
Mizoribine and ribavirin are nucleoside analogs that are phosphorylated intracellularly to 
5’monophosphates and inhibit IMPDH competitively. Mizoribine is approved in Japan for 
multiple indications, including prevention of rejection after renal transplantation, idiopathic 
glomerulonephritis, lupus nephritis, and rheumatoid arthritis (41-42). Ribavirin is approved as an 
inhaled antiviral agent for treatment of respiratory syncytial virus and, orally in combination 
with interferon- , for the treatment of chronic hepatitis C viral infection (43). Tiazofurin acts as 
a nicotinamide adenine dinucleotide (NAD) analogue and has been shown to have anti-
leukaemic properties (44). Merimepodib is a selective, reversible and noncompetitive inhibitor 
of IMPDH and is being studied in phase III clinical trials as a possible treatment for psoriasis or 
for chronic hepatitis caused by hepatitis C virus (45). 
 
Newer inhibitors of IMPDH are currently being developed and include compounds that target 
the NAD binding domain and proteins that also inhibit histone deacetylases and therefore may 
be useful as chemotherapeutic agents (46-48). In addition, inhibitors of Mycobacterium IMPDH 
are being designed (49). To date these agents have not been used in human clinical trials.  
 
 
1.8 Mycophenolate Mofetil 
 
Mycophenolic acid (MPA), the active moiety of MMF, is a fermentation product of several 
penicillium species (50) and its anti-bacterial properties were first described by Florey et al (51). 
MPA is a selective, reversible, noncompetitive inhibitor of eukaryotic inosine monophosphate 
42 
 
dehydrogenase and is five-fold more potent an inhibitor of type II isoform of IMPDH  compared 
to the type I isoform (7, 50). Therefore MMF should specifically inhibit proliferating lymphocytes 
without impeding haemopoiesis (7). MPA does not appear to alter IMPDH I or II messenger 
ribonucleic acid (mRNA) or protein concentrations in activated lymphocytes (52-53).  
 
In addition to its cytostatic effect on lymphocytes, MPA also induces apoptosis of activated T 
lymphocytes which may eliminate clones of cells responding to antigenic stimulation including 
antibody producing B lymphocytes. MMF has also been found to have an anti-proliferative 
effect on fibroblasts, mesangial, vascular smooth muscle, natural killer and dendritic cells and an 
apoptotic as well as anti-proliferative effect on monocytes (1, 54-59). Whilst some of these 
effects are mediated by GTP depletion, it is now thought that MPA has other modes of action 
which are IMPDH independent (60-62). 
 
By diminishing the reserves of guanosine nucleotides, and hence reduced formation of GDP 
mannose and GDP-fucose intermediates, MPA suppresses glycosylation and the expression of 
some adhesion molecules on endothelial cells thereby decreasing the recruitment of 
lymphocytes and monocytes to sites of inflammation (63). GTP depletion may also impair 
functioning of GTP-hydrolyzing (G) proteins involved in signal transduction (64). 
 
The reduction in the concentration of guanosine nucleotides results in a decline of 
tetrahydrobiopterin, a co-factor for the inducible form of nitric oxide synthase which decreases 
concentrations of nitric oxide and consequent tissue damage mediate by peroxynitrite (65). 
There is evidence that MPA inhibits pro-inflammatory responses in the kidney related to 
oxidative stress that occurs during the ischaemia-reperfusion injury at the time of 
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transplantation (66-67). Furthermore MPA may delay allograft fibrosis after transplantation by 
inhibition of transforming growth factor beta 1 (TGF β1) and the Rho and Rho associated protein 
kinase signaling pathway (68-69) and may have anti-atherosclerotic properties (70-71).  
 
These properties of MMF result in diminution of inflammatory and immune responses that 
occur after solid organ transplantation. Consequently MMF was developed commercially with 
the dual aims of being a potent inhibitor of graft rejection with fewer side effects compared to 
azathioprine. Today MMF is used not only in the prevention of acute rejection after organ 
transplantation but also has been used to treat a variety of other diseases including 
glomerulonephritis, multiple sclerosis, systemic lupus erythematosus, lichen planus, bullous skin 
disease, systemic sclerosis, inflammatory bowel disease, autoimmune hepatitis, psoriasis, 
sarcoidosis and myasthenia gravis (72-83). 
 
1.9 MMF and Renal Transplantation 
 
MMF, at a dose of 2 g per day, was found to halve the incidence of acute renal graft rejection in 
three, pivotal randomized trials using the SandimmuneTM (Novartis, Basel, Switzerland) 
preparation of ciclosporin (84-86). In the pooled one year analysis of 1493 patients, a daily dose 
of 2 g of MMF, reduced acute rejection rates to 19.8% compared to 40.8% in azathioprine or 
placebo treated patients (87). Furthermore MMF therapy has been efficacious in the treatment 
of acute rejection (88), interstitial fibrosis and tubular atrophy (89) and has improved graft 
function post-transplantation (90). These findings have supported the rationale for long term 
use of MMF in renal transplantation and have resulted in MMF, since its introduction in 1997, 
44 
 
progressively replacing azathioprine as the drug of choice in the prevention of acute rejection 
following solid organ transplantation in most transplant centres in the world. 
 
However, the two azathioprine controlled studies, when analyzed individually, did not exhibit 
superior graft survival after 3 years in the MMF treated patients, perhaps as the studies were 
statistically underpowered (91). In tacrolimus based studies, doses of 1-2 g of MMF decreased 
the risk of acute rejection but again did not impact on overall graft survival (92-93). Hence the 
early advantages of MMF therapy have not been translated into long term benefits on graft 
survival (91, 94-97). 
 
66,744 renal transplant recipients from the United States Renal Data System (USRDS) and 
Scientific Registry of Transplant Recipients (SRTR) database from 1988 to 1997 were studied and 
a significantly improved death censored graft survival of 85.6% in MMF treated patients 
compared to 81.9% in azathioprine treated patients (p<0.01) was demonstrated at 4 years (98). 
MMF treatment was associated with reduced incidence of acute rejection after 1 year (p<0.01), 
decreased risk of decline in graft function (p <0.01) and a 27% reduction in the risk of graft loss 
after controlling for acute rejection (98). However these results need to be cautiously 
interpreted as this was a retrospective analysis of registry data. In another study of the SRTR 
database, no outcome differences were demonstrated when renal transplant recipients were 
treated with either azathioprine or MMF in combination with tacrolimus (99). Analyses of the 
collaborative transplant study data similarly found no difference in graft survival comparing 
azathioprine and MMF treated patients despite a lower risk of acute rejection with MMF 
therapy (100). In contrast, a systematic review of 19 studies found significantly improved acute 
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rejection rates and graft survival when MMF was compared with azathioprine with any 
calcineurin inhibitor (101).  
 
In the current era of transplantation, interest in calcineurin inhibitor minimization protocols to 
prevent nephrotoxicity has resulted in trials using sirolimus to replace either ciclosporin or 
tacrolimus in MMF based treatment regimens (102-105). ‘Spare the Nephron’ study 
demonstrated comparable renal function and a trend towards reduced acute rejection and graft 
loss at 2 years in patients treated with MMF and sirolimus compared with MMF and a 
calcineurin inhibitor (102). In addition, studies of patients treated with MMF and tacrolimus 
have suggested that minimization of corticosteroid therapy may yield equivalent outcomes to 
those continuing on corticosteroids (106-107). However, although calcineurin inhibitor and 
corticosteroid minimization protocols appear favourable in patients receiving MMF, direct 
comparison of MMF with azathioprine has not been examined and so it cannot be concluded 
that MMF is superior to azathioprine in this context. 
 
Therefore, despite the initial improvement of acute rejection rates, graft survival benefits have 
not been demonstrated in prospective studies when MMF is compared with azathioprine. 
Investigators have considered the possible causes for this and it has been suggested that MMF 
dose and exposure has not been optimized in a significant number of patients which may 







1.10 MMF Dose Reductions 
 
MMF therapy is associated with adverse events such as gastrointestinal toxicity, bone marrow 
suppression and infection which lead to dose reductions in patients. It has become apparent 
that between 34 and 70% of patients are unable to tolerate full dose MMF therapy and 
subsequent dose reductions and drug discontinuation are associated with increased acute 
rejection rates, reduced graft function and particularly if the MMF dose is reduced due to  
gastrointestinal side effects, then a two-fold increase in graft loss has been reported (108-113). 
One study of patients in the first post-transplant year observed inferior acute rejection rates 
(23.3% v 3.7% p <0.01) with dose reduction compared to if no change in MMF dose was made 
(110). Furthermore, an estimated 4% increase in the relative risk of acute rejection for each 
week that the dose of MMF was reduced below 2 g per day was demonstrated and the 
cumulative number of days that the MMF dose is below 2 g per day was found to be a significant 
predictor of acute rejection (108). Analysis of the USRDS database revealed an amplified hazard 
of graft loss with a greater than 50% dose reduction (Hazard Ratio [HR] 1.7, Confidence Interval 
[CI] 1.1-2.5, p <0.01) or discontinuation (HR 8.3, CI 6.9-10.2, p <0.001) of MMF therapy between 
12 and 36 months after transplantation (112). A recent systematic review found that graft 
survival was reduced in patients with gastrointestinal complications related to MMF therapy and 
when MMF was discontinued particularly with ciclosporin based immunosuppression regimens 
(114). However, it should be noted that a robust, prospective study in the current era of 
immunosuppression in this area is lacking. 
 
There is in vitro evidence suggesting that acyl mycophenolic acid glucuronide (acyl MPAG) might 
be involved in MPA related adverse events (115-116). Preliminary in vivo studies reported higher 
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acyl MPAG concentrations in patients with anaemia (117) and correlation between free MPA 
concentrations and haematological toxicity (118). However no association between acyl MPAG 
exposure and the occurrence of diarrhoea was found (119). The clinical observation that 
tacrolimus and MMF combined therapy leads to an increased incidence of gastrointestinal 
intolerance has led to speculations that it is the increased intestinal concentration of acyl MPAG 
compared to ciclosporin treated patients, due to inhibition of the enterohepatic recirculation of 
MMF, which may be responsible for toxicity (119). In addition, it has been suggested that the 
anaemia related to MMF treatment occurs as a direct consequence of IMPDH inhibition (120). 
 
1.11 MPA Exposure Variability 
 
Recent studies have demonstrated a ten-fold inter-individual variability in MPA exposure for a 
given drug dose (121-123). Furthermore there is a non-linear relationship between MMF dose 
and MPA exposure with bioavailability decreasing for increasing MMF dose (124). Many factors 
relating to the in vivo metabolism of MMF contribute to altered MPA exposures in patients 
(Figure 8). After oral ingestion, MMF is rapidly hydrolyzed to MPA and hydroxyethyl morpholine 
which is metabolized and excreted into urine. MPA is almost completely absorbed into the 
blood and avidly binds albumin such that 97-99% of MPA is protein bound (121). MPA 
concentrations are maximal within 1 h and reach a plateau within 3 to 4 h after rapid 
distribution to tissues (121). Mainly in the liver and to a lesser extent in the gastrointestinal tract 
and the kidney, MPA is converted largely by uridine diphosphate glucuronosyltransferase 1A9 
(UGT1A9) to the chief metabolite mycophenolic acid glucuronide (MPAG), with minor 
contribution UGT1A8 and to acyl MPAG and MPA phenylglucoside primarily by UGT2B7, with 
lesser contribution from UGT1A8 (125). MPAG, via efflux transporter ATP-binding cassette 
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transporter multidrug resistance 1-related protein 2 (MRP2) or ATP-binding cassette sub-family 
C member 2 (ABCC2), is excreted into bile before secretion into the gastrointestinal tract via the 
enterohepatic recirculation (126-127). MPAG is further converted back into its active moiety in 
the gut by bacterial glucuronidase cleavage, resulting in a second peak of MPA concentration at 
4 to 8 h which accounts for 35-40% of the total MPA concentration between 0 to 12 h. 
Circulating MPAG also binds avidly to albumin and both MPAG and acyl MPAG may have 
inhibitory effects on IMPDH activity before excretion via the kidneys. 95% of an oral MPA dose is 







Figure 8 The metabolism of MPA (131) 
MMF-mycophenolate mofetil. MPA-mycophenolic acid. MPAG-mycophenolic acid glucuronide. 
UGT-uridine diphosphate glucuronosyltransferase. MRP2-multidrug resistance 1-related protein 
2. MMF is hydrolyzed to MPA in the small bowel before absorption into the bloodstream. It is 
converted primarily in the liver to MPAG via the UGT1A enzymes. MPAG is excreted into the bile 
by the MRP2 transporter before conversion to MPA. Finally MPAG is excreted by the kidneys. 
 
Factors contributing to the variability of MPA exposure are shown in tables 4 and 5. 
Hypoalbuminaemia and liver impairment result in increased free fraction of MPA. In the latter 
case this is due to the competitive displacement of MPA from albumin by bilirubin. The 
increased concentration of free MPA leads to enhanced MPA clearance and lower overall drug 
exposure. The inconsistent effect of renal function on MPA exposure may be related to the time 




is reported in patients with an estimated glomerular filtration rate (eGFR) of 20 mL/min early 
after transplantation compared with later in the post-transplantation course (132). Early after 
transplantation, renal impairment results in increased concentrations of MPAG and 
displacement of MPA from albumin leading to lower MPA exposure (129, 132-133). Ciclosporin 
also decreases MPA exposure by inhibition of MRP2 which interrupts enterohepatic 
recirculation (134). Other factors such as diarrhoea limit MPA absorption from the gut and 
antibiotic therapy inhibit gut bacteria preventing cleavage of MPAG (135). Ethnicity also effects 
MPA exposure as in Asian patients a higher MPA concentration is achieved for a similar MMF 
dose compared to white and black patients (136-137). However, the mechanism of ethnicity 








Suggested Mechanism References 
Ciclosporin 
↑MPA1 AUC2 
↑ acyl MPAG3 AUC2 
 
Inhibition of MRP24 and 








Bind MMF5, MPA1 and 
MPAG in gut lumen 




and proton pump 
inhibitors may reduce 
hydrolysis of MMF in 
stomach. 
(140) 
Antibiotics ↓MPA1 AUC2 
Reduced bacterial 
deglucuronidation of 







↑acyl MPAG3 and 
MPAG3 AUC2 
 
Induction of UGT6 
isoenzymes. 
Possible competitive 




Table 4 Table of drugs affecting MPA exposure along with suggested mechanism (131, 142) 
1MPA-mycophenolic acid. 2AUC-area under the curve. 3MPAG-mycophenolic acid glucuronide. 





Factors  Pharmacokinetic 
Parameter 












Uraemic state and elevated 
MPAG3 displace protein 
bound MPA1, leading to 
increased MPA1 free 




recirculation and /or 












Decreased serum albumin 
leading to increased MPA1 
free fraction and MPA1 








Increased MPA1 free 
fraction and MPA1 
clearance. 





Increased MPA1 free 
fraction and MPA1 
clearance. 
(151) 











Increasing serum albumin 
and improving renal 
function lead to reduced 






Table 5 Clinical variables affecting MPA exposure along with suggested mechanism (131) 
1MPA-mycophenolic acid. 2AUC-area under the curve. 3MPAG- mycophenolic acid glucuronide. 









1.12 MPA Therapeutic Drug Monitoring 
 
In order to optimize MMF therapy, the effects of MPA therapeutic drug monitoring (TDM) were 
investigated. Many immunosuppressive drugs including calcineurin inhibitors, proliferation 
signal inhibitors (for example, sirolimus) and MPA have narrow therapeutic windows, with 
evidence that drug concentrations relate to drug efficacy and toxicity, and large inter-individual 
differences in pharmacokinetics and pharmacodynamics. Hence TDM is standard practice for the 
calcineurin and proliferation signal inhibitors (131, 156). It has been suggested that MPA TDM 
could improve outcome as a relationship between exposure and efficacy has been shown in 
several studies. However, the usefulness of MPA TDM remains controversial (122, 157-159).   
 
The OptiCept trial randomized 720 renal allograft recipients to fixed dose MMF and standard 
dose calcineurin inhibitor, concentration controlled dose of MMF (based on trough MPA 
concentrations, 1.3 mg/L for the ciclosporin treated group and 1.9 mg/L for the tacrolimus 
treated group) and standard dose calcineurin inhibitor, or concentration-controlled dosing of 
MMF and low dose calcineurin inhibitor in order to determine the benefits of dosing MMF 
according to MPA concentrations (160). At 1 year no difference in acute rejection rates, graft 
survival, and renal function was observed. It was suggested that this was not surprising as there 
was a poor correlation between MPA trough concentration and MPA exposure (r2 between 0.23 
and 0.652). However, a post hoc analysis of 590 patients receiving tacrolimus showed that the 
risk of rejection was significantly lower in patients with a trough MPA concentration of >1.6 
mg/L. The concentration controlled MMF and low dose calcineurin inhibitor regimen facilitated 
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higher MMF doses without an increase in adverse events suggesting that MPA TDM is beneficial 
in calcineurin inhibitor minimization protocols (160). As no fixed dose MMF and low dose 
calcineurin inhibitor arm was incorporated in this study it is not possible to conclude that MPA 
TDM rather than low dose calcineurin inhibitor was responsible for the results.   
 
The Adaption de Posologie du MMF en Greffe Renale (APOMYGRE) study was a randomized 
controlled trial of 137 renal allograft recipients receiving either concentration controlled MMF 
(area under the curve (AUC) target 40 mg.h/L) or fixed dose (2 g per day) of MMF therapy (161). 
The results demonstrated decreased incidence of acute rejection by 12 months in the 
concentration controlled group (12% v 31%, p =0.01) in ciclosporin treated transplant recipients. 
The investigators used pharmacokinetic models and Bayesian estimators specifically set up for 
plasma MPA concentrations as determined by high performance liquid chromatography (HPLC) 
(available on Immunosuppressants Bayesian Adjustment website https://pharmaco.chu-
limoges.fr/abis.htm) to determine dose adjustments.  
 
In contrast the fixed dose concentration controlled (FDCC) study of 452 renal transplant 
recipients randomized to either fixed dose MMF or concentration controlled MMF (target 
exposure 30-60 mg.h/L) revealed that in spite of MPA AUC measurements, clinicians did not 
make the necessary dose adjustments required to achieve target MPA concentrations as 
compliance with dose adjustments was only 52% compared to 85% in APOMYGRE (162). As a 
result, no difference in acute rejection rates was observed. However, a significant relationship 
between MPA AUC on day 3 and the incidence of biopsy proven acute rejection within the first 
month (p =0.009) and first year post-transplantation (p =0.006) was found. Furthermore, a post 
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hoc analysis revealed that a 12 h MPA AUC of less than 30 mg.h/L in the first month was 
associated with an increased risk of rejection in high risk transplant recipients suggesting that 
achieving target concentrations of MPA early after transplantation is important (163). In 
comparison with the APOMYGRE study, the FDCC trial included a diverse population including 
adult and paediatric patients receiving either ciclosporin or tacrolimus and hence these factors 
may have contributed to differential results. 
 
These studies have demonstrated a relationship between early MPA exposure and acute 
rejection in the first three months after transplantation but uncertainty remains in high risk 
patients and for predicting later rejection episodes. Furthermore no relationship between MPA 
AUC or trough concentrations and toxicity was demonstrated. Interestingly, a recent trial found 
no reduction in acute rejection rates by three months with TDM for MMF therapy in low 
immunological risk renal transplant recipients receiving ciclosporin and corticosteroid for the 
first week after transplantation, suggesting that perhaps TDM for MMF therapy should be 
reserved for high risk patients (164). 
 
TDM for MPA has its limitations as there remain practical difficulties in taking sufficient samples 
to obtain an AUC to determine MPA concentrations. In addition, therapeutic ranges may be 
dependent on type of transplant, time since transplant or other concurrent immunosuppression 
drugs. Current guidelines suggest that an AUC of between 30 and 60 mg.h/L is an acceptable 
target range, in low risk patients receiving a calcineurin inhibitor, as several studies have 
revealed an increased risk of rejection when the AUC ≤30 mg.h/L and no additional efficacy 
when the AUC ≥60 mg.h/L (157, 160-162, 165). Limited studies have associated adverse events 
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when the AUC ≥ 60mg.h/L (165). In addition, a 12 h trough target range of between 1.5-3.0 mg/L 
is recommended. In high risk patients with calcineurin or corticosteroid withdrawal, higher MPA 
exposure may be required (166).  
 
1.13 Enteric Coated Mycophenolate Sodium  
 
Enteric coated mycophenolate sodium (ECMPS) was developed in 2004 with the objective of 
reducing gastrointestinal side effects in MPA treated patients. It was approved in over 80 
countries for the prevention of rejection in kidney transplantation as it was found to be equally 
efficacious as MMF. Unfortunately, despite several open label and retrospective studies showing 
benefit, ECMPS has not proven to be reliably superior in reducing the incidence of 
gastrointestinal adverse events in randomized blinded clinical trials (167-175).  
 
It has been demonstrated that administration of an equimolar dose of ECMPS and MMF (720 
and 1000 mg respectively) results in bioequivalent MPA exposure, similar exposure to MPAG 
and acyl MPAG, comparable IMPDH inhibition and equivalent graft and patient outcomes (176-
180). Of interest, recent studies have suggested that ECMPS treated patients require fewer dose 
reductions which may be associated with decreased acute rejection rates and improved graft 




Attempts to optimize ECMPS drug exposure have been complicated due to the prolonged 
metabolism of the drug. After oral ingestion of ECMPS, desolvation of mycophenolate sodium 
and subsequent MPA absorption is delayed leading to the MPA peak concentration at around 4 
h (176-177). Hence a later, lower and more variable maximum concentration occurs and 
subsequently leads to delayed enterohepatic recirculation and consequently higher and more 
variable trough concentrations (177, 183-184). Therefore, MPA trough concentration monitoring 
is likely to be more problematic for ECMPS than for MMF (r2 for correlation between trough 
concentration and dose interval AUC = 0.02 and 0.48 for ECMPS and MMF, respectively) and so 
clinically feasible limited sampling strategies may not reliably reflect MPA exposure (183). 
 
1.14 Pharmacodynamic Monitoring of MMF Therapy 
 
IMPDH activity exhibits considerable inter-individual variation and therefore a 
pharmacodynamic approach to MMF dosing may lead to superior renal allograft outcomes 
particularly as pre-transplant IMPDH activity may be associated with MMF dose reduction and 
acute rejection rates (185). It has been postulated that the variation in IMPDH activity is related 
to single nucleotide polymorphisms (SNPs) in the IMPDH I and II genes. Hence, by genotyping 
transplant recipients for relevant IMPDH polymorphisms and measuring pre-transplant activity, 
perhaps the dose of MMF can be adjusted to maximize efficacy and tolerability. 
 
Other methods of monitoring the immunosuppressive action of MPA currently being 
investigated include assessment of lymphocyte functions and cell surface markers in cell culture 
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and whole blood and to measure the degree of inhibition of proliferation by MPA using aliquots 
of patients plasma who are being treated with MMF in immortalized cell lines (84, 186-188). 
 
1.15 Conclusions and Aims 
 
Renal transplantation is the treatment of choice for patients suffering with end stage renal 
disease. Acute rejection following renal transplantation has been minimized with the 
introduction of calcineurin inhibitors, mycophenolate mofetil and recent developments in 
induction therapies. The current challenge is to optimize long term graft and patient outcome. A 
potentially important strategy to achieve this is to improve immunosuppressive drug regimens 
to limit toxicity without compromising efficacy. Intra-individual differences in the response to a 
drug arises from the pharmacokinetic, pharmacodynamic and pharmacogenetic variability 
between patients and hence ‘one size fits all’ for drug dosing is likely to become an obsolete 
term.  
 
MMF is widely used as an immunosuppressant to prevent acute rejection as it inhibits IMPDH 
and thereby reducing lymphocyte activation. However, the recommended patient dose of 2 g 
per day is limited by side effects, principally gastrointestinal and haematological, which are dose 
dependent. Moreover, reduction of drug doses may be associated with episodes of acute 
rejection and inferior graft survival. It is proposed that individualized dosing regimens should be 
adopted to minimize these adverse effects without compromising efficacy. IMPDH activity 
displays a wide variability between patients receiving renal replacement therapy and it is 




The aims of this thesis are to compare the long term outcome of MMF and azathioprine treated 
transplant recipients in the UK. A further objective is to measure and evaluate the IMPDH 
activity in patients listed for kidney transplantation and study the effects of baseline 
characteristics in relation to IMPDH activity. By sequencing IMPDH I and II genes, a study of SNPs 
and correlation to IMPDH activity, MMF dose and outcome after transplantation will be 
undertaken.  
 
Collectively it is hoped that these investigations to correlate IMPDH activity with genetic 
polymorphisms will be useful in devising targeted and personalized MMF dosing regimens to 
improve drug tolerance and graft outcome. 
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COMPARISON OF MMF AND  


















MMF and azathioprine both inhibit de novo purine synthesis required for DNA synthesis and cell 
division, particularly targeting T and B lymphocytes which lack the salvage pathway for purine 
synthesis (189). Recent findings suggest that azathioprine and its metabolites also modulate 
GTPase Ras related complement component 3 botulinium toxin substrate (Rac)1 activation after 
CD28 co-stimulation of T cells and promote apoptosis by inhibition of signal transducer and 
activator of transcription 3 (STAT3) and nuclear factor kappa beta (NF-κB) thus preventing 
acute rejection (190). In addition, its active metabolite, 6-mercaptopurine inhibits IMPDH PRPP 
amidotransferase and adenylsuccinate synthase leading to reduced GTP concentrations. 
However, currently it is not clear if this is related to its anti-proliferative effect (191).    
 
In the UK, in September 2004, the National Institute of Clinical Excellence (NICE) published 
recommendations for immunosuppression therapy following renal transplantation 
(http://publications.nice.org.uk/immunosuppressive-therapy-for-renal-transplantation-in-
adults-ta85). MMF was not recommended for adults routinely but only if intolerance to 
calcineurin inhibitors was exhibited or if nephrotoxicity risk necessitated avoidance of 
calcineurin inhibitors. As discussed previously, MMF has not improved graft survival in 




Patients in clinical trials are perhaps monitored more intensely than patients in routine practice 
and this may account for some of the favourable outcomes achieved. Therefore in order to 
investigate the effect of MMF, in a real life setting, on graft outcome relative to azathioprine in 
the UK, this first paired kidney analysis was undertaken. This form of analysis, whereby one of 
the donor kidneys is given to a recipient treated with azathioprine and the other to a recipient 
receiving MMF minimizes donor variability and bias. As the effect of reduced dose MMF in 
comparison to azathioprine has not been reported, it was decided to evaluate the consequences 






Kidney donors and recipients were identified from the national transplant database held at 
National Health Service (NHS) Blood and Transplant, Stoke Gifford, Bristol, UK. This database 
includes all renal transplantation centres in the UK and therefore provides a national 
perspective minimizing geographical variation. Patients were excluded if the donor or recipient 
were under the age of 18 years or if the patient died or the graft failed within the first 90 days 
after transplantation. No information regarding induction agents or rationale for 
immunosuppression dose changes was available. 
 
2.2.1 Renal Allograft Outcome with MMF and Azathioprine: A Paired Kidney Analysis 
 
238 deceased donors who donated, after brain death, one kidney to a patient treated with MMF 
and the other kidney to a patient receiving azathioprine, between 1st January 1999 and 31st 
December 2002, were identified. A paired kidney analysis was undertaken to account for all 
donor and era effects. In this intention to treat analysis, immunosuppression medications were 
recorded from the 3 month evaluation form so that the effects of early changes in medication 
were discounted. The impact of the drugs on graft survival and function, delayed graft function 
(defined as the requirement for dialysis in the first week), acute rejection rates and patient 





2.2.2 The Effect of MMF and Azathioprine Dose on Renal Allograft Outcome 
 
1464 patients, receiving either a deceased (donation after brain death) or living donor kidney, 
were identified as taking either MMF or azathioprine therapy immediately post-transplantation 
and continued to receive that drug for the duration of the first year after transplantation. This 
was confirmed from the immediate, 3 and 12 month evaluation forms. Graft survival, function 
and acute rejection episodes were initially compared between all patients receiving either MMF 
or azathioprine after transplantation. Subsequently analyses of graft outcome in those taking 2 g 
or more of MMF (G1) n=209, those receiving 1-2 g (G2) n= 267, those taking less than 1g of MMF 
(G3) n=71, those receiving 100 mg or more of azathioprine (G4) n=504 and those taking less 
than 100 mg of azathioprine (G5) n=413 at one year after transplantation were undertaken. 
 
2.2.3 The Relationship between Gender and Ethnicity and MMF Dose 
 
1190 recipients receiving kidney transplants from donors following brain death, between 1st 
January 1999 and 31st December 2005, were receiving MMF therapy immediately post-
transplantation and continued to take MMF for 12 months after transplantation. Patients were 
divided into 3 groups according to MMF dose received at 12 months; those prescribed 2 g or 
more, those taking 1-2 g and those receiving 1 g or less and the possible association with gender 





2.2.4 Statistical Analyses 
 
Univariate analyses using Students t-test for continuous variables and Chi square tests for 
categorical variables were performed. Graft and patient survival were analyzed using univariate 
Kaplan-Meier plots and log-rank tests. Graft survival was defined as the time taken from 
transplantation to failure, censoring for death with a functioning graft for the paired kidney 
analyses and as the period from one year after transplantation to failure, censoring for death 
with a functioning graft for the drug dose study. Multivariate Cox regression models, adjusted 
for recipient and donor age; sex; ethnicity; type of transplant (deceased or live donor); waiting 
time on dialysis for deceased donor transplants; cold ischaemia time for deceased donor 
transplants; panel reactive antibody (PRA) level; immunosuppression therapy; human leukocyte 
antigen (HLA)-A, -B, and -DR mismatches; graft number; year of transplant; primary diagnosis; 
graft function at 1 year and transplantation centre, were fitted to determine the relative impact 
of the drugs and their doses on graft and patient survival. 
 
Multiple regression analyses were instigated to determine differences in serum creatinine and 
eGFR [calculated by four variable of Modification of Diet in Renal Disease (MDRD) formula (192)] 
at yearly intervals after transplantation. Rates of change of inverse serum creatinine and eGFR 
were calculated from one year to subsequent yearly intervals. In order to minimize potential 
bias to the graft function analysis from a failing graft, if the eGFR was calculated as less than 10 
mL/min and the graft had failed in the subsequent three months, the eGFR was not included in 
the analysis. For the paired kidney study, each pair of recipients were only included in this 
assessment if both recipients had functioning grafts and a serum creatinine recorded. The 
incidence of acute rejection in the first year after transplantation and delayed graft function 
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rates were calculated and compared using logistic regression analyses adjusted for the variables 
described above.  
 
All analyses were performed using Statistical Analysis Software (SAS) version 9.1.3 (SAS Institute, 






2.3.1 Renal Allograft Outcome with MMF and Azathioprine: A Paired Kidney Analysis 
 
Demographic and clinical variables associated with 476 renal graft recipients are listed in Table 
6. 9%, 16%, 39% and 36% patients received their transplant in 1999, 2000, 2001 and 2002 
respectively with a mean follow-up period of 1203 (91-2236) days. Donors had a mean age of 47 
years, 51% were male and 1% was of Black ethnic origin. MMF treated patients were more likely 
to receive tacrolimus (47% v 26%) compared to ciclosporin (43% v 64%), less likely to be treated 










Recipient age in years (SD1) 47 (14) 46 (13) 0.49 
% Recipient male (n) 59 (140) 62 (148) 0.57 
% Recipient black (n) 2.5 (6) 3.4 (8) 0.88 
% Diabetics (n) 6.3 (15) 6.3 (15) 0.25 
% First Grafts (n) 54 (129) 46 (109) <0.01 
Time on waiting list in days (SD1) 710 (750) 816 (924) 0.17 
% on dialysis at time of transplantation (n) 94 (224) 92 (219) 0.68 
% Highly sensitized (>85% PRA2) (n) 3 (7) 7 (17) 0.12 
Mean % PRA 2 (SD1)  10 (24) 14 (29) 0.11 
% 0 HLA  mm at:     
A locus (n) 33 (78) 29 (70) 0.15 
B locus (n) 24 (48) 26 (62) 0.75 
DR locus (n) 79 (188) 78 (186) 0.93 
% 000 HLA mm (n) 8 (40) 7(35) 0.63 
Mean CIT3 / h (SD1)  23 (16) 22 (15) 0.52 
% on Ciclosporin (n) 64 (152) 43 (102) <0.01 
% on Tacrolimus (n) 26 (62) 47 (112) <0.01 
% on Prednisolone (n) 95 (226) 85 (202) <0.01 
Ciclosporin dose at 3 months / mg (SD1) 306 (110) 309 (126) 0.83 
Tacrolimus dose at 3 months / mg (SD1) 8 (4) 8 (5) 0.65 
 
Table 6 Demographic and clinical variables for paired kidney analysis 
1SD-standard deviation. 2PRA-panel reactive antibody. 3CIT-cold ischaemia time. MMF treated 
patients were more likely to receive tacrolimus compared to ciclosporin, less likely to be treated 
with corticosteroid therapy and less likely to be first graft recipients. 
 
Univariate Kaplan-Meier plots (Figure 9) demonstrated inferior graft survival in MMF treated 
patients (90% v 95%, log rank, p=0.02) but patient survival was similar (92% v 95%, log rank, 
p=0.18). Multivariate Cox regression analysis of graft and patient survival were used to study the 
effect of MMF compared to azathioprine therapy (Table 7). The hazard risk of graft failure for 
MMF relative to azathioprine was 2.21 (95% CI 0.78-6.24, p=0.14) and patient survival was 0.77 
(95% CI 0.11-5.51, p=0.79) at 3 years. Ciclosporin treatment was the only factor found to be 
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favourably associated with a reduced risk of graft failure. 3 year adjusted graft survival was 91% 




Figure 9 Univariate Kaplan-Meier for death censored graft survival for paired kidney analysis  





 Hazard Ratio 95% CI
1 p value 
Recipient age < 50 yrs 0.72 0.28-1.85 0.50 
Recipient male 1.39 0.55-3.50 0.49 
Black recipient 0.99 0.28-3.56 0.99 
Diabetic recipient 0.48 0.05-4.37 0.52 
Waiting time <183 days 0.90 0.27-2.96 0.86 
On dialysis 1.45 0.11-18.40 0.77 
Second graft 1.92 0.29-12.94 0.50 
1 mismatch at HLA-A 1.25 0.24-6.58 0.79 
1 mismatch at HLA-B 0.40 0.12-1.36 0.14 
1 mismatch at HLA-DR 4.80 0.30-77.03 0.27 
HLA mm:  
100,010,001 v 000 
110,101,011 v 000 
111,201,210,120,102 v 000 
211,121,112 v 000 
221,212,122 v 000 






















PRA2 <10% 0.68 0.22-2.13 0.51 
CIT3<12 h 0.91 0.08-10.31 0.86 
On Ciclosporin 0.20 0.05-0.85 0.03 
On Tacrolimus 0.96 0.06-15.36 0.98 
On Prednisolone 1.45 0.19-10.97 0.72 
Episode of acute rejection 2.13 0.80-5.67 0.13 
No delayed graft function 0.88 0.20-3.80 0.87 
 
Table 7 Multivariate risk estimates for end point of overall graft loss for paired kidney analysis 
1CI-confidence interval. 2PRA-panel reactive antibody. 3CIT-cold ischaemia time. Ciclosporin 




In multivariate models, adjusted for cofactors described above, there were no differences in 
overall graft survival, serum creatinine or eGFR after transplantation between patients treated 
with MMF and those receiving azathioprine, despite a trend towards superior graft function in 
the MMF treated group as seen in Figure 10. In addition, there were no disparities in rates of 
change of inverse serum creatinine and eGFR. Multivariate analysis of the whole group (not 
stratified for treatment with either MMF or azathioprine) revealed that acute rejection episodes 
and donor age were strongly associated with eGFR at 1 year (p<0.01). Moreover, graft function 





Figure 10 Graft function for paired kidney analysis 




Delayed graft function rates were 10% and 12% in the azathioprine and MMF treated groups 
respectively and did not appear to affect graft function in this study. The diagnosis of an episode 
of acute rejection was determined by the clinicians in the individual transplant centres. The 
severity and type of rejection was not available. Furthermore no data were available regarding 
whether the acute rejection episode was clinically determined or biopsy proven.  Acute rejection 
was MMF treated patients experienced increased rates of rejection in the first year after 
transplantation (44% v 31%). In logistic regression analyses, the odds ratio for development of 
one or more episodes of acute rejection in the first year after transplantation for MMF (with 
azathioprine as the reference) was 2.35 (95% CI 1.24-4.46, p<0.01).  
 
As this was an intention-to-treat study, it is inevitable that some patients would stop or switch 
inhibitor therapy. An intention-to-treat study, whereby participants are analyzed according to 
the drug they received at the start of the study regardless of whether they adhered to that 
treatment regimen, is preferable as the results then reflect the effects of allocating a patient to 
either MMF or azathioprine rather than the effects of adhering to the respective drug. 73% of 
patients treated with MMF and 82% of patients prescribed azathioprine were reported to still be 
taking the original drug at the end of the first year. 11% of patients in the azathioprine treated 
group were taking MMF and 7% of patients in the MMF treated group were receiving 
azathioprine by 36 months.  
 
Subgroup analyses of 154 paired first graft recipients showed persistent baseline anomalies in 
ciclosporin therapy (45% v 65%, p<0.01) and tacrolimus therapy (23% v 44%, p <0.01) between 
MMF and azathioprine groups. Unadjusted graft survival was inferior in MMF treated patients 
(90% v 96%, log-rank test p=0.03) but patient survival was similar (92% v 95%, log-rank test 
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p=0.16). In multivariate Cox regression analysis, adjusting for covariates including type of 
calcineurin inhibitor therapy, the hazard estimate for MMF (with azathioprine as the reference 
group) for graft loss was 2.06 (95% CI 0.37-11.60, p=0.41). 3 year graft survival was 97% in the 
azathioprine group and 92% in the MMF group (log rank, p=0.09). There was no statistical 
difference in graft function, delayed graft function (10% v 12%, p=0.48) or acute rejection rates 
in the first year after transplantation (45% v 30%, p=0.25) between MMF and azathioprine 
groups. 
 
Subgroup analyses were undertaken on 87 paired recipients receiving the same calcineurin 
inhibitor. 72% of patients were taking ciclosporin and 28% were receiving tacrolimus. There 
were no differences in baseline variables between these groups. Unadjusted graft survival (93% 
versus 92%, log-rank, p=0.77) and patient survival (92% v 96%, log-rank, p=0.31) were similar. 3 
year graft survival was 95% in azathioprine treated patients and 93% in MMF treated patients 
(log rank, p=0.68). Graft function was similar in both groups but acute rejection rates were 
higher in the MMF treated group (46% v 31%) in the first year after transplantation although this 
was not statistically significant in multivariate analyses (p=0.06). Finally, analysis of individual 
centres demonstrated that 22 out of 27 centres had an increased incidence of acute rejection in 
the MMF group (p<0.01). 
 
2.3.2 The Effect of MMF and Azathioprine Dose on Renal Allograft Outcome 
 
547 patients were taking MMF and 917 patients were receiving azathioprine (Table 7) in the first 
year after transplantation. In the MMF treated group, 38% of these were taking 2 g or more of 
MMF by 1 year (G1), 49% were taking between 1 and 2 g (G2) and 13% taking less than 1 g of 
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MMF (G3) compared to the azathioprine treated groups where 55% were receiving more than 
100 mg per day (G4) and 45% of patients were receiving less than 100 mg (G5). At one year, 75% 
in G3 were taking 500 (range 250-750) mg of MMF per day and 94% in G5 were taking either 50 
or 75 (range 12.5-75) mg of azathioprine.  
 
Comparing baseline variables, the groups were found to have similar % PRA, HLA mismatches, 
cold ischaemia times and donor characteristics (Table 8). However, patients taking 2 g or more 
of MMF or taking at least 100 mg of azathioprine were more likely to be male (p<0.01) and to 
have received a live donor kidney transplant (p<0.01). Patients prescribed azathioprine therapy 
were more likely to be of White ethnicity (p=0.02), receiving their first kidney transplant 
(p<0.01) and be taking ciclosporin (p<0.01) rather than tacrolimus (p<0.01) as part of their 
immunosuppression regimen. If the patient received a transplant in 1999-2000 then 
azathioprine was more likely to be prescribed compared to MMF (p<0.01). Patients taking MMF 
were more likely to have waited for their kidney transplant for longer (p<0.01). 
 
This was an intention to treat analysis whereby patients were allocated to the group according 
to the drug they received for the duration of the first year and the dose recorded from the 1 
year evaluation form. By 4 years, 8% (n=43 from G4, n=31 from G5) initially treated with 
azathioprine were receiving MMF and 4% (n=8 from G1, n=12 from G2) taking MMF 
immediately after transplantation were receiving azathioprine indicating a similar degree of 






















% Recipient male 71 58 63 69 51 <0.01 

































) 43 (1) 43 (1) 45 (2) 45 (1) 44 (1) 0.33 
% Donor male 46 54 55 52 53 0.45 

































) 45 (1) 45 (1) 47 (2) 45 (1) 45 (1) 0.82 









































































% Diabetic 7 5 4 6 7 0.74 
% First graft 74 76 73 86 88 <0.01 
% Live donor kidney 
transplant 
33 30 18 27 18 <0.01 







































) 13 (2) 13 (2) 14 (3) 10 (1) 9 (1) 0.22 
% Ciclosporin 52 34 28 80 82 <0.01 
% Tacrolimus 45 66 72 21 19 <0.01 
% Prednisolone 93 88 99 99 99 <0.01 
Table 8 Demographic and clinical variables for MMF and azathioprine (Aza) treated patients.  
1SE-standard error. 2DDT-deceased donor transplants. 3CIT-cold ischaemia time. 4PRA-panel 
reactive antibody. There was no significant difference in the proportions of patients with the 
different HLA mm groups in G1-5 (p=0.12).  
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2.3.2.1 Overall Comparison between MMF and Azathioprine Treated Patients 
 
Overall univariate Kaplan-Meier plots of patient survival (95% v 95%, log rank p=0.51) and death 
censored graft survival (92% v 91%, log rank p=0.17) were comparable between patients 
receiving MMF and azathioprine. Furthermore, there was no disparity in risk-adjusted HR of 
graft failure at 4.5 years (HR 1.24, 95% CI 0.74-2.07, p=0.41) (Table 9). In multivariate models, 
there was no difference in graft function between patients receiving MMF or azathioprine up to 
36 months. The odds ratio (OR) for incidence of acute rejection in the first 3 months and 3 -12 










% Graft survival 92 91 
Log rank, p=0.17 
HR for graft loss at 
4.5 years = 1.24 (0.74-2.07) 
p=0.41 
 
% Patient survival 95 95 Log rank, p=0.51 
Mean eGFR 12 months (SE1) 49 (1) 50 (1) 0.77 
Mean eGFR 24 months (SE1) 50 (1) 47 (1) 0.15 









































OR 1.15 (0.82-1.61) 
p=41 
 
Table 9 Overall comparison between MMF and azathioprine treated patients 
1SE-standard error. There were no differences in graft outcome between both groups. 
 
2.3.2.2 Dose Comparison between MMF and Azathioprine Treated Patients 
 
Kaplan-Meier plots illustrated inferior death censored graft survival in patients taking less than 
1g of MMF or less than 100 mg of azathioprine at the end of the first year post-transplantation 
compared to those patients receiving all other doses of MMF and azathioprine ≥ 100 mg/day 
(91% v 92% v 87% v 94% v 89%, G1 v G2 v G3 v G4 v G5, log rank P=0.04). Furthermore, there 
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was approximately a 3-fold increased hazard of graft failure in patients receiving less than 1 g of 
MMF and a 2-fold amplified risk in those receiving less than 100 mg of azathioprine compared to 
100 mg or more of azathioprine at 4.5 years (HR 3.06 [95% CI 1.14-8.18], p=0.03, HR 1.93 [95% 
CI 1.02-3.65], P=0.04) but no difference in the risk of graft failure when evaluated against 2 g or 
more of MMF (Table 10). In addition, less than 100 mg of azathioprine (G5) was not superior to 
less than 1 g of MMF (G3) and 2 g or more of MMF (G1) was not advantageous compared to 100 
mg or more of azathioprine (G4). The risk of graft failure was similar with 1-2 g of MMF (G2) 
compared to all other doses of MMF and azathioprine. Males and patients with an eGFR of less 
than 25 mL/min at 1 year were significantly associated with increased risk of graft failure. 
 
In order to determine the effect of acute rejection on graft survival, acute rejection rates were 
added to the analysis (Table 11). The increased hazard of graft loss remained significant in the 
group receiving 1 g or less of MMF (G3) implying that this heightened risk of graft loss is 
independent of acute rejection rates. Interestingly, there was no increased hazard of graft 
failure in the lower azathioprine dose group (G5) when the model was adjusted for acute 
rejection rates. Males and patients with increased PRA (>10%) and an eGFR of less than 25 






 Hazard Ratio (95% CI1) p value 
Recipient <65 v >65 years 0.71 (0.29-1.72) 0.45 
Recipient male v female 2.27 (1.30-3.99) <0.01 
No diabetes v diabetes 0.74 (0.29-1.88) 0.53 
Donor age <65 v >65 years 1.32 (0.50-3.47) 0.57 
Donor male v female 1.08 (0.67-1.75) 0.76 
Waiting time for deceased donor kidneys <730 v >730 days 1.52 (0.93-2.64) 0.09 
CIT2 for deceased donor kidneys <24 v >24 h 1.20 (0.63-2.28) 0.59 
PRA3 <10 v >10 % 0.62 (0.34-1.10) 0.11 
Mismatches at HLA A,B or DR locus 1.00 (0.83-1.20) 0.99 
First graft v Second or third graft 0.78 (0.42-1.48) 0.45 
Deceased donor v Live donor 1.61 (0.72-3.58) 0.25 
Transplanted in 2001-2002 v 1999-2000 0.91 (0.53-1.59) 0.75 
Receiving ciclosporin v tacrolimus 1.14 (0.65-1.98) 0.65 
No prednisolone v prednisolone 0.89 (0.44-1.77) 0.73 
eGFR at 12 months <25 v >25 mL/min 5.29 (2.76-10.12) <0.01 
G1 v G4 
G2 v G4 
G3 v G4 
G5 v G4 
G2 v G1 
G3 v G1 
G5 v G1 
G2 v G5 
G3 v G5 






















Table 10 Multivariate risk estimates for end point of overall graft loss after 1 year for MMF 
and Azathioprine treated patients n=1129 
1CI-confidence intervals. 2CIT-cold ischaemia time. 3PRA-panel reactive antibody. There was 
approximately a 3-fold increased hazard of graft failure in patients receiving less than 1 g of 
MMF and a 2-fold amplified risk in those receiving less than 100 mg of azathioprine compared to 
100 mg or more of azathioprine at 4.5 years  but no difference in the risk of graft failure when 
evaluated against 2 g or more of MMF. Males and patients with an eGFR of less than 25 mL/min 








Hazard Ratio (95% CI1) 
(with acute rejection) 
p value 
Recipient <65 v >65 years 0.65 (0.26-1.60) 0.35 
Recipient male v female 2.43 (1.34-4.43) <0.01 
No diabetes v diabetes 0.66 (0.26-1.68) 0.36 
Donor age <65 v >65 years 1.12 (0.42-2.98) 0.83 
Donor male v female 1.00 (0.61-1.65) 0.99 
Waiting time for deceased donor kidneys <730 v >730 days 1.51 (0.89-2.59) 0.13 
CIT2 for deceased donor kidneys <24 v >24 h 1.29 (0.66-2.51) 0.46 
PRA3 <10 v >10 % 0.53 (0.29-0.98) 0.04 
Mismatches at HLA A,B or DR locus 0.95 (0.78-1.15) 0.58 
First graft v Second or third graft 0.86 (0.45-1.65) 0.64 
Deceased donor v Live donor 2.00 (0.81-4.94) 0.13 
Transplanted in 2001-2002 v 1999-2000 0.89 (0.49-1.60) 0.69 
Receiving ciclosporin v tacrolimus 2.19 (0.88-5.40) 0.57 
No prednisolone v prednisolone 0.90 (0.44-1.82) 0.76 
eGFR at 12 months <25 v >25 mL/min 4.43 (2.16-9.07) <0.01 
G1 v G4 
G2 v G4 
G3 v G4 
G5 v G4 
G2 v G1 
G3 v G1 
G5 v G1 
G2 v G5 
G3 v G5 






















Table 11 Multivariate risk estimates for end point of overall graft loss after 1 year for MMF 
and azathioprine treated patients n=1129 after including the effects of acute rejection 
1CI-confidence intervals. 2CIT-cold ischaemia time. 3PRA-panel reactive antibody. Patients 
receiving 1 g or less of MMF experienced an increased risk of graft failure which appears to be 
independent of acute rejection rates. Males and patients with increased PRA and eGFR of less 





Univariate Kaplan-Meier plots demonstrated similar patient survival between all groups (94% v 
96% v 96% v 96% v 94%, G1 v G2 v G3 v G4 v G5, log rank p=0.51) with no disparity in cause of 
death (p=0.48) due to cardiovascular disease (1.4% v 0.4% v 1.4% v 0.4% v 0.7%) or malignancy 
(0% v 1.1% v 0% v 1.2% v 0.5%). In addition, the incidence of malignancy in the first year after 
transplantation was similar in all groups (0.7% v 1.0% v 0% v 1.9% v 1.8%, p=0.56).  
 
In multivariate models studying graft function, all groups are simultaneously compared. This 
method increases the risk of a type 1 error occurring and a false association between MMF and 
azathioprine dose and eGFR being concluded. This therefore needs to be taken into account 
when interpreting the individual p values. In order to address this issue with multiple 
comparisons, the Bonferonni correction can be applied. In this case, the statistical significance 
level would be at 0.005 as there are 10 comparisons. However, the data suggest that less than 1 
g of MMF (G3) and less than 100 mg of azathioprine (G5) were associated with significantly 
reduced eGFR at 12 months when contrasted to 2 g or more of MMF (G1) or 100 mg or more of 
azathioprine (G4) respectively  (Table 12). However, there was no difference in eGFR between 
less than 1 g of MMF (G3) and less than 100 mg of azathioprine (G5) or between 2 g or more of 
MMF (G1) and 100 mg or more of azathioprine (G4). The analysis indicates that at 12 months, 
taking 1-2 g of MMF may be advantageous compared to less than 1 g of MMF. However, this 


























51 (1) 51 (1) 45 (2) 50 (1) 47 (1) 
G1 v G4 p=0.76 
G2 v G4 p=0.34 
G3 v G4 p=0.14 
G5 v G4 p=0.02 
G2 v G1 p=0.80 
G3 v G1 p<0.01 
G5 v G1 p=0.06 
G5 v G2 p=0.56 
G5 v G3 p=0.08 






51 (1) 50 (1) 45 (2) 48 (1) 46 (1) 
G1 v G4 p=0.23 
G2 v G4 p=0.77 
G3 v G4 p<0.01 
G5 v G4 p =0.22 
G2 v G1 p=0.56 
G3 v G1 p=0.02 
G5 v G1 p=0.02 
G5 v G2 p=0.38 
G5 v G3 p=0.24 






50 (1) 49 (1) 44 (2) 48 (1) 45 (1) 
G1 v G4 p=0.60 
G2 v G4 p=0.67 
G3 v G4 p=0.02 
G5 v G4 p=0.04 
G2 v G1 p=0.79 
G3 v G1 p=0.05 
G5 v G1 p<0.01 
G5 v G2 p=0.14 
G5 v G3 p=0.45 
G3 v G2 p=0.07 
 
Table 12 Graft function for MMF and azathioprine (Aza) treated patients  
1SE-standard error. Taking less than 1 g of MMF (G3) and less than 100 mg of azathioprine (G5) 
was associated with significantly reduced eGFR at each of 12, 24 and 36 months time points 




Acute rejection rates in the first three months were comparable in all groups (Table 13). 
Surprisingly, patients receiving less than 1 g of MMF (G3) were found to have the lowest acute 
rejection rates between 3 and 12 months after transplantation. No information regarding biopsy 
findings, treatment given or severity and resolution of rejection episodes was available. 
Nonetheless in multivariate logistic regression analyses accounting for covariates described 
above, there was a reduced OR for development of acute rejection in the group receiving less 
than 1 g of MMF (G3) compared to 2 g or more of MMF (G1) (OR 0.3 [95% CI 0.10-0.89] G3 v G1, 
p=0.03).  The incidence of acute rejection was similar between patients receiving either 2 g or 
more of MMF (G1) or 100 mg or more of azathioprine (G4) (OR 1.00 [95% CI 0.61-1.64] G1 v G4, 
p=0.23). However, there appeared to be an increased risk of acute rejection in those treated 
with less than 100 mg of azathioprine (G5) compared to less than 1 g of MMF (G3) (OR 2.49 




































































1.26 (0.79-2.00)G1vG4 p=0.10 
1.26 (0.71-1.63) G2vG4 p=0.41 
0.65 (0.31-1.34) G3vG4 p=0.18 
0.85 (0.58-1.23) G5vG4 p=0.48 
0.98 (0.58-1.64) G2vG1 p=0.92 
0.59 (0.23-1.49) G3vG1 p=0.26 
0.70 (0.41-1.19) G5vG1 p=0.89 
1.46 (0.65-3.27) G5vG2 p=0.36 
0.65 (0.29-1.45) G5vG3 p=0.30 








































1.00 (0.61-1.64) G1vG4 p=0.23 
0.90 (0.58-1.41) G2vG4 p=0.45 
0.43 (0.18-0.98) G3vG4 p=0.06 
0.80 (0.55-1.20) G5vG4 p=0.88 
0.93 (0.53-1.62) G2vG1 p=0.79 
0.30 (0.10-0.89)G3vG1 p=0.03 
0.86 (0.49-1.51) G5vG1 p=0.17 
0.95 (0.57-1.57) G5vG2 p=0.83 
2.49 (1.00-6.22)G5vG3 p=0.05 
0.57 (0.23-1.41) G3vG2 p=0.22 
 
Table 13 Acute rejection rates for MMF and azathioprine (Aza) treated patients 
Patients receiving less than 1 g of MMF per day experienced the lowest rejection rates between 
3 and 12 months. 
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2.3.3 The Relationship between Gender and Ethnicity and MMF Dose 
 
At 12 months after transplantation, 1190 patients were identified as still receiving MMF therapy 
from the national database held at NHS Blood and Transplant. 605 patients were taking 
ciclosporin and 585 patients were receiving tacrolimus. Table 14 and 15 show the numbers of 
patients taking 1 g or less of MMF, between 1-2 g of MMF and taking 2 g or more of MMF with 
either ciclosporin or tacrolimus by 12 months after transplantation.  Males were significantly 
more likely to be receiving a higher dose of MMF compared to females in both ciclosporin and 
tacrolimus treated patients. Interestingly, subgroup analyses revealed that only males of White 
ethnicity were more likely to be taking 2 g or more of MMF at 12 months compared to their 
female counterparts. Black patients tolerated significantly higher doses of MMF compared to 
White or Asian patients (Ciclosporin group taking 2 g or more of MMF: White 50% v Asian 34% v 
Black 62%, p=0.01. Tacrolimus group taking 2 g or more of MMF: White 16%  v Asian 22% v Black 
43%, p<0.01) .  Black males were more likely to have received 2 g or more of MMF compared to 
males of other ethnicities (Ciclosporin group: White 57% v Asian 41% v Black 59%, p=0.04. 
Tacrolimus group: White 13%  v Asian 26% v Black 48%, p<0.01) and in tacrolimus treated 
patients, Black females were taking higher doses of MMF compared to females of other 




 MMF dose ≤ 1 g 
n=235 
MMF dose 1-2 g 
n=72 





























































































































 MMF dose ≤ 1 g 
n=300 
MMF dose 1-2 g 
n=180 































































































































There was no difference in graft outcome between the MMF and azathioprine groups in the 
paired kidney analyses although MMF therapy was associated with increased acute rejection 
rates. These results are at variance with the pivotal randomized trials and may be due to several 
reasons. Firstly it could be related to the methodology of this study. A paired kidney analysis of 
registry data has many advantages over other studies as it excludes donor and era effects and 
permits inclusion of large numbers of patients with longer follow-up periods. However, it cannot 
demonstrate causality, eliminate subtle selection bias or control for recipient and centre effects. 
In contrast to randomized trials, centres select the treatment group for their patients, 
presumably based on recipient variables and individual centre protocols. Of note only 9 pairs of 
kidneys went to the same centre for transplantation and therefore the majority of kidneys went 
to different transplant centres. In addition, information regarding induction agents was 
unavailable. Therefore high risk patients may have been selected for treatment with MMF which 
may have significantly biased the results. 
 
In order to minimize these effects, multivariate analysis adjusting for the variables already 
described, was undertaken and confirmed that MMF therapy was independently associated with 
an increased risk of acute rejection. In addition, examination of individual centres confirmed 
increased acute rejection rates in the MMF treated groups in 22 out of 27 centres. Finally, 
subgroup analyses of first graft recipients and patients receiving the same calcineurin inhibitor 




















Log rank P= 0.02 
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Another explanation for these results may be that MMF is no more efficacious in preventing 
acute rejection than azathioprine in the current era of transplantation. The original trials were 
based on the SandimmuneTM formulation of ciclosporin. Between 1999 and 2002, NeoralTM 
(Novartis, Basel, Switzerland), a microemulsion preparation of ciclosporin was in widespread use 
as it was found to be more rapidly, completely and reproducibly absorbed than SandimmuneTM 
(193-194). The only randomized trial with NeoralTM comparing MMF and azathioprine was the 
Mycophenolate Steroid Sparing Study (MYSS) of 336 patients, in which NeoralTM was 
administrated intravenously for the first 3 days (97). Unlike previous studies (85-86), 12 h trough 
(C0) and 2 h post-dose (C2) concentrations were reported and were shown to be similar in both 
groups. At 6 months after transplantation there was no difference in acute rejection rates and 
graft function and survival at 5 years (96-97).  This suggests that the beneficial effects of MMF 
may be reduced compared to azathioprine when used with better formulations of calcineurin 
inhibitors. Patients in the MYSS study may be considered relatively low risk as they were 
predominantly young white males receiving their first kidney transplant with few diabetic 
patients included. This perhaps accounts for mean doses of 1893 mg of MMF for the first six 
months and 1760 mg of MMF for the next 15 months of the trial. The patients in our study 
reflect the real life transplant population in the UK which is ethnically diverse and include 
diabetic patients and those with higher immunological risk of graft rejection and failure. In these 
patients optimal drug doses are less likely to be achieved.  
 
A further study comparing NeoralTM and MMF with Tacrolimus and MMF or azathioprine also 
showed similar overall biopsy proven acute rejection rates in all groups  although the 
azathioprine group required significantly more treatment with anti-lymphocyte agents, implying 
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that tacrolimus, although improving graft function, may not be superior to Neoral™ in 
combination with MMF in preventing acute rejection (95). In contrast the SYMPHONY trial 
reported that low dose tacrolimus in combination with MMF resulted in reduced acute rejection 
rates, improved graft function and survival at 1 year but in subgroup analysis MPA 
concentrations were found to be significantly increased in this group compared to Neoral™ 
treated patients (139, 195). The 3 year observational follow-up study revealed that acute 
rejection rates remained favourable in the low dose tacrolimus group but that there was no 
longer a significant improvement in graft function and survival highlighting the importance of 
long term follow-up data (196).  
 
A recently published trial compared ciclosporin in combination with azathioprine with 
tacrolimus and MMF in an anti-thymocyte globulin (ATG) and corticosteroid based 
immunosuppression regimen and found that the tacrolimus and MMF treated group 
experienced lower rates of biopsy proven acute rejection (p=0.013) and improved eGFR at 1 
year (p=0.007) with no differences in patient or graft survival (94). However, this study cannot 
differentiate whether the improved outcome was related to tacrolimus or to MMF therapy.  
 
The second part of this analysis investigated the effects of MMF and azathioprine dose on renal 
allograft outcome in a larger cohort of recipients receiving either live or deceased donor 
kidneys. MMF was not found to be beneficial compared with azathioprine on 4.5 year graft 
survival or function or in the incidence of acute rejection. 62% of patients were found to be 
taking less than 2 g dose of MMF at 1 year after transplantation and 45% were taking less than 
100 mg of azathioprine in the UK. Patients receiving 2 g or more of MMF, 1-2 g of MMF and 100 
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mg or more of azathioprine had similar graft outcome. In addition, there were no advantages 
with less than 1 g of MMF compared to less than 100 mg of azathioprine. 
 
Treatment with less than 1 g of MMF resulted in a 3-fold increased risk of graft failure compared 
to 100 mg or more of azathioprine even after the model was adjusted for acute rejection. 
Moreover, less than 1 g of MMF was associated with inferior graft function up to 36 months 
suggesting that this reduced dose of MMF may protect against acute rejection but is not 
sufficient to prevent chronic allograft nephropathy. Comparing groups receiving 2 g or more of 
MMF and less than 1 g of MMF, no disparity in graft loss was found despite decreased graft 
function in patients receiving less than 1 g of MMF were observed. This may seem incongruous 
as reduced acute rejection rates in patients taking less than 1 g of MMF were found.  However, 
it must be remembered that this is a retrospective observational study and it is therefore 
difficult to exclude confounding effects. It may be that the MMF dose reduction owing to side 
effects was only achieved in patients who did not experience acute rejection. It is perceivable 
that clinicians would be more hesitant to reduce the dose of MMF in patients with repeated 
acute rejection experiences. Furthermore, details regarding acute rejection episodes were not 
available.  
 
Less than 100 mg compared to 100 mg or more of azathioprine was associated with a 2-fold 
increased risk of graft loss at 4.5 years which may be related to the incidence of acute rejection. 
In addition, a lower dose of azathioprine therapy was associated with reduced graft function 
compared to 2 g or more of MMF and 100 mg or more of azathioprine up to 3 years.  
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Both therapies may have beneficial effects in preventing chronic allograft nephropathy. (85, 
189-190, 197-198). However it appears that this may not be achieved if the doses of the drugs 
are below 1 g in the case of MMF and less than 100 mg with azathioprine. This study 
encompasses a large number of patients treated in a variety of transplant centres with long 
term follow-up. It also reflects the outcome in the clinical setting in which most patients receive 
their care. Nevertheless, the reasons for drug selection, dose reduction of MMF and 
azathioprine are not recorded and so it is possible these patients had other co-morbidities which 
contributed to their inferior graft outcome. However, it is worth noting that variables related to 
co-morbidity including age and prevalence of diabetes mellitus were similar in all groups. 
Moreover, patient survival and death rates from cardiovascular disease or malignant disorders 
were comparable suggesting that these factors were not dissimilar in each treatment arm. In 
other reports, the main reasons for dose reduction of these two therapies include bone marrow 
suppression, infection and with MMF gastrointestinal intolerance may also occur (96-97, 108-
111, 113).   
 
Patients who died, returned to dialysis or had discontinued MMF during the first year after 
transplantation were excluded due to the concern that perhaps only some of the patients would 
have had their evaluation forms returned at 1 year, which would have biased the analysis and 
also because our interest was primarily in studying the effects of MMF dosing in the 
maintenance phase after transplantation.  
 
Mean eGFRs were contrasted between MMF and azathioprine treated patients. eGFRs were 
calculated using the four variable MDRD formula which is known to have limitations with 
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extreme body weights and if the GFR is greater than 60 mL/min. This could therefore be 
considered a limitation of this study. However a recent publication, found that in kidney 
transplant patients MDRD formula was found to provide the best estimate of GFR when 
compared to Chronic Kidney Disease Epidemiology Collaboration formula, Nankivell formula and 
Cockcroft and Gault formula when compared with the gold standard of inulin clearance (199). In 
this group of patients 494 out of 1297 patients had a GFR ≥ 60 mL/min as measured by inulin 
clearance. 
 
Neither azathioprine nor MPA concentrations are routinely measured but recently studies have 
focused to determine targets for exposure to MPA by C0 and AUC measurements which 
correlate with increased drug efficacy and reduced toxicity (84, 122, 157, 160-162, 164). The 
FDCC study reveals, in spite of MPA AUC measurements, clinicians do not always make the 
necessary dose adjustments required to achieve target MPA concentrations (162). Therefore the 
dose of MMF given remains a pragmatic guide to MPA exposure. In the UK, 13% of kidney 
recipients are receiving less than 1 g of MMF per day and 45% are receiving less than 100 mg of 
azathioprine at 1 year after transplantation. This is associated with inferior long term graft 
survival and function and represents inadequate protection against chronic allograft 
nephropathy. Efforts should be made to optimize therapy in these patients. 
 
Finally it was interesting to discover that Black males manage to take higher doses of MMF 
compared to White or Asian males in both ciclosporin and tacrolimus treated patients.  Black 
females tolerated higher doses of MMF, however this was only found in patients also taking 
tacrolimus.  Perhaps this is not surprising as patients of Black ethnicity may be prescribed larger 
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doses of MMF as studies have suggested that this is required to prevent acute rejection (200). In 
terms of gender, it appears that there is significant difference in the dose of MMF tolerated in 
White patients only. Perhaps the difference in MMF dose tolerated is related to the variation in 
IMPDH activity and it would be interesting, therefore, to measure IMPDH activity in male and 
female patients of different ethnic groups to investigate this further. 
  
In summary these studies have shown that MMF therapy, despite being theoretically superior, is 
currently not more efficacious than azathioprine. Hence further research is required to optimize 
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3 INOSINE MONOPHOSPHATE DEHYDROGENASE ENZYME ASSAY 




In order to investigate the relationship between pre-transplant IMPDH activity and renal 
allograft outcome and MMF dose tolerated, it was decided to measure IMPDH activity in 
patients listed for renal transplantation. This chapter describes the development and validation 
of the IMPDH enzyme assay in our laboratory.  
 
3.1.1 Assays for the Determination of IMPDH Activity  
 
IMPDH was first described by Magasanik, Moyed, and Gehring in Aerobacter aerogenes in 1957 
and then in extracts of other bacteria, plants and animals (201-206). It was not possible to 
measure IMPDH activity directly in crude tissue extracts due to interfering substances and low 
concentrations of the enzyme. Therefore, IMPDH needed to be purified and then incubated with 
substrate followed by separation of products by ion exchange chromatography. Finally detection 
of XMP, by measuring the increase in optical density at 290 nm, and change in concentration of 
NAD, by monitoring the change in absorbance at 340 nm (204, 206) was used to calculate 
enzyme activity (207). However there were difficulties in the recovery of IMPDH during the 
purification process such that measured activity did not always reflect accurately the 
concentrations of IMPDH within tissues. As a result, radiochemical methods were developed 
whereby crude tissue extracts were incubated with (14C) IMP and inhibitors of nucleotidases and 
allopurinol (xanthine oxidase inhibitor) to prevent the destruction of IMP and XMP before 
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separation of products and detection as described previously (208-209). Another radiometric 
method of measuring radioactive XMP formation from 14C-labelled IMP and separating products 
by electrophoresis improved reproducibility and sensitivity in quantifying IMPDH activity in 
crude tissue extracts (210).  
 
Further techniques were developed to measure IMPDH activity in blood cells and these are 
summarized in Table 16. Radiometric methods involved the incorporation of substrate isotopes 
into purine nucleotides suspended in cell preparations and incubated with IMP and cofactor 
NAD. Langman et al., in animal models and then in renal transplant recipients, quantified IMPDH 
activity by measurement of 3H release from [2,83H] IMP in whole blood samples to assess MMF 
mediated inhibition (211). However, using this method it was not possible to obtain a stable 12 
h baseline in individual patients (188). 
 
Nonradioactive methods, to measure IMPDH activity, involved lysis of cells isolated from whole 
blood, followed by incubation with IMP and NAD and then separation of XMP by reversed phase 
HPLC and detection by absorbance under ultraviolet (UV) light or quantification of xanthine 
formed from acid catalyzed cleavage of produced XMP by HPLC (212). The former method was 
developed originally in erythrocytes and then modified to lymphocytes (213). Glander et al. 
adapted the technique to measure IMPDH activity in peripheral mononuclear cell (PMNC) 
lysates with a reduced sample volume (214). PMNCs include lymphocytes and monocytes and 
are therefore of interest clinically as prevention of lymphocyte activation via inhibition of IMPDH 
enzyme activity by MMF is required in order to ameliorate acute rejection. Daxecker and 
colleagues incubated samples with xanthine, hypoxanthine and inosine such that each 
compound could be separated by ion pair chromatography and its effect on IMPDH activity 
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calculated (215). However the large blood volumes required for this analysis limited the 
usefulness of this method to assay IMPDH activity. A summary of the HPLC conditions required 
to separate and identify the enzymatic products of IMPDH are shown in Table 17.  
 
3.1.2 High Performance Liquid Chromatography 
 
A short summary of the basic principles of separating compounds by HPLC is now described. In 
reversed phase HPLC, the stationary phase consists of a non-polar surface, usually octadecyl 
silane packings and the mobile phase is polar, for example water with a small amount of 
methanol added. The separation mechanism depends on the hydrophobic binding interaction 
between the solute molecule in the mobile phase and the immobilized hydrophobic ligand, i.e. 
the stationary phase. This results in molecules of the sample becoming partitioned by the 
bonded alkyl chain and the mobile phase producing a separation in which polar compounds 
elute first followed by non-polar compounds. In ion-pair chromatography a large counter ion of 
opposite charge to the ions being analyzed is added to the mobile phase. The counter ion 
interacts with the alkyl chains and forms an ion exchange surface on the stationary phase. This 
creates competition between the sample ions and the hydrogen ions in the mobile phase 











hypoxanthine or 3H 
inosine, quantification 









treatment for ≥2 y 
(n=5) 
Normal human subjects 
(n=23). Renal transplant 
recipients taking 
azathioprine, ciclosporin 




incubation with 3H 
hypoxanthine or 3H 
inosine, quantification 




subjects 2-12 months 
of MMF (n=9) 2 y of 
MMF (n=8) 
Normal human subjects 
(n=1) 
(218) 
PBMC incubation with 
3H hypoxanthine or 3H 
inosine, quantification 
of 3H release 
Intra-individual time-
course of IMPDH 
activity 
Stable renal transplant 
recipients (n=26), 6-14 
months of MMF 
 (219) 
PBMC incubation with 
3H hypoxanthine or 3H 
inosine, quantification 
of 3H release 
Inter-individual 
variability 
Stable renal transplant 
recipients (n=27) 6-24 
months of MMF 







incubation with 14C 
hypoxanthine, 
quantification of 14C 
XMP 
Biological effects of 
long term therapy 
with MMF 
Heart transplant 
recipients more than 1 
y after switch to MMF 
(n=22) 
Heart transplant 
recipients ≥ 1 y after 
ciclosporin, azathioprine 
and corticosteroid (n=21) 
(220) 
Lysis of erythrocytes, 
incubation sodium 
phosphate, KCl, NAD 
and IMP. HPLC 
quantification of XMP. 
IMPDH activity in 
children with 




N/A Healthy children (213) 
Lysis of whole blood, 
incubation with IMP 








recipients with stable 
function (n=8) 
Healthy subjects (n=6) 
Renal transplant 
recipients with ciclosporin 
and corticosteroid (n=2) 
(212) 
Lysis of PBMC, 
incubation with IMP 
and NAD, HPLC 




receiving their first 
dose of MMF (n=7) 
(n=7, activity/time profile) (221) 
Lysis of PBMC, 
incubation with IMP 
and NAD, HPLC 




receiving their first 
dose of MMF (n=10) 
Healthy subjects (n=60) (214) 
Lysis of PBMC, 
incubation with IMP 
and NAD, HPLC 




Stable renal transplant 
recipients (n=6, MMF 
longer than 1 year) 
 (222) 
Lysis of PBMC, 
incubation with IMP 
and NAD, HPLC 




Dialysis patients prior 
to renal 
transplantation 
Healthy subjects (n=10), 



















Not known 25 mL whole blood 
2.5-5 mL whole 
blood 







100mmol/L KCl 0.5 
mmol/L NAD, 
1mmol/L IMP 
0.25 mmol/L IMP, 
0.25 mmol/L NAD 
1 mmol/L IMP, 0.5 
mmol/L NAD 
0.27mmol/L IMP, 
0.27 mmol/L NAD 
Incubation time 120 min 30/60 min 150 min 120 min 
HPLC column 
125 x 4.6 mm 
column packed 
with 3 µm ODS2 
Hypersil (Hichrom 
UK) 
2 Nucleosil C18 
columns 150x4.6 
mm ID 5 μm 
particle size in 
series 
250 mmx3.1 mm 
Prontosil 120 to 5 









































Cycle time 26 min 25 min 35 min 20 min 
Mobile Phase 
0.1 mol/L Buffer A: 
KH2PO4 ph 5.5, 8 
mmol/L TBA
1 
Buffer B: 70% 




4% methanol, pH 
1.8 
6% methanol, 50 






H3PO4, 10 mmol/L 






























Table 17 Comparison of HPLC assays for determination of XMP in mononuclear cell lysates 
(223) 








In order to optimize the IMPDH enzyme assay, XMP concentrations were measured in 9 healthy 
volunteers. Patients listed for deceased donor renal transplantation were identified and 
counselled for the purposes of this study. Informed consent was obtained in all cases. The study 




All materials were obtained from Sigma Aldrich (Gillingham, Dorset, UK) unless otherwise 
specified. 
 
3.2.3 Peripheral Blood Mononuclear Cell Isolation 
 
PBMC isolation was based on a method developed by Glander et al. (214). Two blood samples of 
5 mL from each patient were collected in lithium-heparin containing tubes (BD Lithium Heparin 
Vacutainers from Becton Dickinson, Oxford, Oxfordshire, UK) and stored at room temperature 
for a maximum of 6 h. For patients receiving peritoneal dialysis or attending a clinic 
appointment, blood was taken from a peripheral vein. For patients receiving haemodialysis 
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therapy, blood was taken from the ‘A’ line during the dialysis procedure. Blood samples were 
transferred to 15 mL polypropylene tubes. 5 mL of phosphate buffered saline (PBS, pH 7.4 
containing 0.138 mol/L sodium chloride and 0.0027 mol/L potassium chloride at 25 °C) was 
added to each sample and then carefully layered on 4 mL of HistopaqueTM and centrifuged for 
40 min at 20°C (ambient room temperature) at 1200 g. PBMC were collected from the interface 
and resuspended in 4 mL of PBS. Samples were centrifuged at 20°C for a further 5 min at 1200 g 
and the supernatant discarded. 250 μL of distilled water was added to each cell pellet and the 
sample had a vortex mix for 20 s. Samples underwent two freeze thaw cycles with at least 30 
min at -80˚C and a 20 s vortex mix for each cycle. After the final thaw, samples were centrifuged 
at 20°C for 5 min at 1000 g. Supernatants were used for the enzyme assay and protein 
determination. The protein content of cell lysates was assayed with Bicinchoninic Acid (BCA) 
Protein Assay Reagent using 96 well plates with bovine serum albumin as standard according to 
the instructions by the manufacturer (Perbio Science UK, Cramlington, Northumberland, UK). 
 
3.2.4 IMPDH Enzyme Assay 
 
IMPDH activity of the cell lysates was determined according to the methods published by 
Montero and Glander with minor modifications (213-214). 100 μL of cell lysate (as above) was 
added to 240 μL of substrate buffer, 1 mmol/L IMP, 0.5 mmol/L NAD, 40 mmol/L sodium 
phosphate and 100 mmol/L potassium chloride, pH 7.4, and 20 μL of water into a 1.5 mL 
Eppendorf (Eppendorf UK Limited, Cambridge, UK) and underwent a vortex mix for 10 s. The 
tubes were incubated at 37 ˚C in a water bath (with shaking) for 2.5 h. The reaction was then 
terminated by the addition of 40 μL of 4 mol/L ice-cold perchloric acid and vortex mixed for 10 s. 
The deproteinized incubation mixture was centrifuged at 15800 g for 5 min and then 340 μL of 
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the mixture was added to 20 μL of 5 mol/L of potassium carbonate in order to neutralize the 
sample, and then vortex mixed for 10 s. The sample was frozen at -80 ˚C for at least 30 min 
before complete thawing and centrifugation at 15800 g for 2 min. 300 μL of the supernatant 
was stored at -80 ˚C for HPLC.  
 
3.2.5 Optimization of XMP Separation and Detection by HPLC 
 
The separation of XMP was optimized by varying the individual mobile phase conditions for 
HPLC. In particular, the pH was varied between 4 and 5.5. The flow rate (FR) was modified 
between 0.6 and 1 mL/min and the ion pair concentration was varied between 7-9 mmol/L and 
the wavelength (λ) adjusted between 230 and 270 nm. These conditions were altered whilst 
processing known concentrations of nucleotides (AMP, XMP, GMP, IMP, NAD and ATP) and 
samples from healthy volunteers and patients. Finally, 20 µmol/L of exogenous XMP was 
processed via the HPLC apparatus at pH between 2 and 8 to determine the maximum 
absorbance spectra. The optimum conditions for XMP separation and detection by HPLC were 
thus determined and all further samples were processed using these ‘standard conditions’. 
 
3.2.6 XMP Identification 
 
The identification of XMP was confirmed by several methods. Firstly the absorbance spectrum of 
exogenous XMP was compared to that of patient derived XMP. The peak area attributed to XMP 
in patient HPLC samples was observed before and after the addition of exogenous XMP (15 
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µmol/L). In addition, the disappearance of the XMP peak was noted when the enzyme reaction 
was incubated without NAD or IMP or if MPA was added.  
 
3.2.7 Method Validation for IMPDH Enzyme Assay and Patient Derived XMP Detection 
 
The enzyme activity assay was validated according to criteria published in Bioanalytical Method 
Validation, May 2001 by the United States Food and Drug Administration 
(http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf). The lower limit of 
quantification (LLOQ) can be calculated in 4 different ways: based on precision and accuracy 
data; based on signal to noise ratio; based on standard deviation of the response from blank 
samples; based on calibration curve in the range of LLOQ. LLOQ was determined using the first 
method such that the concentration of exogenous XMP was progressively reduced and 
processed by HPLC. The LLOQ should be at least 5 times the response compared to a blank 
response and the analyte peak should be identifiable, discrete and reproducible with a precision 
of 20% and an accuracy of 80-120%. Water was used in the place of patient lysates in the 
enzyme assay to determine whether this caused any interference at the LLOQ for XMP. 
 
Specificity of the process to identify XMP was confirmed by measuring IMPDH activity in 6 
individual patient samples and comparing the derived chromatograms with those achieved 
when water was substituted for the patient sample or the substrate buffer in the enzyme 
activity assay. The calibration curve for exogenous XMP was derived using 10 calibrants for XMP 
between 1.5 µmol/L and 300 µmol/L. The linearity and proportionality of the enzyme reaction 
was investigated by altering incubation times between 0 and 4 h. Linearity of the assay was 
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confirmed by serial dilution of a cell lysate to 4 different concentrations and subsequent 
measurement of IMPDH activity. 
 
The guidelines state that the analytical method should have a mean value that is within 15% of 
the actual value and that the precision determined at each concentration should not exceed 
15% of the coefficient of variation (CV). CV is defined as the ratio of the standard deviation to 
the mean. In order to determine precision and accuracy, 3 patient cell lysates were selected at 
random and incubated with the substrate buffer according to the conditions described above on 
5 separate occasions. Each sample was processed by HPLC 5 times and XMP concentration was 
quantified. The presence of endogenous XMP in the patient cell lysates could potentially 
interfere with accurate calculation of IMPDH activity. Hence quantification of endogenous XMP 
in patient cell lysates was performed by processing these samples by HPLC under ‘standard 
conditions’. 
 
8 different exogenous XMP standards ranging between 1.2 µmol/L and 480 µmol/L were 
incubated with the substrate mix and treated as above and then processed via HPLC to 
determine recovery and sensitivity of the enzyme activity assay. From the chromatograms the 
areas of the XMP peaks were calculated and used to derive a calibration curve. This was 
repeated on 3 separate occasions. The LLOQ of XMP concentration was also determined. By 
comparing patient derived XMP peak area to the calibration curve, the concentration of XMP 
was calculated.  
 
Stability of patient HPLC samples and exogenous XMP (60 µmol/L) were analyzed by processing 
three samples after storage at -80 °C for 3 months and after thawing for 24 h at room 
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temperature. Freeze thaw stability was determined by subjecting 3 patient HPLC samples  and 
exogenous XMP (60 µmol/L) to 3 cycles of 24 h of storage at -80 °C followed thawing at room 
temperature. In addition, in order to determine the effect of incubating HPLC samples at room 
temperature in the autosampler, 3 samples were processed at the beginning and end of each 
cycle. Exogenous XMP of known concentrations followed by water was processed via the HPLC 
to investigate ‘carry over’ effects i.e. the concentration of XMP present in the current sample 
from the preceding sample. 
 
3.2.8 IMPDH Activity and XMP Concentration 
 
0.25 - 1 µg of recombinant human IMPDH II was incubated with 240 µL of substrate mixture and 
20 µL of water at 37 °C for 2.5 h with shaking. Samples were treated in the same manner as 
described above and then processed for HPLC after dilution 1:3 with water. 5 µL was injected 
onto the HPLC column. The XMP peak area was plotted against concentration of recombinant 
IMPDH. Using this graph, IMPDH concentration in patient cell lysates could be calculated after 
determining the XMP peak area. However, as the graph is linear, it was felt that the rate of XMP 
production could be used instead of calculating IMPDH concentration and hence IMPDH activity 
was expressed in nmol/mg of protein/mL/h. 
 
3.2.9 IMPDH Activity in Immortalized Cell Lines 
 
IMPDH activity was measured in four immortalized cell lines.  The cell lines and their culture 
media are detailed below. LLC PK1 (pig kidney proximal tubular cells) (European Collection of Cell 
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Culture, ECACC) and HEK 293 cells (human kidney embryonic 293 cells immortalized by 
transformation with human adenovirus 5) (ECACC) were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) medium. Jurkat cells (human leukaemic T cell lymphoblasts) (ECACC) were 
cultured in Roswell Park Memorial Institute (RPMI) 1640 medium and finally HK-2 cells (human 
renal proximal tubular epithelial cells immortalized by transduction with human papilloma virus 
16 E6/E7 genes) (American Type Culture Collection) were cultured in DMEM/Ham’s F12. The 
media were supplemented with 10% heat inactivated fetal bovine serum (FBS) and 1% antibiotic 
solution (100 U/mL penicillin, 100 µg/mL streptomycin and 0.25 µg/mL amphotericin B). The 
cells were nurtured in a humidified incubator (95% air and 5% carbon dioxide) at 37 °C in 150 
cm3 flasks. The medium was replenished twice per week and at 80% confluence the cells were 
harvested by the addition of 10 mL of trysin ethylenediaminetetraacetic acid (EDTA) solution 
with the exception of the Jurkat cells which were cultured in suspension. The cells were 
transferred to a 50 mL Falcon tube and then centrifuged at 2000 g for 5 min. The supernatant 
was discarded and the cell pellet was lysed with 2 mL of distilled water as previously described. 
Protein content was assayed using BCA Protein Assay Reagent using the 96 well plate format 
with bovine serum albumin as standard according to the instructions by the manufacturer 
(Perbio Science UK). IMPDH activity was measured using the assay described in section 3.2.4 and 
separation of XMP was achieved using a mobile phase pH of 4, with 9 mmol/L of tetra-n butyl 





3.3.1 Optimization of XMP Separation and Detection by HPLC 
 
Initially nucleotides were processed individually to determine retention times. Subsequently 20 
μL of mixtures of the nucleotides 3.3 μmol/L AMP, 3.3 μmol/L XMP, 3.3 μmol/L GMP, 20 μmol/L 
IMP, 10 μmol/L NAD and 1 mmol/L ATP were processed at different pH (4-5.5), FR (0.6-1 
mL/min), ion pair concentrations (7-9 mmol/L) and λ (230-270 nm) as shown in Figures 11-16. 
The IMP and GMP derived peaks appeared fused under all conditions. As pH increased from 4 to 
5.5, XMP peak fused with the IMP/GMP peak (Figures 11-13). At FR 1 mL/min, XMP peak fused 
with IMP/ GMP peak (Figure 14). At the lower ion pair concentrations IMP/GMP peak fused with 




Figure 11 Chromatogram of nucleotide mix at pH 4, FR 0.6 mL/min and 9 mmol/L tetra-n butyl 
ammonium hydrogen sulphate 
Peak of NAD retained at 6.21 min, fused peak IMP/GMP retained at 6.92 min, peak of XMP 
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Figure 12 Chromatogram of nucleotide mix at pH 5, FR 0.6 mL/min and 9 mmol/L tetra-n butyl 
ammonium hydrogen sulphate 
At pH 5, XMP peak fuses with IMP/GMP peak. 
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Figure 13 Chromatogram of nucleotide mix at pH 5.5, FR 0.6 mL/min and 9 mmol/L tetra-n 
butyl ammonium hydrogen sulphate 
At pH 5.5, XMP peak is completely fused with IMP/GMP peak. 
Minutes 













   
 
   
 
   
 
   
 
 
   
  
   
 









Figure 14 Chromatogram of nucleotide mix at pH 4, FR 1 mL/min and 9 mmol/L tetra-n butyl 
ammonium hydrogen sulphate 
At FR 1 mL/min, XMP peak completely fuses with IMP/GMP peak. 
Minutes 
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Figure 15 Chromatogram of nucleotide mix at pH 4, FR 0.6 mL/min and 7 mmol/L tetra-n butyl 
ammonium hydrogen sulphate 
At lower ion pair concentrations, NAD peak completely fuses with IMP/ GMP peak and XMP 
peak starts to fuse with AMP peak. 
 
Minutes 





























     
 
   
 
     
 
   
 
     
 
   
 
     
 
   
 
     
 
   
 
     
 




   
Fused NAD and 
IMP/GMP peaks 











Figure 16 Chromatogram of nucleotide mix under standard conditions with absorbance 
measured under different λ (230-270 nm) 
XMP is retained at 7.75 min and has a maximum absorbance spectrum at 254 nm. 
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Optimal separation for XMP in nucleotide samples occurred with a mobile phase pH of 4, with 9 
mmol/L of tetra-n butyl ammonium hydrogen sulphate, a FR of 0.6 mL/ min and UV detection at 
254 λ. In addition, the maximum absorbance spectrum for XMP was 254 nm between pH 4 and 
8.  
 
In order to determine whether these conditions were optimal for measuring patient derived 
XMP, patient samples were processed at different pH (4-5), FR (0.6-1 mL/min), ion pair 
concentrations (7-9 mmol/L) and λ (230-270 nm) as shown in Figures 17-21. As pH increased 
from 4 to 5, XMP peak fused with the IMP peak (Figures 17-18). At FR 1 mL/min, XMP peak fused 
with IMP peak (Figure 19). At the lower ion pair concentrations IMP peak fused with the NAD 






Figure 17 Chromatogram of patient sample at pH 4, FR 0.6 mL/min and 9 mmol/L tetra-n butyl 
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Figure 18 Chromatogram of patient sample at pH 5, FR 0.6 mL/min and 9 mmol/L tetra-n butyl 
ammonium hydrogen sulphate 
XMP peak fuses with IMP peak. 
Minutes 








   











Figure 19 Chromatogram of patient sample at pH 4, FR 1 mL/min and 9 mmol/L tetra-n butyl 
ammonium hydrogen sulphate 
XMP peak fuses with IMP peak. 
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Figure 20 Chromatogram of patient sample at pH 4, FR 0.6 mL/min and 7 mmol/L tetra-n butyl 
ammonium hydrogen sulphate 
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Figure 21 Chromatogram of patient sample under standard conditions with absorbance 
measured under different λ (230-270 nm) 
XMP is retained at 7.41 min and has a maximum absorbance spectrum at λ 254 nm. 
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Optimal separation for XMP in patient derived samples and nucleotide samples occurred with a 
mobile phase pH of 4, with 9 mmol/L of tetra-n butyl ammonium hydrogen sulphate, a FR of 0.6 mL/ 
min and UV detection at 254 λ. Therefore all samples were processed under these ‘standard 
conditions’. 
 
3.3.2 XMP Identification 
 
Pure exogenous XMP and XMP formed from IMPDH activity co-eluted and produced identical 
spectra when scanned from 200-650 nm (Figure 22). XMP produces a double peak when scanned 
which may be due to keto-enol tautomerism (ketone group of xanthine in equilibrium with hydroxy 
group). Whilst this has not been proven here, the published spectra for xanthine looks very similar to 









Figure 22 Chromatograms for exogenous XMP 120 µmol/L (A1) and patient sample (B1), under 
standard conditions, with the XMP peak then scanned at all  to provide a spectra (A2 and B2)  
This figure demonstrates that exogenous XMP and XMP formed from IMPDH activity co-elute and 
produce identical spectra when scanned from 200-650 nm. 
 
 
The addition of exogenous XMP at a concentration of 15 µmol/L to a patient sample resulted in an 







































































































Figure 23 Chromatogram of patient sample (A), after addition of exogenous XMP 15 μmol/ L (B) 
and with both traces overlaid (C) 









































































Figure 24 Chromatogram of patient samples incubated with substrate buffer without NAD 
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Figure 25 Chromatograms of patient samples incubated with substrate buffer without IMP 
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XMP was not detectable when 11 μmol/L of MPA was incubated with the enzyme assay (Figure 26). 
 
Figure 26 Chromatogram of patient sample incubated with substrate 11 μmol/L MPA 
XMP is not detected as IMPDH activity is inhibited by MPA. 
 
3.3.3 Method Validation for IMPDH Enzyme Assay and Patient Derived XMP Detection 
 
The LLOQ for exogenous XMP detection was found to be 1.5 µmol/L. The calibration standards are 
shown below along with an example for the calibration curve and a summary of all the calibration 
curves run (Figure 27 and Table 18). These calibration standards were processed prior to each batch 















    
 
   
 
    
 



























Figure 27 An example of a calibration curve 
These concentrations of XMP were run prior to each batch of patient samples to minimize errors and 























XMP μmol/L   
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 R2 Slope (y/x) 
Run 1 0.9972 812 
Run 2 0.9972 1185 
Run3 0.9973 1001 
Run 4 0.9976 986 
Run 5 0.9994 966 
Run 6 0.997 1014 
Run 7 0.9997 1051 
Run 8 0.9993 1031 
Run 9 0.9989 1057 
Run 10 0.9977 1187 
Average 0.9981 1029 
SD 0.0011 107.8 
%CV 0.1067 9.6 
 























The specificity of the method for XMP detection was confirmed as no XMP peak was identified when 
water was processed 6 times instead of patient cell lysates (even when compared to the LLOQ) 
(Figure 28). In addition, no XMP was detected when the substrate buffer was substituted for water 
in the enzyme activity assay confirming specificity of the enzyme assay (Figure 29). 
 
Figure 28 Chromatogram of water substituting the patient cell lysate in enzyme assay  





















   
 
   
 
   
 








Figure 29 Chromatogram of water substituting the substrate buffer in enzyme assay  




Exogenous XMP was used to derive a standard curve as shown in Figure 27 and demonstrates the 




The linearity of XMP production was demonstrated with increasing incubation periods of the enzyme 
reaction and is shown in Figure 30. Linearity of the assay was confirmed with 5 serial dilutions of the 
cell lysate (Figure 31). 
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Figure 30 Linearity between XMP formation and incubation time 
There is a linear relationship between increasing the incubation time of the enzyme assay and the 





































Figure 31  Linearity between assay response and sample dilution 
Each sample was processed twice by HPLC. The zero point represents the addition of distilled water 
instead of a cell lysate. The protein concentration of the cell lysate was 3 mg/mL. There is a linear 
relationship between the concentration of IMPDH in the cell lysate and the concentration of XMP 
formed by the assay. 
 
 
3.3.3.4 Accuracy and Precision 
 
Table 19 shows the XMP peak areas derived when IMPDH activity was assayed in 3 patient samples 
on 5 separate occasions. The CV is 9.6% (5.8-11.8). The % CV for XMP determination from 2 samples 






























Patient ID XMP Peak Area    
 Run1 Run 2 Run 3 Run 4 Run 5 Average SD %CV 
301         
Enzyme Assay 1 5850 5204 5246 5105 5381 5357 292.77 5.46 
Enzyme Assay 2 4944 5103 5142 5176 5088 5091 88.86 1.75 
Enzyme Assay 3 5949 5972 6085 4896 3322 5245 1177.87 22.46 
Enzyme Assay 4 4626 4630 5000 5310 4341 4781 376.90 7.88 
Enzyme Assay 5 3917 4128 3918 3758 4266 3997 199.55 4.99 
      4894 546.09 11.16 
302         
Enzyme Assay 1 7886 6044 7986 5870 7896 7136 1079.10 15.12 
Enzyme Assay 2 5207 6491 7007 6902 5304 6182 868.33 14.05 
Enzyme Assay 3 6492 6039 6282 8126 7326 6853 860.70 12.56 
Enzyme Assay 4 4783 6646 6238 7442 6672 6356 981.28 15.44 
Enzyme Assay 5 6847 6395 7490 7260 5893 6777 646.90 9.55 
      6661 386.81 5.81 
303         
Enzyme Assay 1 5714 7746 8034 6897 7000 7078 902.70 12.75 
Enzyme Assay 2 7123 7045 6937 6478 7010 6919 255.23 3.69 
Enzyme Assay 3 9738 9365 10350 10350 6163 9193 1745.34 18.99 
Enzyme Assay 4 7233 9357 7479 8472 8685 8245 879.29 10.66 
Enzyme Assay 5 8279 8994 8709 8227 6905 8223 801.70 9.75 
      7932 939.31 11.84 
Overall      6495.67 624.07 9.60 
 
Table 19 IMPDH enzyme assay completed on 5 separate occasions for 3 different patients with 
each HPLC sample run 5 times 
























Mean XMP  
nmol/mg of protein/mL/ h 
%CV 
301 37.75 35.00 36.38 5.33 
302 58.99 47.35 53.17 15.48 
303 69.03 70.87 69.95 1.86 
304 49.38 51.13 50.25 2.46 
305 65.68 68.41 67.05 2.88 
306 57.59 58.90 58.24 1.61 
307 58.91 63.48 61.19 5.30 
308 66.69 60.36 63.52 7.04 
309 35.34 38.80 37.07 6.61 
   Mean 5.40 
 
Table 20 %CV of XMP determination from 2 blood samples taken at the same time from 9 healthy 
volunteers 


















Figure 32 shows that no endogenous XMP was detected in patient cell lysates processed under 
‘standard conditions’ by HPLC.  
 
 
Figure 32 Chromatogram of patient cell lysate 
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Figure 33 shows an example of the calibration curve derived from incubation with substrate of 8 
different exogenous XMP standards (1.5 – 500 µmol/L). Each sample was processed 5 times by HPLC. 
The intra run CV was 5.1% (range 0.9-17.3%). The experiment was repeated on 3 separate occasions 
and the with-in run CV was 10.7% (range 1.4-19.9%). Table 21 shows the % recovery when these 
curves are compared to calibration curves from exogenous XMP. The mean % recovery was 113 with 
CV of 16.6%. 
 
 








































1 500 512839 505849 101 0.9995 1019 
 250 251760 252925 100   
 100 94276 101170 93   
 50 46003 50585 91   
 20 19553 20234 97   
 10 10111 10117 100   
 7.5 7307 6913 106   
 1.5 1568 1163 135   
Average    103   
SD    13.74   
%CV    13.38   
2 500 527995 505849 104 0.9958 1056 
 250 251167 252925 99   
 100 131701 101170 130   
 50 62001 50585 123   
 20 26151 20234 129   
 10 14401 10117 142   
 7.5 8012 6913 116   
 1.5 1662 1163 143   
Average    123   
SD    13.07   
%CV    16.12   
3 500 515919 505849 102 0.9994 1029 
 250 257413 252925 102   
 100 95310 101170 94   
 50 47613 50585 94   
 20 27142 20234 134   
 10 14608 10117 144   
 7.5 7237 6913 105   
 1.5 1553 1163 133   
Average    114   
SD    17.84   
%CV    20.26   
Overall 
Average 
   113 0.9982 651 
Overall 
SD 
   14.88 0.0021 12.15 
Overall 
%CV 
   16.59 0.2111 1.86 
 
Table 21  % Recovery compared to calibration curves derived from exogenous XMP 





Exogenous and patient derived XMP remained stable after storage at -80 °C (p=0.82) with CV of 
1.37% and 12.13% respectively. Three freeze thaw cycles of 24 h each also did not affect XMP peak 
areas (p=0.86) with an average CV of 3.49% for patient samples and 13.85% for exogenous XMP. 
Finally thawing samples for 24 h at room temperature did not significantly affect XMP peak areas in 
patient samples (CV= 15.52%) or exogenous XMP (CV= 3.6%) (p=0.86) (Table 22).  
 
  XMP Peak Area       
Patient ID Before  After 3 months of storage at -80 °C Average SD %CV 
307 6264 7933 7099 1180.16 5.36 
308 8117 8756 8457 451.84 16.63 
309 8994 7332 8163 1175.21 14.4 
      12.13 
XMP 73883 75998 74940 1027.42 1.37 
  Before After 3x 24 h freeze thaw cycles Average SD %CV 
301 9882 9687 9784 138.24 1.4 
302 11102 12507 11804 993.13 8.4 
303 15357 15494 15425 97.22 0.6 
      3.49 
XMP 73883 60703 67293 9320.02 13.85 
  Before After 24 h thaw Average SD %CV 
301 9166 8049 8608 790.19 9.18 
302 14631 10698 12665 2781.05 21.96 
303 13638 16979 15308 2362.8 15.43 
      15.52 
XMP 73883 70218 72050 2591.9 3.6 
 
Table 22 Stability of patient samples and exogenous XMP 
XMP derived from patient samples and exogenous XMP remains stable after 3 months of storage at  
-80 °C, after 3 freeze thaw cycles and after a 24 h thaw. 
 
The effect of storing HPLC samples in the autosampler at room temperature was found to be 
minimal as seen in table 17 where run 5 for patient ID 302 enzyme assay 3 and 4 and patient ID 303 
enzyme assay 2 were set up as the last run in the autosampler. Carry over effects were minimal and 
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did not seem to vary with the XMP concentration. Between the range of 0.1 nmol to 2 nmol XMP the 
average carry over area was 1881 with SD 165.15. 
 
3.3.3.7 IMPDH Protein Concentration and XMP Concentration 
 
Figure 34 shows the relationship between recombinant human IMPDH II protein concentration and 
XMP peak area. As IMPDH I and II have similar catalytic activities (7), the calibration curves derived in 
figure 27, can be used to calculate XMP concentration. Furthermore, using figure 34, IMPDH protein 
concentration can be calculated in patient cell lysates assuming that endogenous and exogenous 
derived IMPDH have similar catalytic properties. However, as this has not been investigated and the 
relationship between IMPDH protein concentration and XMP peak area is linear, IMPDH activity has 














Figure 34 Linearity of the relationship between IMPDH protein and XMP peak area 
IMPDH protein weight refers to the amount of IMPDH protein incubated with substrate buffer 





































3.3.4 IMPDH Activity in Immortalized Cell Lines 
 
XMP was reproducibly detected in immortalized cell lines. Figures 35-38 show an example of the 









































Figure 36 An example of the chromatogram derived from HEK-293 cells 
 
 
Figure 37 An example of the chromatogram derived from HK-2 cells 
Minutes 
















































































This IMPDH assay using XMP detection by HPLC methodology has been validated according the 
criteria published in the Bioanalytical Method Validation, May 2001 by the Food and Drug 
Administration. The specificity and linearity of the assay was confirmed and the precision (XMP 
concentrations measured following multiple incubations of the same cell lysate and from identical 
samples) was found to have a %CV of 9.6 (5.8-11.8). XMP determined from two samples of blood 
taken at the same time from one person displayed a %CV of 5.4 (1.6-15.5). These values compare 
favourably to those achieved by others using a similar method to assay IMPDH activity and measure 
XMP concentrations (Table 23). Furthermore, these results are comparable to the CV of less than 
10% described in the original method developed by Glander and colleagues in 2001 (214).   
 
Sample %CV Reference 
PMNC in healthy volunteers and patients with inflammatory bowel 
disease 
<7 (225)  
PMNC from diabetic and nondiabetic kidney transplant  
recipients receiving MMF therapy 
<5 (226) 




Table 23 Comparison of %CV achieved for the IMPDH activity assay and XMP detection 
 
 
The optimal separation of XMP via HPLC from PBMC occurred with a mobile phase pH of 4, 9 mmol/L 
of tetra-n butyl ammonium hydrogen sulphate, a FR of 0.6 mL/ min and UV detection at 254 nm. The 
LLOQ for exogenous XMP detection was found to be 1.5 µmol/L. Using this method, IMPDH activity 





This technique to determine IMPDH activity is labour intensive and is subject to operator error and 
can be poorly reproducible (228). The isolation of the peripheral blood mononuclear cells is likely to 
be the step most subject to error. Glander et al. found that the variability for harvesting PBMC from 
the interface was 19% (n=6) and for cell counts of same PBMC suspension the %CV was 6-28 using a 
cell counter and 6-19 and 8-17 for two experienced researchers (228). The normalization to cell 
counts therefore, needs to be rigorous. In this study, it was therefore decided to normalize to 
protein concentration. However this assumes that the sample is not contaminated with extracellular 
proteins and non-peripheral blood mononuclear cells as not all the supernatant can be removed 
from the pellet just before cell lysis and therefore there will be a variable amount of extracellular 
proteins which will be measured in the protein assay. Furthermore errors can occur during cell lysis 
as it is likely that the cytoplasm including the IMPDH enzymes will be released into the lysis medium 
and although nondisrupted cells are removed after centrifugation, this will again affect the 
calculation of protein concentration.  
 
Contamination with erythrocytes can lead to a reduction in IMPDH activity by approximately 10% 
(228). In addition, although IMPDH enzyme activity is accurate following storage of whole blood for 
24 h at room temperature, it was found that the yield of cells is reduced and contamination with 
erythrocytes increased after storage for 22 h compared to 5 h (228).   
 
In this study, several techniques were employed to minimize these errors. All blood samples were 
separated within 6 h. Following cell lysis, those samples contaminated with erythrocytes were 
discarded and samples were diluted with the same volume of water. Most importantly two separate 
samples at the same time were taken from each patient to ensure an accurate measurement of 




Since this study, further efforts have been made to optimize the assay. Glander and colleagues have 
used AMP, which was found to be stable between patients, to normalize XMP concentrations. This 
method, detailed in table 24 and compared to their previous published method, was found to have a 
CV, for XMP production in samples isolated from the same volumes of identical blood, of 0.6-3.4%. 
In addition, in 20 volunteers they compared IMPDH enzyme activity normalized to cell count, protein 
content and AMP concentrations and found that the %CV was 11.2-39.8, 11.8-12.4 and 6.6-8.5 
respectively (214, 228). 
 
More recently IMPDH activity has also been determined using liquid chromatography-coupled 
tandem mass spectrometry method for the quantification of XMP and AMP for normalization in 
PBMC lysates of hematopoietic stem cell transplant recipients (229). 
 
The method described here for the determination of IMPDH activity compares favourably with these 
recent advancements and has been validated extensively in this chapter. This enzyme assay and 
separation of XMP by HPLC was used to measure IMPDH activity in patient derived samples in the 











Parameters analyzed Glander 2001 (214) Glander and 
Sombogaard 2009 (228) 
Volume of whole blood  5 mL 2.5 mL 




In 250 µL ice-cold water 
Column temperature 45°C 40°C 
Eluant Isocratic Isocratic 
Gradient 
Flow rate 0.7 mL/min 1.0 mL/min 
Injected sample volume  15 µL 5 µL 





pmol/incubation sample µmol/L 
Normalization of XMP 
production 
Protein concentration AMP concentration 
Expression of IMPDH 
Activity 
nmol/h/mg protein µmol/s/mol AMP 
 






























4.1.1 Inter-Individual and Intra-Individual IMPDH Activity Variation 
 
IMPDH activity demonstrates considerable inter-individual variability in patients with renal disease 
and in healthy volunteers. Studies have shown a 12-fold variability in IMPDH activity (10.7 -121.6 
disintegrations per minute (dpm)/min) measured in whole blood (217) and a 8-fold variability in the 
lymphocytes of healthy volunteers (4.0-32.9 nmol/h/mg) (230). In patients receiving renal 
replacement therapy IMPDH activity varies to a lesser degree. In a cohort of 79 patients receiving 
renal replacement therapy, mean IMPDH activity was found to be 9.56 ± 4.27 nmol/mg of protein/h. 
The aetiology of inter-individual differences in IMPDH activity remains unknown as no correlations 
with age, gender or ethnicity have been demonstrated (185). Intra-individual IMPDH activity is more 
consistent with %CVs of between 7.1-26.0 in dialysis patients and of between 7.7-21.1% in healthy 
volunteers (185). 
 
4.1.2 Pre-Transplant IMPDH Activity and MMF Dose 
 
Pre-transplant IMPDH activity is associated with MMF dose reductions after transplantation. Glander 
and colleagues found that 63% of patients required a dose reduction due to MMF induced side 
effects (38% gastrointestinal intolerance, 31% infection, 24% leukopenia, 7% anaemia) within the 
first 6 months after transplantation (185). Those that required a dose reduction in MMF had a 
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significantly reduced pre-transplant IMPDH activity compared to those that tolerated full dose MMF 
therapy (8.4 ± 3.8 v 11.7 ± 3.9 nmol/mg protein/h, p<0.006) and those with the lowest IMPDH 
activity had the shortest time to MMF dose reduction (p<0.006). Moreover, those with a high pre-
transplant IMPDH activity and subsequent MMF dose reduction experienced an increased rate of 
acute rejection (185). 
 
4.1.3 Time Course of IMPDH Inhibition by MMF  
 
The pharmacodynamic monitoring of MMF by measurement of inhibition of IMPDH activity in whole 
blood was first demonstrated in rabbit and canine models (211, 231). Langman and colleagues 
showed that peak inhibition of IMPDH (40%) in whole blood occurred after 1 h after MMF dosing 
and persisted for 8 h in 5 patients receiving long term therapy with MMF (217). In an in vitro system, 
the concentration of MPA required for 50% inhibition of IMDPH was approximately 2-5 mg/L. 
Furthermore the maximum inhibition of IMPDH achieved in intact cells was 60-70% but if the 
lymphocyte membrane was disrupted then complete inhibition of the enzyme was possible, 
suggesting that enzyme inhibition is limited by intracellular drug uptake. Other groups have 
confirmed that peak inhibition of IMPDH occurs within 1-2 h after MMF administration and is linked 
to MMF dose and MPA concentration (Table 25). These factors are of importance if 









Number of patients IMPDH inhibition Reference 
27 transplant patients 
37-60% IMPDH inhibition 1-2 h after 
MMF depending on MPA 
concentrations. 
(219) 
9 normal human 
subjects 
60-90% IMPDH inhibition which 
lasted for 4 h. 
Enzyme activity returned to pre-
dose concentrations after 6 h. 
(218) 
7 patients on the day 
before transplantation 
78 ±15% IMPDH inhibition in PBMC 
occurred in 1 h 
(221) 
6 transplant patients on 
maintenance MMF 
therapy 
87% IMPDH inhibition occurred 
after 1 h at the same time as peak 
drug concentrations. Persistent 
inhibition after 2 h despite much 
lower drug concentrations at this 
time 
(222) 
24 patients on the day 
before live 
transplantation 
1 g of MMF resulted in reduction of 
T cell proliferation (93%), IMPDH 
activity (74%), CD25 (46%) (i.e. T cell 
activation) and CD71 (50%) after 1 h 
of drug administration. All markers 
apart from IMPDH activity returned 
to baseline. 
(232) 
8 dialysis and 8 
transplant patients 
Maximum IMPDH inhibition (75-
100%) with 1 g dose of MMF after 1 
h in PBMC cells. Inhibition persisted 
for 4 h and then returned to 
baseline by 11 h. 
(230) 
4 healthy volunteers 
Maximum IMPDH inhibition 
occurred 1 h after MMF intake and 
IMPDH activity returned to predose 
concentrations after 6 h in whole 
blood. 
(233) 
10 dialysis patients  
Maximum IMPDH inhibition (47-
95%) occurred 1 h after 1 g of MMF. 
No correlation between pre- and 
post-IMPDH activity and between 










4.1.4 Post-Transplant IMPDH Activity and Gene Expression 
 
IMPDH gene expression and subsequent enzyme activity alters after kidney transplantation (234-
235). Immediately after commencing immunosuppression therapy including MMF, it appears that 
IMPDH I gene expression increases in whole blood and lymphocytes and IMPDH II gene expression 
decreases in whole blood but increases in lymphocytes. It has been suggested that these immediate 
changes may be associated with glucocorticoid therapy (234, 236-237). Gradually over a 2 week 
period, IMPDH I gene expression reduces but remains above baseline in whole blood and 
lymphocytes. IMPDH II expression, however, remains elevated in lymphocytes and gradually 
increases in whole blood above baseline. The net effect is an instant reduction in pre-dose IMPDH 
activity in whole blood which gradually increases to above baseline by 2 weeks. Conversely in 
lymphocytes, pre-dose IMPDH activity is immediately increased which then declines towards but still 
remains above baseline 2 weeks after transplantation (234). Treatment with MMF for up to 2 years 
is associated with further induction of IMPDH activity compared to the first three months after 
transplantation in whole blood and this correlates with increased expression of both genes (235). 
 
It appears that factors other than MMF therapy affect IMPDH activity after transplantation. Patients 
suffering with diabetes mellitus were found to have reduced IMPDH activity between 0-12 h after 
ingestion of ECMPS particularly if they were receiving concomitant ciclosporin rather than 
tacrolimus. This may be related to reduced pre-dose IMPDH protein expression in diabetic patients 
(226) as it is hypothesized that insulin related phosphorylation of IMPDH leads to translocation of 




In summary, intra-individual IMPDH activity after transplantation varies considerably and is affected 
by co-morbidity, time after transplantation as well as immunosuppressive medication. Furthermore 
it requires multiple blood samples for measurement of IMPDH activity to be taken in a timely 
fashion. Hence the measurement of the less variable pre-transplant IMPDH activity may represent a 
more practical, feasible option in real-life clinical settings. Therefore it was decided to investigate the 
relationship between pre-transplant IMPDH activity and demographic, clinical variables before and 








All materials were obtained from Sigma Aldrich (Gillingham, Dorset, UK) unless otherwise specified. 
 
4.2.2 HPLC Method for the Determination of XMP Concentration in Patient Cell Lysates 
 
Samples were processed using two HPLC systems. The first HPLC apparatus comprised of a 127 
gradient solvent pump module and 166 UV/Vis variable wavelength detector from Beckman 
Instruments (UK) Ltd. (High Wycombe, Bucks, UK) set at a wavelength of 254 nm. The pump was 
connected to a manual RheodyneTM valve injector (model 7725i) fitted with a 20 μL loop from 
Rheodyne, Inc. (Cotati, California, USA). Peak area was calculated by using a ChromJet Integrator 
from Thermo Separations Products (Stone Business Park, Stone, Staffordshire, UK). The second HPLC 
apparatus comprised of a PU-2089 Quarternary Low Pressure Gradient Pump and MD-2010 
Photometric Diode Array UV/ Vis Detector (195-650nm) from Jasco Instruments Ltd. (Dunmow, 
Essex, UK). The pump was connected to an AS-2055 Autosampler. Peak area was calculated by 
EZChrom Elite software. For both systems a ACETM  C18 column (4.6 mm x 15 cm, 5 μm particle size) 
from Hichrom Ltd. (Theale, Reading, UK) was used in reversed phase mode. In order to clarify any 
possible effect of changing HPLC apparatus on XMP detection several patient samples were 




For ion-pair reversed-phased HPLC determination of XMP, the mobile phase consisted of 6% 
methanol, 94% buffer (50 mmol/L potassium dihydrogen phosphate (KH2PO4) and 9 mmol/L tetra-n-
butylammonium hydrogen sulphate, pH 4). 20 μL of sample (diluted 1 in 3 with distilled water) was 
injected onto the column with a flow rate of 0.6 mL/min and a run time of 12 min. The column was 
cleaned after each run with 100% methanol for 30 min and the injector was cleared with distilled 
water. Values were quantified against known standard concentrations of XMP. Each sample was 
processed twice. A standard mix containing 3.3 μmol/L  XMP, 3.3 μmol/L GMP and 3.3 μmol/L AMP 
to ensure adequate separation of nucleotides was performed prior to each sample run.  
 
4.2.3 IMPDH Activity Determined by Enzyme Assay using Patient Cell Lysates 
 
IMPDH activity was measured in 9 healthy volunteers as described previously (3.2 Methods). 
Patients listed for deceased donor renal transplantation were identified and counselled for the 
purposes of this study. Informed consent was obtained in all cases. The study was approved by the 
NHS Research Ethics Committee (05/Q0603/206) (Appendix 1). IMPDH activity was compared 
between patients according to demographic and clinical variables. Finally the intra-individual 
variability in IMPDH activity was investigated by repeated blood samples and measurement of 








4.2.4 IMPDH Activity Determined by Western Blotting using Patient Cell Lysates 
 
30 µL of patient cell lysates obtained as previously described (3.2 Methods) were denatured by the 
addition of 10 µL of NuPAGE Lithium Dodecyl Sulfate (LDS) (Invitrogen, Paisley, Renfrewshire, UK) 
sample buffer and heated to 99 °C for 5 min. The 4-12% NuPAGE Bis-Tris gel (Invitrogen) was 
prepared by removing tape and comb and rinsing the gel walls with 3 washes of NuPAGE 3-
morpholinopropane-1-sulfonic acid (MOPS) sodium dodecyl sulfate (SDS) Running Buffer 
(Invitrogen). The XCell SureLock Mini-Cell (Invitrogen) was set up and filled with NuPAGE MOPS SDS 
Running Buffer. 25 µL of each sample was loaded into each well and 7 µL of the molecular weight 
marker (Santa Cruz) was added to one well. The electrophoresis conditions were 200 V for 1 h. The 
transfer membrane was prepared by immersing in 100% methanol for 20 s and then rinsing with 
water for 20 s and soaking in 1x NuPAGE Transfer Buffer (Invitrogen) along with filter paper and 
blotting pads. After electrophoresis, the gel was placed in between a piece of pre-soaked filter paper 
and transfer membrane covered by a further piece of pre-soaked filter paper. Two blotting pads 
were then placed on either side and inserted into the XCell II Blot Module (Invitrogen). The central 
blot module was filled with 1x NuPAGE Transfer Buffer and the outer chamber was filled with water 
and attached to a 30 V power supply for 1 h. The membrane was removed and washed in 20 mL Tris-
Buffered Saline and Tween 20 (TBS-T) for 10 s. 20 mL of Startblock (Perbio Science UK, Cramlington, 
Northumberland, UK) was then added for 30 min with shaking. Blocking buffer was then removed 
and 20 mL of the anti-IMPDH antibody was added at a dilution of 1:1000 or 20 mL of anti- β actin 
antibody (Sigma Aldrich A5316) was added at a dilution of 1:5000 and incubated with shaking for 1 
hour. IMPDH I was detected using a mouse monoclonal raised against partial recombinant IMPDH I 
(Abnova, supplied by Novus Biologicals, Cambridge, UK) and the IMPDH II antibody was a mouse 
monoclonal antibody raised against full length recombinant IMPDH II (Abnova, supplied by Novus 
Biologicals). Three 10 min washes with 20 mL TBS-T followed before incubation with goat anti-
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mouse antibody linked to horseradish peroxidise (Santa Cruz Biotechnology, supplied by Insight 
Biotechnology Ltd., Wembley, UK) at a dilution of 1:2000 with shaking for 1 h. A further three 10 min 
washes with 20 mL TBS-T  buffer were performed and then bound antibody was detected using EZ-
ECL Chemiluminescent Reagent (Perbio Sciences UK) on X-ray film. 
 
4.2.5 Patient and Graft Outcome 
 
By March 2012, 27 patients from the initial cohort received a kidney transplant. At the Royal London 
Hospital patients receive immunosuppression therapy according to immunological risk (Appendix 2). 
All patients received a combination of drugs which included ciclosporin, mycophenolate mofetil and 
prednisolone. MMF is prescribed at a dose of 1 g twice a day except in those of Black ethnicity who 
receive 1.5 g twice a day. After transplantation patients are seen in the clinic thrice weekly for 6 
weeks and then twice weekly for 6 weeks before the time between visits is gradually lengthened 
such that by 1 year patients are seen on a monthly basis. At each visit, patients are clinically 
assessed, and blood tests to measure renal function, haematological indices and drug concentrations 
and to detect cytomegalovirus (CMV) reactivation are taken. Data were collected on graft function at 
3, 6, 9, 12, 24 and 36 months after transplantation, as well as on changes in immunosuppression 
therapy and related side effects, MMF dose adjustments, acute rejection episodes and infection as 
well as graft and patient survival. These variables were correlated with pre-transplant IMPDH 
activity. In addition, the causes for MMF dose reduction were investigated and correlations with 






4.2.6 Statistical Analyses 
 
IMPDH activity was found to be of normal distribution in this patient population. For univariate 
analyses, Student’s t test and analysis of variance (ANOVA) for continuous variables and Chi-square 
tests for categorical variables were performed. All analyses were performed using SAS software 
(version 9.1.3; SAS Institute, Marlow, Bucks, UK).  
 
In order to detect a difference in IMPDH activity of approximately 5 nmol/mg of protein/mL/h with 
80% power, assuming an alpha error level of 5%, 32 patients would be required in each group. This 













4.3.1 HPLC Method for Determining XMP Concentration in Patient Cell Lysates 
 
In order to confirm that XMP concentrations measured by Beckman Gold HPLC System and Jasco 
apparatus were comparable, 8 random patient samples were separated using both systems and the 
results were found to be similar (Table 26). The mean CV was 11.95% (range 4.85-22.89). Figure 39 











XMP nmol/mg of 
protein/mL/h 
Mean SD %CV 
109 18.86 13.61 16.23 3.72 22.89 
119 35.61 27.93 31.77 5.43 17.08 
130 27.69 29.65 28.67 1.39 4.85 
172 24.75 30.43 27.59 4.02 14.57 
174 23.82 27.12 25.47 2.33 9.16 
178 26.02 29.46 27.74 2.43 8.76 
180 21.79 19.13 20.46 1.88 9.18 
192 19.41 22.09 20.75 1.89 9.13 
      
  Mean 24.84 2.89 11.95 
 
Table 26 Comparison of XMP concentrations obtained by processing samples on Jasco and 
Beckman HPLC apparatus 
The mean CV was 11.95% demonstrating that similar results were obtained when patient samples 











Figure 39 Chromatogram of the same patient sample using Beckman (A) and Jasco (B) HPLC 
systems 
Using the Beckman System the XMP concentration (retained at 10.61 min) was calculated as 23.82 
nmol/mg of protein/mL/h and using the Jasco System the XMP concentration (retained at 7.41 min) 
























































4.3.2 IMPDH Activity measured in Healthy Volunteers 
 
IMPDH activity was measured in 9 healthy volunteers. Demographic data and corresponding IMPDH 
activity (XMP nmol/mg of protein/mL/h) are shown in table 27 with corresponding % CV. CV1 
represents the coefficient of variance between IMPDH activity measured in 2 samples from the same 
patient taken at the same time. The mean CV1 was 5.40%. CV2 represents the mean coefficient of 
variance between XMP peak areas obtained following 2 separations via HPLC. The mean CV2 was 
2.21%. The XMP concentrations were between 36.38 and 67.05 nmol/mg of protein/mL/h with a 
mean of 55.20 nmol/mg of protein/mL/h demonstrating a 2 fold variation in activity. There was no 




Age Gender Ethnicity XMP nmol/mg of protein/mL/ h %CV1 %CV2 
301 32 Male White 36.38 5.33 0.91 
302 43 Male Asian 53.17 15.48 3.05 
303 33 Male White 69.95 1.86 9.29 
304 46 Male White 50.25 2.46 5.27 
305 32 Female Asian 67.05 2.88 0.36 
306 35 Male Asian 58.24 1.61 0.73 
307 36 Female White 61.19 5.30 0.01 
308 44 Male White 63.52 7.04 0.22 
309 40 Male Asian 37.07 6.61 0.02 
 








4.3.3 IMPDH Activity Determined by Enzyme Assay using Patient Cell Lysates 
 
IMPDH activity was measured in 55 patients. The mean age of the patients was 48 (range 25-71) 
years. 61.8% (n=34) were male. Ethnic groups were defined as White, Asian (including patients from 
the South Asian Subcontinent) and Black (including patients from Africa and the Caribbean). 31% 
(n=17) were White, 45% (n=25) were Asian and 24% (n=13) were of Black ethnicity. Patients were 
also characterized according to whether they were receiving renal replacement therapy 
(haemodialysis or peritoneal dialysis) or if they had chronic kidney disease not requiring renal 
replacement therapy (pre-dialysis).  
 
IMPDH activity (XMP nmol/mg of protein/mL/h) was between 11.68 and 46.09 nmol/mg of 
protein/mL/h with a mean of 25.50 nmol/mg of protein/mL/h demonstrating an approximately 4-
fold variation in activity as shown in figure 40. The mean CV1 was 8.4% (range 0.1-17.7%) and CV2 
























Figure 40 IMPDH activity variation between patients  
 
Males (n=34) had an increased IMPDH activity compared to females (n=21) (27.37 v 22.46 XMP 
nmol/mg of protein/mL/h, p=0.01) as seen in Table 28. There was no overall difference in IMPDH 
activity between ethnic groups (White 24.04, Asian 26.33, Black 25.80, XMP nmol/mg of 
protein/mL/h, p=0.61). To compare the combined effect of gender and ethnicity on IMPDH activity, a 
factorial analysis of variance was performed (Table 28). White and Asian males did not have a 
statistically significant increased IMPDH compared to their counterpart females. However, Black 
males have significantly increased IMPDH activity compared to Black females (31.00 v 19.74 XMP 
nmol/mg of protein/mL/h, p=0.01). There was no difference in IMPDH activity in males of Black, 
Asian or White ethnicity (p =0.08) and between females of Black, Asian and White ethnicity (p=0.64).  
 


































IMPDH Activity XMP nmol/mg of  
protein/mL/h ± SD 
p value 
Gender   
Males n=34 27.37±6.24 0.01 
Females n=21 22.46±8.00  
Ethnicity   
White n=17 24.04±8.19 0.61 
Asian n=25 26.33±8.38  
Black n=13 25.80±0.33  
White Ethnicity   
Males n=10 24.23±6.81 0.91 
Females n=7 23.75±10.50  
Asian Ethnicity   
Males n=17 27.73±4.65 0.10 
Females n=8 23.37±8.09  
Black Ethnicity   
Males n=7 31.00±7.43 0.01 
Females n=6 19.74±4.53  
Age   
≤65 years n=50 25.19±7.32 0.32 
>65 years n=5 28.61±7.11  
Dialysis Modality   
Haemodialysis n=45 24.82±7.18 0.11 
Peritoneal Dialysis n=9 29.08±7.67  
Pre-Dialysis n=1 23.46  
Primary Renal Disease   
Adult Polycystic Kidney Disease n=2 25.02±1.95 0.08 
Congenital n=1 28.70  
Diabetes Mellitus n=17 28.94±7.49  
Glomerulonephropathy n=14 21.64±7.43  
Hypertension n=5 22.89±5.11  
Tubulointerstitial Nephritis n=10 26.91±5.67  
Other n=1 22.77  
Unknown n=5 24.45±9.74  
  








In order to calculate the intra-individual variability of IMPDH activity in patients, repeated samples 
were taken from 5 patients at a separate time point and IMPDH activity was measured (Table 29). 
The mean CV for intra-individual variability in patients was 15.12% (range 9.95-18.41%). 
 
Patient ID 
First IMPDH Activity 
XMP nmol/mg of 
protein/mL/h 
Second IMPDH Activity 
XMP nmol/mg of 
protein/mL/h 
Mean SD %CV 
133 23.59 18.16 20.88 3.84 18.41 
134 28.70 23.17 25.93 3.92 15.10 
137 28.37 24.65 26.51 2.64 9.95 
144 19.53 15.13 17.33 3.11 17.94 
165 23.73 29.04 26.39 3.76 14.23 
  Average 23.41 3.45 15.12 
 





4.3.4 IMPDH Activity Determined by Western Blotting using Patient Cell Lysates 
 
Figure 41 shows the western blot obtained from patient cell lysates that were probed with 
antibodies raised against IMPDH I and IMPDH II. The IMPDH protein is 56 kDa and is located 
between the markers 55 kDa and 90 kDa. (Markers are 132 kDa, 90 kDa, 55 kDa, 43 kDa, 34 kDa, 23 
kDa). The intensity of the protein band as determined by densitometry for IMPDH I and II is shown in 
figure 42 along with the IMPDH activity as measured by the enzyme assay. There does not appear to 
be a significant correlation between protein expression and enzyme activity (IMPDH I r2=0.176, 













Figure 41 Western blot obtained with patient cell lysates probed with antibodies raised against 

























Figure 42 IMPDH activity measured by enzyme assay to compare with results obtained by 
densitometry of the western blot in figure 36 
There does not appear to be a significant correlation between protein expression and enzyme 
activity (IMPDH I r=0.176, p=0.65, IMPDH II r=0.130, p=0.74) suggesting that enzyme activity is not 


































































































4.3.5 Patient and Graft Outcome 
 
27 of the 55 patients analyzed for IMPDH activity received a kidney transplant by March 2012. 10 
patients died whilst waiting for a kidney transplant. One patient received a kidney pancreas 
transplant at another centre and remained under follow-up there. One patient enrolled onto 
another study and received AdvagrafTM (Astellas Pharma UK Limited, Camberley, Chertsey, UK) and 
azathioprine. These two patients were excluded from further analysis. For the remaining 25 patients, 
overall death censored graft survival was 80% and patient survival was 84%. 4 patients had less than 
1 year follow-up data as they received their transplant after March 2011. Therefore the 1 year death 
actuarial graft survival was 86% (n=18) and 1 year patient survival was 81% (n=17). All 25 patients 
received initial immunosuppression with ciclosporin, MMF and prednisolone as per unit protocol. 
28% (n=7) had induction therapy with interleukin 2 receptor antagonist, 12% (n=3) received ATG, 4% 
(n=1) received plasma exchange and intravenous immunoglobulin therapy prior to transplantation. 
21 (84%) patients received a deceased donor kidney transplant. The mean follow-up period after 
transplantation was 588 (range 81-1078) days. 
 
The mean dose of MMF therapy at 1 year was 1.294 (range 0-3) g. Further analysis of patients with 
greater than 1 year follow-up data (i.e. Patients and grafts that survived more than 1 year or patients 
who received a transplant before March 2011) revealed that 4 patients required a temporary 
reduction in MMF dose and 12 patients a permanent reduction in MMF dose within the first year of 
transplantation. Only 1 patient did not require an adjustment to his MMF dose. The reasons for 
MMF dose reduction were infection, which included CMV, herpes zoster virus, herpes simplex virus, 
varicella zoster virus, pneumocystis carnii, pneumonia, cellulitis, urinary tract infections and 




One patient experienced an episode of acute rejection (n=6%) within the first year after 
transplantation (Table 30). Interestingly she had the highest IMPDH activity in this cohort (40.83 v 
23.34 XMP nmol/mg of protein/mL/h) and had a dose reduction in MMF due to infection and 
leukopenia at day 44 after transplantation. There was no significant association between pre-
transplant IMPDH activity and MMF dose achieved at 1 year (p=0.19). In addition, MMF associated 
side effects including gastrointestinal intolerance and leukopenia were not related to pre-transplant 
IMPDH activity. There was no association between the number of days to permanent dose reduction 
of MMF therapy and IMPDH activity (P=0.33) (Table 30). Furthermore, there was no association 
between IMPDH activity and eGFR at 3 (p=0.74), 6 (p=0.53), 9 (p=0.78), 12 (p=0.63), 24 (p=0.60) and 
36 (p=0.76) months (Table 31) and similarly there was no correlation between MMF dose at 1 year 
and eGFR at 3 (p=0.52), 6 (p=0.64), 9 (p=0.85), 12 (p=0.68), 24 (p=0.61) and 36 (p=0.75) months 
(Table 32). Finally in this study, no association between ethnicity, gender and MMF dose at 1 year 






IMPDH Activity  
XMP nmol/mg of protein/mL/h ±SD 
p value 
Acute rejection  N/A 
No n=13 23.34±7.92  
Yes n=1 40.83  
Infection  0.93 
No n=2 22.87±8.13  
Yes n=15 23.40±8.18  
Gastrointestinal side effects with MMF  N/A 
No n=16 23.95±7.75  
Yes n=1 13.55  
Leukopenia related to MMF  0.81 
No n=11 22.98±6.63  
Yes n=6 24.00±10.58  
MMF dose at 1 year  0.19 
≤1 g MMF n=12 21.69±8.36  
≥2 g MMF n=5 27.30±5.57  







Table 30 Relationship between post-transplant events and pre-transplant IMPDH activity 
There was no significant association between pre-transplant IMPDH activity and side effects related 


















XMP nmol/mg of protein/mL/h 
≤25.50 
IMPDH Activity 
XMP nmol/mg of protein/mL/h 
>25.50 
p value 
3 months ±SD 145.45±67.29 156.17±50.38 0.74 
6 months ±SD 121.36±45.61 134.67±28.24 0.53 
9 months ±SD 127.64±47.69 133.67±24.07 0.78 
12 months ±SD 131.55±41.23 122.50±25.00 0.63 
24 months ±SD 135.00±55.78 120.60±21.71 0.60 
36 months ±SD 121.33±52.66 131.33±15.50 0.76 
 
Table 31 Relationship between eGFR and pre-transplant IMPDH activity 
eGFR up to 3 years was not found to be related to pre-transplant IMPDH activity. 
 
eGFR MMF Dose at 1 year ≤1 g MMF Dose at 1 year >2 g p value 
3 months ±SD 142.83±65.15 164.60±50.15 0.52 
6 months ±SD 123.00±46.61 133.40±17.26 0.64 
9 months ±SD 128.50±46.32 132.80±22.99 0.85 
12 months ±SD 125.92±39.84 134.20±26.19 0.68 
24 months ±SD 134.00±51.39 119.25±29.26 0.61 
36 months ±SD 128.17±47.89 117.67±37.81 0.75 
 
Table 32 Relationship between MMF dose at 1 year and eGFR 
No significant correlation between MMF dose at 1 year and eGFR up to 3 years was found. 
 























































Table 33 Relationship between MMF dose at 1 year and gender and ethnicity 








Pre-transplant IMPDH activity was measured in 55 patients listed for renal transplantation and a 4-
fold variation in activity was exhibited. This enzyme assay was extensively validated in chapter 3 and 
minimal intra-individual IMPDH activity has been demonstrated in this chapter. Furthermore we 
found that protein expression of IMPDH I and II was not significantly correlated to enzyme activity. 
This suggests that factors other than protein expression may affect activity and therefore performing 
the enzyme assay is necessary to measure activity. 
 
Black males had significantly increased IMPDH activity compared to Black females but did not 
demonstrate a statistically significant higher enzyme activity compared to males of White and Asian 
ethnicity. There was no association between pre-transplant IMPDH activity and age, dialysis modality 
or primary renal disease. After transplantation, a permanent dose reduction of MMF therapy 
occurred in 71% of patients. Patients achieving a dose of 1 g or less of MMF per day at 1 year did not 
display a statistically significant reduced pre-transplant IMPDH concentration compared to those 
tolerating doses of 2 g or more. In addition, no relationship was demonstrated between IMPDH 
activity and reason for MMF dose reduction. Furthermore, no association between graft function 
and IMPDH activity or MMF dose at 1 year was shown.  
 
The analyses of NHS Blood and Transplant database in chapter 2 demonstrated a relationship 
between MMF dose of less than 1 g at 1 year with reduced eGFR at 12 and 24 months. This was not 
confirmed in this patient cohort. Interestingly males were able to tolerate higher doses of MMF 
compared to females (2.3 Results) and this is consistent with this study which shows that males have 
higher IMPDH activity. However, analyses of gender and ethnicity subgroups in chapter 2 
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demonstrated that White males tolerate higher MMF doses than White females and Black males and 
females take larger MMF doses than those of White and Asian ethnicities. This was not validated in 
this study perhaps as the number of patients was small. Longer term follow-up of this cohort will 
establish any correlation between pre-transplant IMPDH activity and MMF dose and graft outcome. 
 
This study does not confirm previous results which reported an association between a dose 
reduction of MMF after transplantation and acute rejection rates with pre-transplant IMPDH activity 
(185). Two more recent studies have also investigated this with conflicting results as Raggi et al. 
found that pre-transplant IMPDH activity was higher in the group experiencing acute rejection (239) 
whereas Sombogaard and colleagues did not find an association (240). In our study only a small 
number of patients had received a transplant and had completed 1 year of follow-up. This is in 
contrast to the larger study of Glander et al. This together with probable differing clinical strategies 
to manage immunosuppression related side effects, may account for the difference. However, an 
important result from both studies is the finding that if a patient with very high IMPDH activity 
experiences a dose reduction, the risk of acute rejection is increased (185). Perhaps therefore there 
is a role for measuring pre-transplant IMPDH activity to determine patients not suitable for MMF 
therapy (241). Furthermore, these studies suggest that the MMF dose tolerated is not only related 
to IMPDH activity but is linked to other factors as yet not fully identified. This is not surprising as 
MMF has modes of action that are independent of IMPDH inhibition. It seems likely that 
gastrointestinal side effects, for example, are attributed to pro-inflammatory metabolites of MMF, 
acyl MPAG (116).  
 
In this study, we did not demonstrate a statistically significant difference in IMPDH activity related to 
ethnicity which may have accounted for the reduced efficacy of MMF observed at a dose of 2 g in 
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preventing acute rejection in African American patients. This was demonstrated in the post-hoc 
analysis of the pivotal MMF trials (200). African American patients, the majority of whom were male, 
required a dose of 3 g of MMF to achieve reduced acute rejection rates and treatment failure 
compared to those treated with azathioprine (24.2% v 57.5%, P<0.01). Furthermore acute rejection 
rates of 3 g of MMF v 2 g of MMF v azathioprine were 12.1% v 31.8% v 47.5% compared to non 
African Americans 18.8% v 15.7% v 35.5%. Subsequently several further studies have demonstrated 
that Black patients are at increased risk for acute rejection and have inferior graft survival compared 
to White patients (242-244) and it has been suggested that this is related to increased immune 
responsiveness (137, 245-249), inferior HLA matching as well as longer waiting times for a transplant 
(250). Until recently, no variation in MPA exposure related to ethnicity was found to account for this 
increased acute rejection (123, 137, 251) but now a study has demonstrated increased MPA 
clearance in patients of Black ethnicity (252). We hypothesize that inferior acute rejection rates in 
Black patients may be in part related to increased IMPDH activity but larger studies will be required 
to confirm this.  
 
As previously mentioned, one of the limitations of this study was the small number of patients in 
whom IMPDH activity could be measured. The sample size calculation suggested that at least 32 
patients in each group would be required to detect a difference of 5 nmol/mg of protein/mL/h in 
IMPDH activity with 80% power. This was not possible due to time limitations and the labour 
intensive nature of the PMNC isolation, enzyme assay and XMP detection. However, a strength of 
this work was that due to the location of our centre, blood sampling from all ethnic groups was 
possible. 
 
Conceivably, measurement of post-transplant IMPDH activity may be more efficacious. One of the 
first studies to demonstrate increased IMPDH activity prior to an episode of acute rejection was a 
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study of heart transplants in rabbits (253). A recent study found that post-transplant IMPDH 
inhibition, measured at 5 time-points after MMF ingestion at weeks 1 and 2 was lower in patients 
suffering with acute rejection (239). This has been confirmed in other studies as shown in table 34. 
Another potential strategy is to measure IMPDH mRNA and a few studies have demonstrated 
correlation between acute rejection episodes and IMPDH I and II gene expression (234-235, 240). 
However, it is suggested that measurement of post-transplant IMPDH activity and mRNA is labour 
intensive and because of the additional time constraints may be impractical. 
 
 
Table 34 Post-transplant IMPDH activity and acute rejection (241) 
Post-transplant IMPDH activity may be increased in patients experiencing an episode of acute 
rejection. 
 
This study provides further support for the hypothesis that ‘one size of immunosuppression does not 
fit all’ by showing that pre-transplant IMPDH activity varies by 4-fold between individuals and is 
correlated with gender and ethnicity. The long term consequences of this differential IMPDH activity 
remain unconfirmed and currently MMF dose remains a pragmatic marker of MPA exposure and 
IMPDH inhibition and those achieving doses of 1 g or less should be considered for alternative 
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therapies particularly in those with high pre-transplant IMPDH activity. The feasibility and usefulness 
of measuring both post-transplant IMPDH activity and mRNA transcription merit further 
investigation with larger prospective studies and longer follow-up. Furthermore, the large 
proportion of patients with MMF intolerance compared to the low acute rejection rate in this study 
suggests that a paradigm shift from concentrating efforts on reducing acute rejection to minimizing 


























Differential enzyme activity is associated with genetic mutations. One relevant example is of a SNP in 
the cytochrome P450 (CYP) 3A5 enzyme which is involved in the metabolism of tacrolimus. Patients 
with the wild type allele (CYP3A5*1) are considered as expressors and those homozygote for the SNP 
(CYP3A5*3) are nonexpressors as they produce low concentrations of the enzyme. Expressors 
experience an increased time to achieve target concentrations of tacrolimus resulting in earlier 
episodes of acute rejection than nonexpressors (255). Furthermore, this SNP is associated with 
ethnicity as the proportion of the population who are expressors increases with proximity of genetic 
origin to the equator (256-258). Similarly it has been postulated that the variation in IMPDH activity 
is related to genetic mutations and in order to appreciate the relationship between SNPs and 















IMPDH I          IMPDH II 
Introns 
IMPDH I          IMPDH II 
A+A’ ~1200  265  
B 44  88  
C 64  ~3200  
1 99 148 ~2000 445 
2 49 49 ~2300 225 
3 102 102 137 107 
4 75 75 278 327 
5 207 207 149 657 
6 88 88 ~1500 73 
7 200 200 ~1400 77 
8 91 91 236 99 
9 96 96 ~1300 1065 
10 144 144 94 83 
11 145 145 288 94 
12 144 144 93 80 
13 84 84 ~1200 89 
14 735 75   
 
Table 35 Comparison of exon and intron sizes for IMPDH I and II genes (259) 
Exons 2-13 of both genes are identical in size. The 5’ and 3’ UTRs and introns of IMPDH I are larger 




IMPDH I gene spans 18 kb in length and is located on chromosome 7q 31.3 whereas IMPDH II is 5.8 
kb in length and is located on chromosome 3 p21.2. The 5’-UTR of IMPDH I is composed of 
approximately 1.3 kb (exons A-C and A’) with nine ATG codons. The exons of the coding region are 
identical in size in both genes but IMPDH I exon 14 includes the 713 bp of 3’-UTR. These 5’- and 3’-
UTRs are much larger than the 5’- and 3’-UTRs of IMPDH II which consist of 50 and 53 bp respectively 





Each of the IMPDH I and II genes encodes a protein of 514 amino acids with 84% sequence identity 
(260) (Appendix 4). The same amino acids are found at each intron-exon boundary as IMPDH II with 
the exception of isoleucine to valine substitution at the exon 5/6 boundary. IMPDH I has large 
introns varying in size from 0.1 to 4 kb compared to IMPDH II suggesting that the two genes diverged 
after an initial gene duplication event. All exon-intron boundaries contain the canonical splice donor 
(GT) and acceptor (AG) consensus sequences, with the exception of a GC splice acceptor site at exon 
4 (259). 
 
IMPDH I is more complex than the type II isoform as it is governed by the presence of three 
alternative promoters in the 5’ flanking region (259) (Figure 43). There are three transcripts of 4 kb, 
2.7 kb and 2.5 kb with respective promoters 1, 2 and 3. The 4 kb transcript is predominantly found in 
peripheral lymphocytes and to a far less extent in cultured tumour cell lines, and its expression is 
increased in activated T cells. The 2.7 bp transcript has been found in cultured tumour cell lines and 
the 2.5 kb transcript, which is the major transcript, is found universally (including in activated T 
lymphocytes). Promoter 1 (P1) region encompasses 245 bp and includes five stimulatory protein 1 
(Sp1) and two activator protein 2 (AP2) sites, one serum response element site, one NF B site that 
overlaps with a sis-inducing factor (SIF) consensus binding sequence, and one endozepine-like 
peptide (ELP) site. There is no TATA box in this region, although a consensus sequence for 
transcription initiation factor IID is present. A highly AT-rich region of 52 bp, containing four AAAAT 
repeats plus stretches of A nucleotides separated by a single T or C is located 3’ to the P1 element. 
The presence of an NF B binding site may be directly relevant as NF B is known to be involved in 
transcription of a number of genes following lymphocyte activation. Promoter 2 (P2) region is 595 bp 
in length and contains 73% GC residues, a number of Sp1 and AP2 binding sites, a purine-binding 
transcription factor (PuF) consensus binding site, and an erythroblast transformation specific 1 (Ets-
1) consensus binding site. Promoter 3 (P3) region is 671 bp in length, is located immediately 5’ to 
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exon 1 and also has a high GC content of 73%. This region contains, in addition to a number of 
potential Sp1 and AP2 binding sites, three early growth response 1 (Egr-1) sites (two of them 
overlapping with Egr-2 sites), three PuF, two serum response elements, and a site for 
CCAAT/enhancer-binding protein (C/EBP), a cyclic adenosine monophosphate response element 
(CRE), and a CCAAT binding site. The Egr-1 binding site may be of importance as Egr-1 is a zinc finger 
protein induced following interleukin 2 stimulation of T lymphocytes that appears to be important 
for cellular proliferation. The variability of expression of the three different transcripts of IMPDH I in 
cell lines suggest that this gene is highly regulated in a tissue or cell specific manner and may have a 
more significant role in cellular responses than just maintaining a basal concentration of guanine 
nucleotides (259). 
 
A single 2.3 kb transcript is predominant product for the IMPDH II gene (261). The transcription 
initiation site was located to a position 50 bp upstream of the translation initiation codon. The 5’ 
flanking region contains the promoter activity and consists of 463 bp upstream of and including the 
translational initiation site. In vitro DNase I footprinting analysis using Jurkat T cell nuclear extracts 
identified four protected regions in the promoter coinciding with consensus transcription factor 
binding sites including AP2, tandem CREs, an overlapping Egr-1/Sp1 site, Sp1 site and an 
nonmetastatic 23 (Nm23) motif (Figure 44) (261). The sequence between -199 and -143 was found 
to be responsible for 72% of promoter activity which contains the Egr-1/Sp 1 binding site and a 
palindromic octamer sequence (POS). Site directed mutagenesis experiments of CRE(A), POS, CRE(B), 
EGR-1/SP1 revealed that promoter activity was decreased by 65, 39, 9 and 25% respectively 
compared to wild type and an 83% reduction in gene expression was noted if mutations in both CRE 
(A) and (B) were present. An enhanced cleavage site at 42 bp upstream from the translation 
initiation codon adjacent to an (acute myeloid leukaemia 1) AML1 binding site was found and 
furthermore mutation of these sequence increased promoter activity to 133%. Therefore, the most 
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important transcription factors regulating IMPDH II may be activated transcription factor (ATF-2) 
which bind to CRE motifs, Sp1 binding the Egr-1/ Sp1 site and an unknown protein between 35-45 





Figure 43 Sequence of IMPDH I P1 (A), P2 (B) and P3 (C) promoters (259) 
IMPDH I gene has three alternative promoters in the 5’ flanking region resulting in three alternative 






Figure 44 Sequence of IMPDH II promoter (261) 






























5.1.2 Single Nucleotide Polymorphisms Identified in IMPDH I and II 
 
Although both genes are highly conserved, several mutations in the binding site of IMPDH of the 
parasites Tritrichomonas foetus, Saccharomyces Cerevisiae and Candida Albicans have been found to 
confer a degree of MPA resistance (262-263). In addition, mutations in IMPDH II created by random 
mutagenesis followed by selection for the ability to grow in the presence of MPA have identified 
SNPs resulting in amino acid substitutions (Gln227Arg, Ala462Thr, Phe465Ser and Asp470Gly) that 
confer MPA resistance in humans (262). 
 
The published gene mutations occurring in IMPDH I and II exons are listed in the table 36. In humans, 
SNPs particularly resulting in amino acid substitutions at position Arg224Pro, Asp226Asn, Val268Ile 
and Gly324Asp in the IMPDH I gene, have been reported in patients with autosomal dominant 
retinitis pigmentosa (264). Asp226Asn is the most commonly occurring IMPDH I mutation and 
accounts for 1-2.5% of all autosomal dominant retinitis cases. Further experiments have shown 
these mutant IMPDH I proteins have distorted protein folding and aggregation with altered affinity 
and specificity for single strand nucleic acids, possibly mediated by the subdomain. Although the 
functional consequences of altered binding to nucleic acids are unclear, protein misfolding is thought 
to initiate neuronal death and hence loss of rod photoreceptors in retinitis pigmentosa (20, 265). 
Furthermore it has been proposed that this mutant IMPDH affects the post-translational regulation 
of rhodopsin mRNA leading to the pathological findings of retinitis pigmentosa (266). Other SNPs 
associated with retinitis pigmentosa include Arg231Pro, Thr116Met, and His372Pro. To date, none of 
these SNPs identified in IMPDH I have demonstrated altered activity in vitro or in vivo (267-269). 
Furthermore, Arg105Trp and Asn198Lys have been reported in two patients with isolated Leber 
congenital amaurosis but similarly differential enzyme activity has not been shown (267). Wang et al. 
examined DNA of 191 renal transplant patients for IMPDH I SNPs and described two novel non-
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synonymous variants Asp301Asn and Gly519Arg but no difference in IMPDH activity was 
demonstrated (270). 
 
Mutations in the IMPDH II gene are not associated with disease. However interestingly, an IMPDH II 
variant has been associated with decreased enzyme activity. Leu263Phe has an allele frequency of 
1%. This residue is located within the α helix of the α/β barrel core domain of IMPDH II protein 
which is responsible for the catalytic activity and was associated with a 10 fold decrease in the Kcat 
(the maximum number of enzymatic reactions catalyzed per second) and 50% less protein 
expression compared with wild type. Clinically, the two patients found with this SNP were liver 
transplant recipients and both developed leukopenia whilst receiving MMF therapy (271).   
 
In order to determine whether a clinically relevant SNP influences enzyme activity, the IMPDH I and 
II genes were sequenced in 55 patients listed for renal transplantation, in whose pre-transplant 

















Location Clinical Correlation 
IMPDH I     
 C > T Exon C Ile47Ile αβ barrel Unknown 
 C > T Exon 2 Arg105Trp αβ barrel Leber Congenital Amaurosis 
 C > T Exon 3 Thr116Met Flanking domain Retinitis Pigmentosa 
rs1042247 G > C Exon 4 Leu150Leu Flanking domain Unknown 
rs34724843 C > T Exon 5 Asn187Asn Flanking domain Unknown 
rs1042252 G > C Exon 6 Lys194Asn Flanking domain Unknown 
 T > G Exon 6 Asn198Lys Flanking domain Leber Congenital Amaurosis 
 C > T Exon 6 Cys215Cys Flanking domain Unknown 
 G > C Exon 8 Arg224Pro Flanking domain Retinitis Pigmentosa 
 G > A Exon 8 Asp226Asn Flanking domain Retinitis Pigmentosa 
 G > C Exon 8 Arg231Pro Flanking domain Retinitis Pigmentosa 
 A > G Exon 8 Lys238Glu αβ barrel Unknown 
 G > C Exon 8 Leu244Leu αβ barrel Unknown 
 A > G Exon 8 Val268Ile αβ barrel Retinitis Pigmentosa 
 G > A Exon 8 Ala285Thr αβ barrel Unknown 
 A > G Exon 8 His296Arg αβ barrel Retinitis Pigmentosa 
rs41281737 C > T Exon 8 Cys300Cys αβ barrel Unknown 
 G > A Exon 8 Asp301Asn αβ barrel Unknown 
rs1042253 C > T Exon 8 Asn315Asn αβ barrel Unknown 
 G > A Exon 8 Gly324Asp αβ barrel Retinitis Pigmentosa 
rs2288550 G > C Exon 8 Leu329Leu Active site loop Unknown 
rs1042254 C > G Exon 8 Leu348Leu αβ barrel Unknown 
 A > C Exon 9 His372Pro αβ barrel Retinitis Pigmentosa 
 A > G Exon 11 Ala440Ala Active site flap Unknown 
 G > A Exon 13 Gly519Arg αβ barrel Unknown 
rs2228075 G > A Exon 13 Ala525Ala αβ barrel Unknown 
 G > A Exon 13 Gly528Arg αβ barrel Unknown 
rs1042259 G > C Exon 14 Ala582Pro αβ barrel Unknown 
IMPDH II     
rs11557543 C > T Exon 3 Leu55Leu αβ barrel Unknown 
rs11557547 A > G Exon 3 Pro64Pro αβ barrel Unknown 
rs11557541 C > T Exon 4 Phe90Phe αβ barrel Unknown 
rs11557545 C > T Exon 5 Ile115Ile Flanking domain Unknown 
 C > T Exon 5 Phe139Phe Flanking domain Unknown 
rs11557542 T > C Exon 5 Leu154Leu Flanking domain Unknown 
rs11557544 C > T Exon 7 Ala240Ala αβ barrel Unknown 
 C > T Exon 7 Leu263Phe αβ barrel MMF related leukopenia 
rs11557546 C > G Exon 9 Val305Val αβ barrel Unknown 
rs11557540 A > G Exon 11 Asp418Gly Active site flap Unknown 
rs1049818 C > T Exon 14 Phe514Phe αβ barrel Unknown 
 
Table 36 Clinical correlations and locations of the single nucleotide polymorphisms identified in 








Patients listed for deceased donor renal transplantation were identified and counselled for the 
purposes of this study. Informed consent was obtained in all cases. The study was approved by the 




All materials were obtained from Sigma Aldrich unless otherwise specified. 
 
5.2.3 DNA Extraction 
 
DNA was extracted using the solutions and protocol provided with the Wizard Genomic DNA 
Purification Kit (Promega, Southampton, Hampshire, UK). 5 mL of blood was collected in EDTA tubes. 
Erythrocytes, white blood cells and their nuclei were lysed. RNA was digested by RNAase followed by 
precipitation of cellular proteins. The remaining DNA in solution was then concentrated and desalted 
by an isopropanol precipitation. The DNA was rehydrated and its concentration determined by 
measuring absorption at 260 nm and its quality established by measuring the absorbance ratio 
between 260 and 280 nm. Each sample was diluted to a final concentration of 5 μg/mL with 










5.2.4 Primer Design 
 
Primer sequences were initially designed based on the published literature (270-271). However 
modification was required as several primer sequence pairs resulted in either no amplification 
product or several amplification products (Tables 37 and 38). In order to design primers of similar 
melting point, favourable GC content with suitable length and low propensity for dimerization, 
Primer 3 Input (v. 0.4.0) was utilized (274). 
 
5.2.5 Polymerase Chain Reaction 
 
IMPDH I and II were amplified by polymerase chain reaction (PCR) using custom primers (Invitrogen 
Paisley, Renfrewshire, UK) listed in tables 37 and 38 with the corresponding annealing temperature. 
The position of the primers in the IMPDH I and II genes is shown in Appendix 3. PCR was carried out 
using 50 ng of genomic DNA, 0.4 μmol/L of forward and reverse primer each and 10 μL of 500 
nmol/L AbsoluteTM QPCR ROX mix (Abgene, Epsom, Kent, UK) with a total volume of 22 μL. PCR 
protocol included 2 min of denaturation at 92 ˚C followed by 36 cycles of denaturation for 10 s at 92 
˚C, annealing for 30 s and extension for 7 min at 68 ˚C, followed by 10 min of elongation at 72 ˚C. 10 
μL of the sample was electrophoresed with 2 μL of loading buffer (40% glycerol, 10 mmol/L tris EDTA 
and 10 mg Brilliant Blue) on a 1% agarose gel supplemented with 2% ethidium bromide at 120 V for 








5.2.6 Gene Sequencing Of IMPDH I And IMPDH II 
 
For purification, 3 μL of genomic DNA and 2 μL of 1:10 dilution of EXOSAPITTM (1 U/μL of  
Exonuclease and 1 U/μL of shrimp alkaline phosphatase) (USB Affymetrix, Little Balmer, Buckingham, 
UK) were incubated at 37 ˚C for 15 min, followed by 80 ˚C for 15 min and 4 ˚C for 5 min. For direct 
DNA sequencing, 1 μL of Big Dye terminator Master Mix (v 3.1)TM (Applied Biosystems, Warrington, 
Cheshire, UK), 3 μL Better BufferTM (Applied Biosystems), 1 μL of the primer (10 μmol/L) and 1.5 μL of 
ultrapure water were added to each well. The primers used are listed in red in tables 36 and 37. If 
the amplification product size (PS) was greater than 400 bp then bidirectional sequencing using 
forward and reverse primers was performed. PCR conditions were incubation at 96 ˚C for 30 s, then 
50 ˚C for 15 s, 60 ˚C for 4 min and finally 4 ˚C for 2 min. The unincorporated Big DyeTM was removed 
by precipitation with 100% ethanol: 7.5 mol/ L Ammonium Acetate (33:1) and then washed with 
chilled 70% ethanol before rehydration with HiDi formamideTM (Applied Biosystems) and sequencing 
on the ABI 3700 sequencer (Applied Biosystems). SNPs were identified by transferring the 
chromatograms to sequence assembly software. Phred (version 0.990722.g) was used for base-
calling (275)., Phrap (version 3.01) for sequence alignment and contig assembly Polyphred (version 
3.5) for detecting SNPs (276) and Consed (version 9.0) for the (http://genome.washington.edu), SNP 
trace view (277). Each base call was compared with the consensus sequence and SNPs were 
confirmed by visual inspection of the chromatograms. If a SNP was identified, its presence was 
confirmed by repeated sequencing of the gene utilizing both forward and reverse primers. 
 
Each SNP found was analyzed in terms of its location within the gene and if it coded for an amino 
acid substitution. Subsequently, IMPDH activity was compared between patients with and without 




















1.1 1 GGCGCGGCGTCAGCAGTAGCAG TCGCCGTGCCACGTCCGTCTGCTC 56 64/71 72/70 367 
1.1 1 GGCGCGGCGTCAGCAGTAGCAG TCGCCGTGCCACGTCCGTCTGCTC 60 64/71 72/70 367 
1.1 1 GGCGCGGCGTCAGCAGTAGCAG TCGCCGTGCCACGTCCGTCTGCTC 65 64/71 72/70 367 
1.1 1 GGCGCGGCGTCAGCAGTAGCAG TCGCCGTGCCACGTCCGTCTGCTC 72 64/71 72/70 367 
1.1C 1 CCATGAATCAGAAGCAGT GCACCTAGGGGTACGAGACC 56 46/58 44/65 988 
1.1C 1 CCATGAATCAGAAGCAGT GCACCTAGGGGTACGAGACC 57 46/58 44/65 988 
1.1E 1 GGCAGAACCGTGTTAGAGGT CACATCTCCAGTTCCCACAC 53 54/54 55/55 923 
1.1E 1 GGCAGAACCGTGTTAGAGGT CACATCTCCAGTTCCCACAC 55 54/54 55/55 923 
1.1F 1 GTCAGCAGTAGCAGCAGCAG GCACCTAGGGGTACGAGACC 56 56/58 60/65 212 
1.1F 1 GTCAGCAGTAGCAGCAGCAG GCACCTAGGGGTACGAGACC 58 56/58 60/65 212 
1.2 2 ACCCCAGTAGACCTTTCGCT ATGCCCTGCCCCTGAGCAAG 56 70/74 54/58 323 
1.3 3 TGGGTGATAAACTCTTTAGCTGG GGAAGTGTGGTCAGAGCCG 56 70/72 53/55 255 
1.3 3 TGGGTGATAAACTCTTTAGCTGG GGAAGTGTGGTCAGAGCCG 58 70/72 53/55 255 
1.3 3 TGGGTGATAAACTCTTTAGCTGG GGAAGTGTGGTCAGAGCCG 60 70/72 53/55 255 
1.3B 3 ACTCTTTACGTGGGCTGTGC CCATGGTCAGTTCCTGTGTG 56 70/70 54/54 186 
1.4 4 CCGGCTCTGACCACACTT GCCTCTGAGGTGGGGACT 56 69/71 53/55 163 
1.3/4 3,4 ACTCTTTACGTGGGCTGTGC AAGGACACGCAGGGAGTGTA 55 60/70 54/54 441 
1.3/4 3,4 ACTCTTTACGTGGGCTGTGC AAGGACACGCAGGGAGTGTA 53 60/70 54/54 441 
1.5 5 GCTTTCTTCCAGCCTGTTCCT ACACCCAGCCCTGCTTCCC 56 71/74 54/58 281 
1.5 5 GCTTTCTTCCAGCCTGTTCCT ACACCCAGCCCTGCTTCCC 60 71/74 54/58 281 
1.5 5 GCTTTCTTCCAGCCTGTTCCT ACACCCAGCCCTGCTTCCC 65 71/74 54/58 281 
1.6 6 CCTTCTCTCTCACCTGCCAAC AACAACGGGACTGTGGAC 56 73/67 56/50 202 
1.7 7 AGTGGAATCTCTGGAGTGGTC CCTGGGTCCTCATAAACCTC 56 71/70 54/54 378 
1.8/9 8,9 TTCATCCACTCAGGCTCTCC CTGGGGAACAAAGGCGAGG 56 70/72 54/55 560 
1.10/11 10,11 ACACTCATCCTGGTGGTATTTG CCATCTGGGGAAGTCGGTG 56 69/72 53/55 643 
1.12 12 AAGAGGTGGGGTGGGGT CAAGGGTGGAGAAGAGCG 56 68/69 52/53 267 
1.12 12 AAGAGGTGGGGTGGGGT CAAGGGTGGAGAAGAGCG 58 68/69 52/53 267 
1.12 12 AAGAGGTGGGGTGGGGT CAAGGGTGGAGAAGAGCG 60 68/69 52/53 267 
1.12 12 AAGAGGTGGGGTGGGGT CAAGGGTGGAGAAGAGCG 65 68/69 52/53 267 
1.13 13 GCTTCCTTTCTCTCGCTCTTC ACCTCGCCAACCCACTGC 56 71/71 54/55 202 
1.14 14 GGGAAAGGGTTCTGGGAAG TGTGCCCAAAAGTGGACAC 56 70/68 53/51 153 
1.14B 14 TCTCAGGGCTTCTCAGCTCT CAGTTATGGAGGGAGGCTGT 56 70/70 54/54 219 
 
Table 37 Primers used for PCR amplification for IMPDH I gene  
1Ta-annealing temperature. 2Tm-melting temperature. 3Fp-forward primer. 
4Rp-reverse primer. 
5PS-









Exon Forward Primer (Fp) Reverse Primer (Rp) Ta
1˚C 
Tm










9&10 1 CTATACGCATGCGCTGTTTC TGAGATGCTTCTCCGTACCC 57 52/54 50/55 489 
9&13 1 CTATACGCATGCGCTGTTTC GCCCCCACTAATCAGGTAG 57 52/53 50/57 234 
14&15 1 CATGGCCGGACTACCTGATTA TTGTAGGTGAGGCCGTCT 57 54/50 52/55 99 
16&10 1 CAGCACAGCAGCTCTTCAAC TGAGATGCTTCTCCGTACCC 57 54/54 55/55 229 
17&18 1 GCTCTGGGTTTCCTTGAGTG ACTTGTAGGTGAGGCCGTCT 57 54/54 55/55 993 
19&20 1 GAAATCGGCTGGTTTATATTGG ACCGCTCCAGATGTCTCAAA 57 51/52 40/50 350 
7&8 2 TGTGCCTGATGGAATTCTTG CAAGCCCAATCTGGTGAGTT 57 50/52 45/50 1161 
11&12 2 TTGGTACATGGGGATGGAGT AGAGGAAACCAGTGGGGTCT 57 52/54 50/55 406 
5&6 3,4,5 TAAGGGATGCTTTCCCACACT CAGAAGCCCCTTGTGTTCAAC 57 52/54 47/52 929 




CCATGTGTTCCTCCATCTCAA CCCACCTGTCTGTTGAAAGAT 57 52/52 47/47 1020 
 
Table 38 Primers used for PCR amplification for IMPDH II gene  
1Ta-annealing temperature. 2Tm-melting temperature. 3Fp-forward primer. 
4Rp-reverse primer. 
5PS-




















5.3.1 Polymerase Chain Reaction  
The A260/280  ratio of isolated DNA ranged between 1.8-2 suggesting that the sample was sufficiently 
purified. Tables 38 and 39 show all the primers that were tested in order to amplify the two genes. 
The ones in bold were found to be successful and hence were used to amplify all DNA samples for 
IMPDH I and II. Tables 39 and 40 include the reasons for failure of some of the primer pairs and 
figures 45-54 denote the gel images of these amplification products. Unfortunately, it was not 





















˚C Result Figure 
1.1 1 GGCGCGGCGTCAGCAGTAGCAG TCGCCGTGCCACGTCCGTCTGCTC 367 56 1 PRODUCT-WRONG SIZE 45 
1.1 1 GGCGCGGCGTCAGCAGTAGCAG TCGCCGTGCCACGTCCGTCTGCTC 367 60 1 PRODUCT-WRONG SIZE  
1.1 1 GGCGCGGCGTCAGCAGTAGCAG TCGCCGTGCCACGTCCGTCTGCTC 367 65 1 PRODUCT-WRONG SIZE  
1.1 1 GGCGCGGCGTCAGCAGTAGCAG TCGCCGTGCCACGTCCGTCTGCTC 367 72 NO PRODUCT  
1.1C 1 CCATGAATCAGAAGCAGT GCACCTAGGGGTACGAGACC 988 56 NO PRODUCT 51 
1.1C 1 CCATGAATCAGAAGCAGT GCACCTAGGGGTACGAGACC 988 57 NO PRODUCT 51 
1.1E 1 GGCAGAACCGTGTTAGAGGT CACATCTCCAGTTCCCACAC 923 53 NO PRODUCT  
1.1E 1 GGCAGAACCGTGTTAGAGGT CACATCTCCAGTTCCCACAC 923 55 NO PRODUCT  
1.1F 1 GTCAGCAGTAGCAGCAGCAG GCACCTAGGGGTACGAGACC 212 56 SEVERAL PRODUCTS 49 
1.1F 1 GTCAGCAGTAGCAGCAGCAG GCACCTAGGGGTACGAGACC 212 58 SEVERAL PRODUCTS 52 
1.2 2 ACCCCAGTAGACCTTTCGCT ATGCCCTGCCCCTGAGCAAG 323 56 1 PRODUCT 45 
1.3 3 TGGGTGATAAACTCTTTAGCTGG GGAAGTGTGGTCAGAGCCG 255 56 2 PRODUCTS 45,46 
1.3 3 TGGGTGATAAACTCTTTAGCTGG GGAAGTGTGGTCAGAGCCG 255 58 2 PRODUCTS  
1.3 3 TGGGTGATAAACTCTTTAGCTGG GGAAGTGTGGTCAGAGCCG 255 60 NO PRODUCT 46 
1.3B 3 ACTCTTTACGTGGGCTGTGC CCATGGTCAGTTCCTGTGTG 186 56 1 PRODUCT 50 
1.4 4 CCGGCTCTGACCACACTT GCCTCTGAGGTGGGGACT 163 56 
1 PRODUCT, FAILED 
SEQUENCING 
45 
1.3/4  ACTCTTTACGTGGGCTGTGC AAGGACACGCAGGGAGTGTA 441 55 NO PRODUCT  
1.3/4  ACTCTTTACGTGGGCTGTGC AAGGACACGCAGGGAGTGTA 441 53 1PRODUCT 53 
1.5 5 GCTTTCTTCCAGCCTGTTCCT ACACCCAGCCCTGCTTCCC 281 56 SEVERAL PRODUCTS 45 
1.5 5 GCTTTCTTCCAGCCTGTTCCT ACACCCAGCCCTGCTTCCC 281 60 SEVERAL PRODUCTS  
1.5 5 GCTTTCTTCCAGCCTGTTCCT ACACCCAGCCCTGCTTCCC 281 65 1 PRODUCT 47 
1.6 6 CCTTCTCTCTCACCTGCCAAC AACAACGGGACTGTGGAC 202 56 1 PRODUCT 45 
1.7 7 AGTGGAATCTCTGGAGTGGTC CCTGGGTCCTCATAAACCTC 378 56 1 PRODUCT 45 
1.8/9 8,9 TTCATCCACTCAGGCTCTCC CTGGGGAACAAAGGCGAGG 560 56 1 PRODUCT 45 
1.10/11 10,11 ACACTCATCCTGGTGGTATTTG CCATCTGGGGAAGTCGGTG 643 56 1 PRODUCT 45 
1.12 12 AAGAGGTGGGGTGGGGT CAAGGGTGGAGAAGAGCG 267 56 SEVERAL PRODUCTS 45 
1.12 12 AAGAGGTGGGGTGGGGT CAAGGGTGGAGAAGAGCG 267 58 SEVERAL PRODUCTS  
1.12 12 AAGAGGTGGGGTGGGGT CAAGGGTGGAGAAGAGCG 267 60 SEVERAL PRODUCTS 47 
1.12 12 AAGAGGTGGGGTGGGGT CAAGGGTGGAGAAGAGCG 267 65 1 PRODUCT 48 
1.13 13 GCTTCCTTTCTCTCGCTCTTC ACCTCGCCAACCCACTGC 202 56 1 PRODUCT 45 
1.14 14 GGGAAAGGGTTCTGGGAAG TGTGCCCAAAAGTGGACAC 153 56 
1 PRODUCT, FAILED 
SEQUENCING 
45 
1.14B 14 TCTCAGGGCTTCTCAGCTCT CAGTTATGGAGGGAGGCTGT 219 56 1 PRODUCT 53 
 
Table 39 All primers tested in order to amplify IMPDH I  
1PS-product size. 2Ta-annealing temperature. Several primers were used to amplify IMPDH I gene. 
These primers are listed along with the number of resultant products and the figure number 

















9&10 1 CTATACGCATGCGCTGTTTC TGAGATGCTTCTCCGTACCC 489 57 NO PRODUCT  
9&13 1 CTATACGCATGCGCTGTTTC GCCCCCACTAATCAGGTAG 234 57 1 PRODUCT  
14&15 1 CATGGCCGGACTACCTGATTA TTGTAGGTGAGGCCGTCT 99 57 NO PRODUCT  
16&10 1 CAGCACAGCAGCTCTTCAAC TGAGATGCTTCTCCGTACCC 229 57 1 PRODUCT  
17&18 1 GCTCTGGGTTTCCTTGAGTG ACTTGTAGGTGAGGCCGTCT 993 57 NO PRODUCT  
19&20 1 GAAATCGGCTGGTTTATATTGG ACCGCTCCAGATGTCTCAAA 350 57 1 PRODUCT 54 
7&8 2 TGTGCCTGATGGAATTCTTG CAAGCCCAATCTGGTGAGTT 1161 57 NO PRODUCT  
11&12 2 TTGGTACATGGGGATGGAGT AGAGGAAACCAGTGGGGTCT 406 57 1 PRODUCT 54 
5&6 3,4,5 TAAGGGATGCTTTCCCACACT CAGAAGCCCCTTGTGTTCAAC 929 57 1 PRODUCT 54 




CCATGTGTTCCTCCATCTCAA CCCACCTGTCTGTTGAAAGAT 1020 57 1 PRODUCT 54 
 
Table 40 All primers tested in order to amplify IMPDH II  
1PS-product size. 2Ta-annealing temperature. Several primers were used to amplify IMPDH I gene. 
These primers are listed along with the number of resultant products and the figure number 

















Figure 45 IMPDH I gene products with annealing temperature of 56 °C (exons 1-14) 
Primers 1.2, 1.6, 1.7, 1.8/9, 1.10/11 and 1.13 correctly amplified exons 2, 6, 7, 8 and 9, 10 and 11 and 
13 respectively of IMPDH I gene. Primers 1.1 resulted in amplification of the wrong product size. 
Primers 1.3, 1.5 and 1.12 amplified several IMPDH I gene products.  
 
 
Figure 46 IMPDH I gene products with annealing temperature of 56 °C and 60 °C (exon 3) 
Primers 1.3 continued to amplify two products at 56 °C and no products at 60 °C 
 
1.1     1.2    1.3     1.4    1.5         1.6      1.7    1.8/9 1.10/11 1.12      1.13      1.14 




Figure 47 IMPDH I gene products with annealing temperature of 60 °C and 65 °C (exon 5 and 12) 
Primers 1.12 amplified several products at 60 °C and primers 1.5 were successful at amplification of 




Figure 48 IMPDH I gene products with annealing temperature of 65 °C (exon 12) 
Primers 1.12 were successful at amplifying exon 12 of IMPDH I at 65 °C. 
 






Figure 49 IMPDH I and II gene products with annealing temperature of 56 °C and 57 °C (exons 1, 
IMPDH I and exons 19 and 20, IMPDH II) 
Primers 1.1F resulted in several amplification products of IMPDH I at 56 °C and primers 19 and 20 
were successful at amplifying exon 1 of IMPDH II at 57 °C. 
 
 
Figure 50 IMPDH I gene products with annealing temperature of 56 °C (exons 1 and 3) 
Primers 1.1B amplified several products of IMPDH I at 56 °C. Primers 1.3B successfully amplified 
exon 3 of IMPDH I. 
1.1B 56°C 1.3B 56°C 




Figure 51 IMPDH I gene products with annealing temperature of 56 °C and 57 °C (exon 1) 






Figure 52 IMPDH I gene products with annealing temperature of 56 °C (exon 1) 











Figure 53 IMPDH I gene products with annealing temperature of 53 °C and 56 °C (exons 3 and 14) 
Primers 1.3/4 successfully amplified exon 3 and 4 of IMPDH I. Primers 1.14B successfully amplified 
exon 14 of IMPDH I. 
 
Figure 54 PCR amplification of IMPDH II gene 
Exon   1         2        3-5     6-9    10-14 
1.3/4 53°C 1.14B 56°C 
         1           2        3-5       6-9     10-14 
201 
 
5.3.2 Single Nucleotide Polymorphisms 
 
Sequencing Primer Exon Variant IMPDH I Wild Type SNP Patient ID 
Minor allele 
frequency 
1.8/9 8 Ala285Thr GCC ACC 171 0.9% 
1.7f 7 Leu244Leu TGC TCC 123,145,199 3.6% 
Table 41 SNPs identified in IMPDH I 
 
A nonsynonymous SNP, coding for the IMPDH I variant Ala285Thr (Table 41), was found in patient ID 
171 (heterozygote GA genotype) and is shown in figure 55. This patient had a low IMPDH activity 
which was quantified at 13 XMP nmoles/mg of protein/mL/h.  
 
Figure 55 SNP C to T (G to A on coding strand) in exon 8 of patient 171  
Patient 171 is heterozygous CT for the SNP. Patient 167 (homozygote CC) is shown for comparison. 
 
Variant Leu244Leu IMPDH I was found in patient IDs 123 (homozygote CC genotype), 145 
(heterozygote GC genotype) and 199 (heterozygote GC genotype) and is shown in figure 56 and 
table 41. There was no difference in IMPDH activity in each of the genotype groups for the 
Leu244Leu mutation (Table 42).  
 
Figure 56 SNP G to C in exon 7 of patients 123 (homozygote CC), 139 (heterozygote GG), 145 




















 GG (n=54) GC (n=2) and CC (n=1) p value 
Mean IMPDH activity  
XMP nmol/mg of 
protein/mL/h 
27.7 31.3 0.68 
 
Table 42 Mean IMPDH activity in genotype group for Leu244Leu variant of IMPDH I 




























Two single nucleotide polymorphisms, Leu244Leu and Ala285Thr were identified in IMPDH I 
following sequencing of the exons of IMPDH I and II in 55 patients listed for transplantation. The 
presence of the genetic variants was confirmed by repeated bidirectional sequencing. Patient ID 171, 
was found to be heterozygote for Ala285Thr IMPDH I variant had reduced enzyme activity which was 
below the 5th centile for this cohort of patients. Therefore it was hypothesized that Ala285Thr 
mutation is associated with decreased enzyme activity. Furthermore, this patient received a kidney 
transplant and required a dose reduction of MMF to 1 g daily because of recurrent bacterial 
infections. Due to time constraints, it was not within the scope of this thesis to express the mutant 
IMPDH in an IMPDH deficient strain of E. Coli to confirm reduction in enzyme activity. This work is 
ongoing in our laboratory. Ala285 is located within the α/β barrel of catalytic domain but is distant 
from the active site and does not interact with IMP or NAD during the conversion of IMP to XMP. It 
was originally found during a screen for polymorphisms in a control population for comparison with 
a cohort of patients suffering with retinitis pigmentosa and has a minor allele frequency of 0.004% 
(267). This low frequency, however, was not confirmed in a population of patients with renal disease 
and therefore its clinical relevance remains undetermined at the current time. To date, the enzyme 
activity of this mutation has not been evaluated in the published literature.  
 
Three patients were found to carry the C allele for the Leu244Leu IMPDH I variant. There was no 
difference in IMPDH activity between these patients and the rest of the cohort which is perhaps not 
surprising as this was a synonymous SNP. No patient in this cohort was identified with the variant 
IMPDH II Leu263Phe. This suggests that although this SNP may account for reduced IMPDH 




It could be expected that SNPs resulting in amino acid changes in key residues involved in interacting 
with either the dinucleotide cofactor or the substrate or that promote stability of the enzyme would 
affect enzyme activity. Furthermore, these residues could be exploited in order to develop improved 
inhibitors of IMPDH (15, 44, 46-49). 
 
This study was unable to identify a non-synonymous SNP that accounted for the 4-fold variation in 
enzyme activity and there may be several explanations for this. Firstly perhaps the SNPs resulting to 
differential activity are located in exon 1 of IMPDH I. Despite several attempts, it was not possible to 
amplify exon 1 of IMPDH I. The initial primers and PCR reaction was based on methods developed by 
Wang and colleagues (107, 270-271). In addition, primers were developed using the online program, 
Primer3 (v.0.4.0). It was attempted to maximize the favourable characteristics for primer formation 
and the PCR reaction. These include optimizing primer length, primer melting and annealing 
temperature. Moreover, the GC content was kept between 40 and 60% and attempts were made to 
minimize primer secondary structures (e.g. hairpins) from forming. Also repeat di-nucleotide 
sequences (for example ATATATAT) and runs of a single base were avoided as these can misprime 
and efforts were made to increase specificity of the primer so that other genes were not amplified. 
Finally, the PCR conditions were varied, in particular varying the annealing temperature, to attempt 
to improve the product. Despite these measures, it was not possible to amplify exon 1 of IMPDH I. 
 
Secondly, it may be that mutations in the introns of IMPDH I and II are related to the variation in 
enzyme activity. These mutations would not have been identified as only the exons were amplified 
and sequenced. Intronic SNPs may result in variable transcription of either gene and hence a change 
in protein expression as a consequence of mutations in the promoter sequences or related to 
transcription factors. In addition, intronic SNPs can affect the stability of mRNA and therefore affect 
protein expression (278). In order to investigate this further, the intron and promoter sequences 
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could be amplified and sequenced or the patients could be genotyped for known intronic SNPs. 
Thirdly, it may be that genetic variation is only partly responsible for differential enzyme activity and 
other factors, including transcription factor activity or metabolic conditions within the lymphocytes 
affects IMPDH activity prior to transplantation. However, to date there is no published literature to 
support this hypothesis.  
 
Finally epigenetic mechanisms such as DNA methylation, histone modification and RNA interference 
are known to affect gene expression and may occur following reperfusion injury during 
transplantation as well as with subsequent viral infections (279-280).  Furthermore there is evidence 
suggesting that DNA methylation and histone modification are related to expression of MHC 
molecules, which are essential for foreign antigen presentation (281). Perhaps therefore epigenetic 
phenomena, as yet uncharacterized, are responsible for the differential IMPDH activity seen. 
 
During the course of this work, studies revealing associations between SNPs in the intronic regions of 
IMPDH I and II and renal allograft outcome were published. It was therefore decided to concentrate 
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The impact of the more frequently occurring intronic SNPs is of increasing interest as they may be of 
clinical relevance. It has been proposed that the effect of intronic polymorphisms, not occurring at 
the intron-exon boundary, may be associated with susceptibility and stability of mRNA, presumably 
resulting in a shorter peptide or decreased amount of encoded protein (278). Furthermore intronic 
SNPs, discovered in population based genome studies have revealed susceptibility to particular 
diseases. For example, intronic SNP rs6495446 in the methenyltetrahydrofolate synthase gene is 
significantly associated with chronic kidney disease (282). 
 
6.1.1 Intronic and Promoter SNPs in IMPDH I and II 
 
It has been hypothesized that inter-individual variation in IMPDH enzyme activity and side effects 
caused by MMF may be related to SNPs in the IMPDH I and II genes and if so transplant recipients 
should receive personalized dosing regimens of MMF which would maximize efficacy and minimize 
toxicity. A substantial number of SNPs occurring in the introns of IMPDH I and II have now been 
described (84, 283-284). A small proportion of these SNPs are associated with a clinical outcome and 
are discussed below. 
 
Two SNPs occurring in intron 7 of IMPDH I (rs2278293 [C>T] and rs2278294 [G>A]) were found to be 
associated with a significantly lower risk for acute rejection in the first year following renal 
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transplantation (270). In a study of 191 patients, carriers of the variant allele (genotype CT and TT for 
rs2278293) had an odds ratio of 0.34 (95%CI 0.15-0.76 p=0.008) of experiencing acute rejection as 
compared to wild type patients (genotype CC) and the incidence of acute rejection was 10% 
compared to 25% respectively. Similarly genotype groups GA and AA (rs2278294) had an odds ratio 
of 0.40 (95%CI 0.18-0.89 p=0.02) compared to the GG group with an incidence of acute rejection of 
11% versus 23% (270). 
 
This effect was not substantiated in a cohort of Japanese patients where the risk of subclinical acute 
rejection with either of these IMPDH I variants was found to be similar (p=0.243 and p=0.735 for 
rs2278293 and rs2278294 respectively) at day 28 post-transplantation. However, carriers of the T 
allele of the rs2278293 with high night-time MPA exposure at day 28 (AUC >60 µg.h/mL and C0 ≥1.9 
µg/mL) had a reduced risk of subclinical acute rejection (p=0.019) (285), suggesting that the risk of 
acute rejection is associated not only with the presence of the SNP but also with MPA 
concentrations.  
 
In a recent study of 456 patients (recruited from the APOMYGRE (161) and FDCC trials (162), only 
IMPDH I variant, rs2278294 was associated with a reduced risk of acute rejection in the first year 
after transplantation and increased risk of leukopenia (283). The fact that acute rejection and 
leukopenia were found to be associated suggests that the SNP protects carriers from developing an 
immunological reaction to the transplanted kidney. Further studies have investigated the 
relationship of IMPDH polymorphisms in other areas of transplantation and have shown that those 
with genotype GG (rs2278294) were more likely to experience acute graft versus host disease 
following allogenic haematopoietic stem cell transplantation (286).  
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Analysis of 237 patients in the ‘Ciclosporin avoidance eliminates serious adverse renal toxicity’ 
(CAESER) study revealed a significant association between rejection and the variant A>G IMPDH II 
(rs11706052) (287). 28 renal transplant recipients carried the relevant polymorphism and the 
incidence of biopsy proven acute rejection by 12 months in this group was 46.4%, as compared to 
24.9% in the AA genotype group, giving an adjusted OR of 3.39 (95% CI 1.42-8.09), p= 0.006.  
 
The explanation for a possible association between the G allele in the variant IMPDH II gene 
(rs11706052) and an increased risk of acute rejection has been investigated by two studies. In the 
first, 19 of 100 healthy volunteers were found to carry the SNP and its presence reduced the anti-
proliferative effect of MPA on lymphocytes by approximately 50% compared with the IMPDH II wild 
type at therapeutic relevant concentrations of 10 and 25 µmol/L (288). A further study by 
Sombogaard and colleagues showed that 12 patients with the G allele of the variant IMPDH II gene 
(rs11706052) had 48% higher IMPDH activity, after intake of MMF, at day 6 post transplantation 
(40.8 v 24.5 µmol/s/mol AMP p=0.02) and a significantly increased AUC for IMPDH activity over 12 h 
(336 v 227 h µmol/s/mol AMP p=0.04) as compared to 89 patients with the AA genotype, with no 
difference in MPA exposure (289). Furthermore, one of the two patients found to be homozygous 
for the variant allele had the highest post-transplant IMPDH activity of the cohort. The authors 
suggested that this polymorphism accounted for 8% of the variation in inter-individual IMPDH 
activity. However, there was no impact of the polymorphism on the acute rejection rate possibly 
because the study was underpowered.  
 
In contrast, three further studies of 191, 456 and 177 patients did not demonstrate an association 
with acute rejection and carriage of the G allele (271, 283, 290). In the latter study the G allele was 
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associated with higher lymphocyte counts and lower risk of lymphopenia which may suggest 
activation of the immune system.  
 
SNPs in the promoter regions of IMPDH I and II have also been identified and their effects on 
transcription investigated. In a study of 96 Caucasian individuals, one patient was found to have a 
mutation affecting the transcription factor binding site, CRE, in the promoter sequence of IMPDH II (-
95T>G). Its functional relevance was examined in HEK293 and Jurkat cell lines which demonstrated 
that the -95T>G mutation led to a significant decrease in transcription of the IMPDH II gene (291-
292). 
 
A 9 base pair insertion (-92-83 GAGCAGTAG) in promoter 3 of IMPDH I was discovered in a patient 
suffering with inflammatory bowel disease who displayed resistance to azathioprine therapy. In a 
luciferase reporter gene assay, this led to significantly reduced promoter activity and transcription of 
the gene as the CRE was abolished (272). Another frequently occurring SNP in the promoter region 
of IMPDH II rs4974081 was studied in 456 patients (minor allele frequency of 24%) but was found 
not to affect acute rejection rates after renal transplantation (283). Finally IMPDH II promoter SNP 
IVS1 (93)G>C was found to be associated with decreased mRNA quantity in lymphoblastoid cell lines 
which may be as a result of disrupted binding of a transcription factor (284).  
 
In summary, the evidence for a relationship between polymorphisms in the IMPDH I and II genes and 
acute rejection remains ambiguous with studies providing conflicting results. Therefore, it was 
decided to investigate the clinical relevance of three frequently occurring intronic SNPs in the IMPDH 
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I (rs2278293 and rs2278294) and II (rs11706052) genes in a large cohort of patients after renal 





6.2.1 Single Nucleotide Polymorphisms in Collaborative Transplant Study 
 
6.2.1.1 Study Design 
The Collaborative Transplant Study (CTS), based at the University of Heidelberg, Germany, collates 
transplant-related information and DNA samples from voluntarily participating transplantation 
centres around the world with the goal of expanding scientific knowledge in the area of 
transplantation (www.ctstransplant.org). Written informed consent for the study was obtained from 
patients at the individual participating centres and approval for the study was granted by the 
University of Heidelberg ethical committee (application number 083/2005). The DNA samples and 
data on patients were collected between 1995 and 2007. All samples were genotyped in a blinded 
fashion in our laboratory and the results were analyzed independently at the study centre in 
Heidelberg, Germany, with respect to clinical outcome. 
 
6.2.1.2 Study Population 
The transplants were performed from 1995 through 2007 in Europe and North America and all 
patients received a calcineurin inhibitor (ciclosporin or tacrolimus) and MMF as part of their 
immunosuppressive regimen. Only DNA from White deceased donors and White recipients was 
available from the bank at the CTS facility. In the DNA bank, each recipient was assigned a patient 
identification number and the corresponding DNA sample was given a separate DNA identification 
number. Both identification numbers were assigned for processing purposes and were not known to 
anyone outside the computing department. The DNA used in this study was systematically, randomly 
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sampled on the basis of identification numbers. All patients with a patient identification number 
with a last digit of 2, 5, or 8 were chosen.  
DNA was isolated from buffy-coat or spleen specimens with the use of a salting-out method (293). 
Approximately 80% of the DNA samples were extracted by staff of the CTS and the remainder of 
samples was donated by the participating centres after isolation. 
 
6.2.1.3 IMPDH Genotyping 
Patients were genotyped for the three polymorphisms (Table 43) using the TaqMan allelic 
discrimination assay using the ABI 7900 Real-Time PCR system (Applied Biosystems). Two assay and 
allele specific oligonucleotide primers labelled with either FAMTM (6-carboxyfluorescein) or VIC® 
(chemical structure not publicly available) fluorescent dyes and a quencher 
(dihydrocyclopyrroloindole tripeptide) for each of the two SNPs tested were produced by Applied 
Biosystems. These probes specifically anneal to the region of DNA containing the SNP. As the pcr 
reaction progresses, Taq polymerase extends the primer and therefore degrades the probe which 
releases either the FAMTM or VIC® fluorescent dye and so removing the inhibitory effect of the 
quencher allowing fluorescence and detection of either FAMTM or VIC® when excited by the cycler’s 
light source. 
 
DNA samples were initially diluted in distilled water to give a final concentration range of 5 – 20 
ng/µL. 2 µL of this solution was added to a 384 well clear optical plate (1 dilution for each SNP) and 
dried in an oven for 24 h at 37 °C. 0.9 µL of reaction mixture was added to each well which consisted 
of the primers diluted 20-fold in distilled water followed by a one in two dilution in TaqMan 
Universal PCR Master Mix (Applied Biosystems). After brief centrifugation, PCR was commenced on 
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the ABI 7900HT Fast Real-Time PCR System. Cycles included one 2 min hold (50 °C); a 10 min 
denaturation (95 °C); and 40 cycles of denaturation (95 °C for 15 s), annealing and extension in one 
step (60 °C for 1 min). Fluorescence data were analyzed with ABI 7900HT Prism sequence detector 
software (SDS Version 2.3, Applied Biosystems) to indicate which alleles were present in each 
sample. Samples were then read for allelic discrimination by an observer blinded for clinical 
outcome, by measuring allelic-specific fluorescence using SDS 2.3 software for allelic discrimination 
(Applied Biosystems). The frequency of the genotypes did not deviate from the Hardy-Weinberg 














IVS 7 (+119) 579+119 
C>T rs2278293 




IVS 8 (-106) 580-106 
G>A rs2278294 
Intron 7 
 IMPDH I 
CCCACTGAGG[A/G]TCCTGGCTTC 40 
C1842928 
IVS 7 (10) 819+10 
A>G rs11706052 




Table 43 SNPs in the IMPDH I and II genes 
1Nucleotides within introns (IVSs) are numbered based in their distance from the nearest splice 
junction, with distances from the 3’-splice junctions assigned positive numbers and distances from 
the 5’ splice junctions assigned negative numbers. 2Human Genome Variation Society nomenclature 
system described by Ogino (2007). 3The current default global population is 1000Genome phase 1 






SNP Frequency p value 
rs2278293   
CC  314 (34%) 0.052 
CT 425 (46%)  
TT 187 (20%)  
rs2278294  0.74 
GG 300 (43%)  
GA 314 (45%)  
AA 87 (12%)  
rs11706052  0.24 
AA 689 (79%)  
AG 169 (19%)  
GG 15 (2%)  
 




6.2.1.4 Statistical Analyses 
Statistical analysis was performed with use of Statistical Package for the Social Sciences (SPSS) 
software, version 15, and R software, version 2.5. We combined the minor allele heterozygotes and 
homozygotes for simplicity and to allow comparison with previous publications. Hence for 
rs2278293 CT and TT genotype groups were compared to CC genotype. For rs2278293 GA and AA 
groups were contrasted with GG group and finally for rs11706052 AG and GG genotypes were 
evaluated against AA genotype. Genotype groups were compared by Chi-square analysis for 
categorical variables and by Mann-Whitney test for continuous variables. The Kaplan-Meier 
algorithm was used to compute survival among genotype groups. In order to determine whether the 
type of calcineurin inhibitor has an influence on the effect of the considered IMPDH genotype on 
renal allograft outcome, the subpopulations of the ciclosporin and tacrolimus patients were also 
analyzed separately. Cox regression analysis was performed adjusting for potential confounders 
(continent of residence, transplant year, transplant number, recipient and donor age and gender, 
cold ischemia time, number of HLA-A, -B, -DR mismatches, panel reactive antibody, primary renal 
disease, and initial immunosuppressive regimen) using a stepwise backward procedure. 
 
In order to detect a reduction in acute rejection rate of 10% in genotype groups CT and TT 
(rs2278293), GA and AA (rs2278293) and AG and GG (rs11706052), with 80% power, assuming an 
alpha error level of 5%, 157 patients would be required in each group. This sample size calculation 






6.2.2 Single Nucleotide Polymorphisms in IMPDH I and II Genes in Patient Samples 
6.2.2.1 Patients 
 
Patients listed for deceased donor renal transplantation were identified and counselled for the 
purposes of this study. Informed consent was obtained in all cases. The study was approved by the 
NHS Research Ethics Committee (05/Q0603/206) (Appendix 1). 
 
6.2.2.2 IMPDH Genotyping 
 
Genotyping of SNPs within the IMPDH I and II genes, (Table 43), was achieved by either custom 
made or commercially available kits from Applied Biosystems. 10 ng of genomic DNA was added to 
2.5 μL of TaqMan Universal PCR Master Mix (2x)TM and 0.125 μL of 40x SNP genotyping assay in 384 
well plates to make a final volume of 4.875 μL. PCR conditions and data analysis were as described 
previously (4.2 Methods).  
 
The presence of a SNP was then investigated for association with variables including ethnicity, 
gender, primary renal disease and pre-transplant IMPDH activity. In addition, in the patients who 
subsequently received a kidney transplant at the Royal London Hospital, potential associations with 
MMF dose reduction was investigated. These patients received immunosuppression medication and 
post-transplant care as described previously (4.3 Results).  
 
6.2.2.3 Statistical Analyses 
 
The statistical analyses investigating the potential associations of SNPs identified in IMPDH I and II 
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from patients awaiting transplantation at the Royal London Hospital included Student’s t test and 
ANOVA for continuous variables and Chi-square tests for categorical variables. All analyses were 







6.3.1 Single Nucleotide Polymorphisms In Collaborative Transplant Database 
6.3.1.1 IMPDH I C>T (rs2278293) 
 
Baseline characteristics of the patients in each genotype group were similar (Table 45) apart from an 
increased proportion of patients with the CC genotype of IMPDH I residing in Europe compared to 
North America. The mean post-transplant follow-up period for patients was 4.9 years. There were 
314 patients with a CC genotype of IMPDH I, 425 were heterozygote (CT) and 187 were homozygote 
(TT) and the allelic discrimination plot is shown in figure 57. Therefore the minor T allele frequency 
was 43%. Kaplan-Meier plots of death-censored graft survival were similar for the two groups (CC 
versus CT+TT) (Figure 58, p=0.51). Cox regression analysis confirmed that both genotype groups had 
similar death censored graft survival (p=0.59) and patient survival at 5 years (p=0.095, Table 45) and 
no association with the type of calcineurin inhibitor and graft survival was found. Moreover, there 
was no difference in rejection rates between patients carrying the T allele compared to the CC 
genotype of IMPDH I (Figure 59, p=0.70). For CC genotype group data were only available on 180 
patients (57%) and for CT and TT genotype groups data were only available on 312 patients (51%). 
Furthermore, there was no disparity in graft function at 1 year as measured by the percentage of 
patients with a serum creatinine greater than 130 µmol/L (46.9% for CC v 49.9% for CT+TT, p=0.51). 
However for those with CC genotype, creatinine data were available only in 192 patients (61%) and 
for genotype CT and TT data were only available in 345 patients (56%). The MMF doses tolerated at 
1 year were similar in both groups (ciclosporin patients: median 24.4 mg/kg/day for CC v 23.5 
mg/kg/day for CT+TT, p=0.24; tacrolimus patients: 14.6 mg/kg/day for CC v 15.6 mg/kg/day for 
CT+TT, p=0.63) as was the MMF dose achieved at 3 years (ciclosporin patients: median 20.8 
mg/kg/day for CC v 21.7 mg/kg/day for CT+TT, p=0.46; tacrolimus patients: 13.7 mg/kg/day for CC v 
14.7 mg/kg/day for CT+TT, p=0.90). Further analysis for subpopulations of ciclosporin or tacrolimus 
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patients demonstrated that the different dose of MMF did not influence the results between CC and 
CC+TT groups (5 year death censored graft survival: ciclosporin patients p=0.26, tacrolimus patients 















Characteristic CC n=314 CT+TT n=612 p value 
Geographic origin 
 Europe 


















































Recipient age (y) 49.5 ± 13.0 48.3 ± 13.7 0.19 
Donor age (y) 45.9 ± 16.5 45.1 ± 17.2 0.45 







































































































































































Table 45 Characteristics of study population for IMPDH I variant (rs2278293) 








5 year Graft Survival 
HR (95% CI) 
5 year Death Censored 
Graft Survival 
HR (95% CI) 
5 year Patient Survival 
HR (95% CI) 
rs2278293 














































6.3.1.2 IMPDH I G>A (rs2278294) 
There were 300 patients with genotype GG, 314 patients with genotype GA and 87 patients with 
genotype AA giving a minor A allele frequency of 35%. Figure 60 shows the allelic discrimination plot. 
Baseline characteristics of the patients were similar apart from patients with GG genotype received 
their allograft from an older donor and experienced a shorted cold ischaemia time (Table 46). 
Kaplan-Meier plots for death censored graft survival are shown in figure 61. After 2 years group GG 
had significantly impaired death censored graft survival (p=0.03). However by 5 years death 
censored graft survival was similar (p=0.24). In multivariable Cox regression analysis, 5 year graft and 
patient survival was comparable (Table 45) and no association with the type of calcineurin inhibitor 
and graft survival was found. No significant difference in the percentage of patients treated for acute 
rejection was found (p=0.37, Figure 62). However for GG genotype group data were only available 
on 154 patients (38%) and for GA and AA genotype groups data were only available on 222 patients 
(74%). Serum creatinine greater than 130 µmol/L (51.5% for GG v 50.2% for GA+AA, p=0.80) was 
comparable but data were only present in 165 patients (41%) of GG genotype group and 237 
patients (79%) in GA and AA genotype groups. MMF dose at 1 year (ciclosporin patients: median 
24.1 mg/kg/day for GG v 23.5 mg/kg/day for GA+AA, p=0.76; tacrolimus patients: 13.9 mg/kg/day 
for GG v 15.5 mg/kg/day for GA+AA, p=0.52) and MMF dose at 3 years (ciclosporin patients: median 
22.2 mg/kg/day for GG v 23.3 mg/kg/day for GA+AA, p=0.94; tacrolimus patients: 13.3 mg/kg/day 
for GG v 14.4 mg/kg/day for GA+AA, p=0.28) were similar. Further analysis for subpopulations of 
ciclosporin or tacrolimus patients demonstrated that the different dose of MMF did not influence 
the results between GG and GA+AA groups (5 year death censored graft survival: ciclosporin patients 







Characteristic GG n=300 GA+AA n=401 p value 
Geographic origin 
 Europe 


















































Recipient age (y) 48.6 ± 13.5 48.8 ± 13.0 0.99 
Donor age (y) 47.2 ± 16.2 45.0 ± 16.4 0.05 













































































































































Table 47 Characteristics of study population for IMPDH I variant (rs2278294) 






















6.3.1.3 IMPDH II A>G (rs11706052) 
  
There were no significant differences in baseline characteristics among the patients in the genotype 
groups (Table 47). There were 689 patients with the AA genotype of IMPDH II, 169 who were 
heterozygous AG, and only 15 patients who were homozygous GG. The allelic discrimination plot is 
shown in figure 63. The minor G allele frequency was 11%. Kaplan-Meier plots and Cox regression 
analysis for death-censored graft survival were comparable in the two genotype groups (Figure 64, 
p=0.64; Cox regression p=0.58, Table 45) and no association with the type of calcineurin inhibitor 
was found. Furthermore, Cox regression analysis of 5 year patient survival was similar (p=0.94) 
(Table 45). In addition, carriage of the G allele did not increase the risk for rejection (Figure 65, 
p=0.35) although data were only available in 340 patients (49%) with AA genotype and 88 patients 
(48%) with AG and GG genotype. Graft dysfunction as measured by the percentage of patients with a 
serum creatinine at 1 year greater than 130 µmol/L (47.9% for AA v 49.5% for AG+GG, p=0.77) was 
similar. For AA genotype group data were available in 601 patients (87%) and for AG and GG 
genotype groups data were available on 163 patients (89%). There was no difference in the MMF 
dose tolerated at 1 year (ciclosporin patients: median 23.0 mg/kg/day for AA v 24.5 mg/kg/day for 
AG+GG, p=0.44; tacrolimus patients:14.9 mg/kg/day for AA v 14.9 mg/kg/day for AG+GG, p=0.23) or 
at 3 years (ciclosporin patients: median 21.6 mg/kg/day for AA v 21.7 mg/kg/day for AG+GG, p=0.86; 
tacrolimus patients:14.3 mg/kg/day for AA v 14.7 mg/kg/day for AG+GG, p=0.66). Further analysis 
for subpopulations of ciclosporin or tacrolimus patients demonstrated that the different dose of 
MMF did not influence the results between AA and AG+GG groups (5 year death censored graft 
survival: ciclosporin patients p=0.78, tacrolimus patients p=0.90; 1 year rejection rate: ciclosporin 






Characteristic AA n=689 AG+GG n=184 p value 
Geographic origin 
 Europe 


















































Recipient age (y) 49.1 ± 13.6 48.2 ± 12.8 0.30 
Donor age (y) 45.4 ± 17.0 44.6 ± 18.1 0.71 





























































































































































Table 48 Characteristics of study population for IMPDH II variant (rs11706052) 































6.3.2 Single Nucleotide Polymorphisms in IMPDH I and II in Patient Samples 
 
6.3.2.1 IMPDH I C>T (rs2278293) 
 
Genotyping was possible in 53 patients and all were found to have genotype CC. 
 
6.3.2.2 IMPDH I G>A (rs2278294) 
 
Genotyping was possible in 20 patients. There were 12 patients with genotype GG and 8 were 
heterozygote for this IMPDH II variant (GA). No patients were found to be homozygote (AA). 
Therefore the minor allele frequency was 20%. 11 patients had received a kidney transplant by 
March 2012. 10 patients had 1 year follow up data as 1 patient died with a functioning graft in the 
first year after transplantation. There was no association between baseline variables including pre-
transplant IMPDH activity and IMPDH I genotypes. In addition after transplantation, MMF related 
side effects and dose achieved at 1 year were not related to genotype group (Table 48).  
 
6.3.2.3 IMPDH II A>G (rs11706052)  
 
Genotyping was successful in 55 patients. There were 49 patients with genotype AA and 6 were 
heterozygote for this IMPDH II variant (AG). No patients were found to be homozygote (GG). This 
gives a minor allele frequency of 5%. 27 patients received a transplant by March 2012. One patient 
received a kidney pancreas transplant at another centre and remained under follow-up there. One 
patient enrolled onto another study and received AdvagrafTM (Astellas Pharma UK Limited, 
Camberley, Chertsey, UK). These two patients were excluded from this study. Further analysis of 17 
patients with greater than 1 year follow-up data (i.e. patients and grafts that survived more than 1 
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year or patients who received a transplant before March 2011) revealed a significant difference in 
primary renal disease in patients in the genotype groups (Table 48). There was no association 
between genotype and pre-transplant IMPDH activity. In addition after transplantation, patients 
with genotype group AG were significantly more likely to experience gastrointestinal side effects 
with MMF therapy. However, this did not result in a difference in MMF dose achieved at 1 year 
(Table 48).  
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 rs2278294 rs11706052 
Baseline Variable GG GA P value AA AG p value 
Gender   0.69   0.06 
Males (%) 8 (40) 6 (30)  31 (56) 3 (5)  
Females (%) 4 (20) 2 (10)  18 (33) 3 (5)  
Ethnicity   0.90   0.30 
White (%) 5 (25) 3 (15)  14 (25) 3 (5)  
Asian (%) 5 (25) 3 (15)  22 (40) 3 (5)  
Black (%) 2 (10) 2 (10)  13 (24) 0  
Primary Renal Disease   0.52   <0.01 
APKD (%) 1 (5) 1 (5)  0 (0) 2 (4)  
Congenital (%) 0 (0) 0 (0)  1 (2) 0 (0)  
Diabetes Mellitus (%) 4 (20) 2 (10)  17 (31) 0 (0)  
Glomerulonephropathy (%) 3 (15) 2 (10)  12 (22) 2 (4)  
Hypertension (%) 0 (0) 0 (0)  5 (9) 0 (0)  
Tubulointerstitial Nephritis (%) 1 (5) 3 (15)  9 (16) 1 (2)  
Other (%) 1 (5) 0 (0)  1 (2) 0 (0)  
Unknown (%) 2 (10) 0 (0)  4 (7) 1 (2)  
Dialysis Modality   0.22   0.94 
Haemodialysis (%) 10 (50) 8 (40)  40 (73) 5 (9)  
Peritoneal Dialysis (%) 2 (10) 0 (0)  8 (15) 1 (2)  
Pre-Dialysis (%) 0 (0) 0 (0)  1 (2) 0 (0)  
IMPDH Activity XMP nmoles/mg 
of protein/mL/h ±SD 
26.90±7.62 26.33±7.22 0.77 23.22±8.35 26.20±6.25 0.48 
Acute rejection   N/A   0.63 
No 7 (70) 3 (30)  13 (76) 3 (18)  
Yes 0 (0) 0 (0)  1 (6) 0 (0)  
Infection   0.24   0.20 
No (%) 2 (20) 0 (0)  1 (6) 1 (6)  
Yes 5 (50) 3 (3)  13 (76) 2 (12)  
Gastrointestinal side effects 
with MMF 
  N/A   0.01 
No (%) 7 (70) 3 (30)  13 (76) 1 (6)  
Yes (%) 0 (0) 0 (0)  1 (6) 2 (12)  
Leukopenia related to MMF   0.55   0.21 
No (%) 4 (40) 3 (30)  10 (59) 1 (6)  
Yes (%) 3 (30) 0 (0)  4 (24) 2 (12)  
MMF dose at 1 year   0.30   0.22 
≤1 g MMF (%) 5 (50) 3 (30)  9 (53) 3 (18)  
≥2 g MMF (%) 2 (20) 0 (0)  5 (29) 0 (0)  
 











Utilizing the DNA bank at the CTS and the patients listed for renal transplantation at the Royal 
London Hospital, the effects of three polymorphisms in the IMPDH I and II genes were evaluated in 
the largest cohort of patients studied to date with the longest duration of follow-up. The presence of 
either the T allele in the rs2278293 variant of IMPDH I, G allele in the rs2278294 variant of IMPDH I 
or the G allele in the rs11706052 variant of IMPDH II had no significant impact on acute rejection, 
MMF dose tolerated and graft function at 1 year and graft survival at 5 years. Of interest, we found a 
significant difference in 2 year death censored graft survival for patients carrying the A allele for the 
IMPDH I variant rs2278294 but this was not demonstrable at 5 years which highlights the 
importance of studies with a long follow-up period. Furthermore, in subgroup analyses, there was no 
difference in outcome associated with the type of calcineurin inhibitor therapy. Finally no 
association between genotype and pre-transplant IMPDH activity was demonstrated for these 
IMPDH I and II variants. 
 
Several smaller studies have shown an association between these SNPs and acute rejection after 
renal transplantation. It is, therefore, important to replicate these studies in a larger cohort to either 
validate or refute previous findings. There are several differences between previously published 
studies and this study that may, in part, account for the differential results. The previous study of 
191 patients, excluded those patients who received MMF therapy for less than one year and who 
lost their graft within the first year after transplantation, and hence the effect of the polymorphism 
on these outcome variables has been discounted (270). In contrast, our much larger study did not 




All the patients in the CAESER trial were selected for low immunological risk and included a more 
ethnically diverse population and kidneys from living as well as deceased donors (287). This is in 
contrast to our study which only included transplant recipients of deceased donor kidneys. 
Furthermore patients in the CAESER study who experienced acute rejection were also found to be 
receiving lower doses of MMF which may have contributed to the findings. In addition, the authors 
only considered a few demographic covariates (age, gender, treatment group and donor type) in 
their multivariate analysis. In contrast our study adjusted for a much wider range of factors. 
Sombogaard and colleagues demonstrated a potential mechanism for increased lymphocyte 
proliferation in patients with the IMPDH II SNP as these patients had higher IMPDH activity (289). 
However, the increased activity of the enzyme did not result in acute rejection rates and this 
therefore confirms the unimportance of this SNP on graft outcome.  
 
Several factors must be taken into consideration when interpreting the results of this study. Firstly, 
patients of White ethnicity were included exclusively and therefore the potential effect of this 
polymorphism in non-white ethnic groups cannot be commented on. Baseline differences in the 
genotype groups were noted and it is difficult to predict whether these variations would significantly 
impact outcome. For example for rs2278293, more patients in the CT and TT groups resided in North 
America rather than Europe. Medical practices do vary geographically and therefore could affect 
treatment of acute rejection and alteration of MMF dose. In the rs2278294 study, patients with the 
A allele were more likely to have received their allograft from a younger donor and have a longer 
cold ischaemia time which may be associated with the risk of developing of acute rejection. 
 
A further consideration is the completeness of the information regarding treatment of acute 
rejection, serum creatinine and MMF dose at 1 year. Substantial number of patients did not have 
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information regarding these variables available at the time of analysis as shown in the figures 63-65, 
68-70,73-75. However, it is likely that missing data would affect the genotype groups equally and 
therefore unlikely to bias our results. Furthermore graft survival data is arguably the most relevant 
outcome and these records were complete. Genotyping was not technically possible on all the 
samples perhaps related to degradation of the DNA.  
 
Given that MPA exposure also varies considerably between patients, it has been hypothesized that 
perhaps SNPs in the enzymes involved in MPA metabolism may affect drug exposure and 
subsequently graft outcome. There is evidence that carriers of SNPs in the UGT1A9 (-275T>A 
rs6714486 and/or -2152C>T rs17868320), the main enzyme involved in the glucuronidation of MPA, 
result in a 20% lower MPA exposure which is associated with a 13-fold increased risk of rejection 
(p=0.04) in patients receiving concurrent tacrolimus therapy (but not ciclosporin) following kidney 
transplantation (294).  
 
It is possible that SNPs in these enzymes are clinically more relevant that SNPs in the IMPDH genes 
and therefore the results of this study may need to be evaluated with the knowledge of SNPs in the 
MPA metabolizing enzymes. Alternatively perhaps prescription of MMF in a concentration controlled 
manner may be associated with the effects of SNPs in the genes of the IMPDH and MPA 
metabolizing enzymes (161-162). For example, it was found that carriers of the T allele in the IMPDH 
I variant with a high night time MPA exposure at day 28 had a significantly reduced risk of rejection 
(285). Unfortunately, we were unable to investigate this hypothesis as MPA concentration, MMF 
related side effects and reason for dose alterations were not available for this study. However we 
note that the MMF dose at 1 year was comparable in the genotype groups for each SNP which may 
suggest that no particular genotype was associated with increased MMF related side effects.  
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In addition, no association between acute rejection rates, MMF dose tolerated at 1 year, pre-
transplant IMPDH activity and IMPDH I variant (rs2278294) or IMPDH II variant (rs11706052) was 
found in patient samples from the Royal London Hospital. Interestingly patients carrying the G allele 
of the IMPDH II variant (rs11706052) were more likely to suffer with gastrointestinal side effects 
related to MMF therapy. However, although other investigators have demonstrated an increased 
IMPDH activity and risk of leucopenia in this IMPDH II variant, this was not confirmed in this study 
(289-290). A limitation of this aspect of the study was the small number of patients who had 
received a kidney transplant. Further long term data on patients with measured pre-transplant 
IMPDH activity will be collected and analyzed. In addition, DNA samples were limited as some had 
either degraded or were insufficient as they had been utilized for sequencing (chapter 5). 
This study has investigated the relationship between three frequently occurring polymorphisms in 
the IMPDH I and II genes. These SNPs have been the subject of a number of recent studies. Our 
results represent the largest cohort of patients with the longest follow-up to date. We have shown 
that there is no association between these IMPDH I and II SNPs and acute rejection but more 
importantly graft survival. Although the ultimate clinical relevance of these polymorphisms can only 
be evaluated in prospective randomized controlled trials, we suggest that the currently available 
evidence does not support routine screening of patients for these SNPs. The search for 











The aim of this study was to evaluate the long term benefits of MMF in renal transplantation in the 
UK and to determine whether MMF dose could be personalized according to pre-transplant IMPDH 
activity and genotype in order to increase tolerability and improve acute rejection rates and renal 
allograft outcome.  
 
A paired kidney analysis of the national database held at NHS Blood and Transplant demonstrated 
that treatment with MMF has not improved graft survival in the UK compared to azathioprine. 
Moreover, a significantly larger proportion of patients required a dose reduction in MMF therapy 
compared to azathioprine during the first year after transplantation and this was associated with 
adverse graft outcome particularly if the dose of MMF was less than 1 g at the end of the first year of 
transplantation. MMF tolerability varied with ethnicity and gender as Black patients were able to 
tolerate higher doses of MMF compared to patients of other ethnicities and White males managed 
higher doses compared to their counterpart females.  
 
In 55 patients listed for renal transplantation pre-transplant IMPDH activity varied 4-fold and Black 
males was found to have significantly higher enzyme activity than Black females. The patient with 
the highest pre-transplant IMPDH activity was unable to tolerate 2 g of MMF per day after 
transplantation and was the only patient in this cohort to experience an episode of acute rejection. 
There was no association between MMF dose achieved at 1 year and pre-transplant IMPDH activity 
and enzyme activity was not linked to graft survival or function. Sequencing of the IMPDH I and II 
genes in these patients revealed the presence of two exonic SNPs, Leu244Leu and Ala285Thr, in 
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IMPDH I. The patient carrying the latter SNP had an IMPDH activity in the 5th centile for the cohort 
and required a dose reduction in MMF therapy after transplantation. Intronic SNPs rs2278293, 
rs2278294 in IMPDH I and rs11706052 in IMPDH II genes were found not to correlate with pre-
transplant IMPDH activity, acute rejection, graft function or survival or MMF dose tolerated after 
transplantation. 
 
In summary these findings demonstrate that MMF has not been shown to be superior to 
azathioprine in renal transplantation in the UK. The inter-individual variation in pre-transplant 
IMPDH activity has been confirmed but at the current time cannot be used to guide MMF dosing 
strategies. However, patients with high enzyme activity, who do not tolerate full dose MMF therapy, 
may be at increased risk of acute rejection. These results suggest that Ala 285Thr mutation may be 
linked with reduced enzyme activity. 
 
Further work would include measuring pre-transplant IMPDH activity in more patients listed for 
renal transplantation to confirm the ethnicity and gender correlations as well as to determine 
whether the effect of patients with high IMPDH activity and dose reduction is consistent. In addition, 
it would be interesting to determine whether Ala285Thr is associated with low IMPDH activity and 
graft outcome in a larger cohort of patients. Due to time constraints it was not possible to study the 
effects of this mutant IMPDH in an IMPDH deficient strain of E. Coli to confirm reduction in enzyme 
activity. This work is ongoing in our laboratory at the current time. 
 
Technical difficulties resulted in an inability to sequence exon 1 of IMPDH I and therefore the search 
for exonic SNP to account for differential IMPDH activity remains incomplete in this thesis. 
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Furthermore, it would have been interesting to sequence promoter regions and study the effects of 
these and other intronic SNPs in the large CTS DNA bank.  
 
This study has focused on renal transplantation but could be expanded to include MMF treated 
recipients of other solid organ transplants and patients suffering with other immunological diseases, 
for example, lupus nephritis. It is likely that in these groups of patients, MMF pharmacokinetics is 
altered and baseline IMPDH activity may also differ. 
 
The strengths of this study are the inclusion of large number of patients in the analyses of long term 
graft outcome by utilization of national and international databases. Clinical practice is often altered 
in the basis of published trials with small numbers of patients with short duration of follow-up. This 
study has demonstrated the value of monitoring large numbers of patients over a relatively long 
duration in order to confirm benefits of treatment rather than using surrogate markers such as acute 
rejection for graft survival. In this era of austerity, it is imperative that treatment options are 
evaluated fully before adoption in routine clinical practice. However registry analyses is limited by its 
retrospective nature and cannot demonstrate causality and this needs to be taken into account 
when interpreting this data. 
 
This work is restricted by the small number of patients in whom it was possible to measure IMPDH 
activity. This was due to the intensive and time-consuming nature of establishing and performing the 
enzyme assay perhaps suggesting that routine measurement of IMPDH activity is not feasible in a 
clinical environment. It is difficult to judge whether a larger cohort of patients would have clarified 
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the relationships between gender, ethnicity and pre-transplant IMPDH activity. Further observation 
of the cohort of patients is continuing to determine transplant outcomes. 
 
In conclusion, optimizing MMF therapy in renal transplantation is likely to require a comprehensive 
knowledge of pre- and post-transplant IMPDH activity in combination with MPA concentrations. This 
will need to be in conjunction with the effects of other concurrent immunosuppressive therapy and 
will therefore require several pre- and post-transplant investigations of the transplant recipient. This 
will need an economic evaluation before it can be introduced into clinical care. Although clinically 
attractive, it seems unlikely that single factor such as a SNP in the IMPDH genes will have a 
significant effect on graft outcome. However, in order to reduce morbidity and mortality related to 











8.1 Appendix 1 




































































































8.1.2 Patient Information Form 
 
 
A research project aiming to optimize the dosing regime of drugs needed for 
your future kidney transplant 
Barts and The London NHS Trust 
 Invitation to Participate in a Research Project 
 We invite you to take part in a research study which we think may be important. The 
information which follows tells you about it.  It is important that you understand what is in 
this leaflet. It says what will happen if you take part and what the risks might be. Try to 
make sure you know what will happen to you if you decide to take part. Whether or not you 
do take part is entirely your choice. Please ask any questions you want to about the 
research and we will try our best to answer them. 
 What is the study about? 
  As you know when you receive a kidney transplant you will be on drugs to prevent 
rejection of your transplant.  Mycophenolate mofetil and Myofortic are drugs which inhibit 
an enzyme involved in causing rejection.  As the activity of the enzyme varies from person-
to-person, the dose of the drugs needed to achieve maximum benefit also varies.  This 
study aims to characterize whether your enzyme has high, medium or low activity.  By 
studying your gene sequence, we hope to understand the factors that determine the 
activity of your enzyme.  In the long term we hope this will lead to personalized dosing 
regimens for these drugs. 
 Why have I been asked? 
It is important to determine the activity of the enzyme in patients’ with renal failure.  As 
you are also on the transplant waiting list, you need to have regular clinic visits and 
blood tests taken.  We would like to take some blood from you with the aim of gaining 
knowledge for future transplant recipients. 
What does it involve? 
On your next visit to clinic we would like to take 20 mls of blood.  The bloods will taken at 
the time of your routine blood tests, so it will not involve any additional visits to the 
hospital or blood tests.  No further blood tests will be required. 
Will the information remain confidential? 
Your confidentiality will be protected and all information stored under the Data Protection 
Act, 1998. Only the principal investigator or others associated with the study will have 
access to your records.  
272 
 
You don’t have to join the study. You are free to decide not to be in this trial or to drop 
out at any time.  If you decide not to be in the study, or drop out, this will not put at risk 
your ordinary medical care.  
What are the benefits for me if I take part in the study? 
There are no immediate benefits as there is a lot more work that needs to be done and 
we are not sure if we will find what we are looking for. The study will give us a better 
understanding of what is involved in this process and one day in the future may lead to 
better treatment.  Although the results of the study will have no impact on your well 
being or treatment you can obtain the results if you chose by contacting Dr Sapna 
Shah (details below). 
           What happens if you are worried or if there is an emergency?  
You will always be able to contact the investigator to discuss your concerns and/or to get 
help. 
  
  Name:  Dr Sapna Shah 
 Address:   Renal Unit 
   Royal London Hospital  
   Whitechapel, 
   London 
   E1 1BB 
 Telephone number:  02073777480 
 
We believe that this study is basically safe and do not expect you to suffer any harm or 
injury because of your participation in it. However, Barts and The London NHS Trust 
has agreed that if your health does suffer as a result of your being in the study then 
you will be compensated. In such a situation, you will not have to prove that the harm 
or injury which affects you is anyone’s fault. If you are not happy with any proposed 
compensation, you may have to pursue your claim through legal action. 
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8.1.3 Consent Form 
CONSENT FORM 
 
TO BE USED WHERE AN OPERATION OR INVESTIGATION WILL 
INVOLVE REMOVAL AND STORAGE OF TISSUE, ORGANS OR 
BODY PARTS FROM THE PATIENT 
 
 
Three copies of this form should be signed.  
One should be given to the patient, one filed in the hospital notes, and one retained by the 
researcher. 
 
Patient’s details:  Name ………………………………………………………………………………………………. 
 
   Hospital number …………………………………………………………………………………… 
 
   D.O.B ……………………………………………………………………………………………… 
 
Patient’s condition requiring treatment ………………………………………………………………………………………… 
 
 
Intended operation / investigation ……………………………………………………………………………………………… 
 
Tissue, organs or body parts involved …………………………………………………………………………………………. 
 
Blood will taken for your routine blood tests at your clinic appointment.  This is routine practice, 
essential for diagnosis and planning further treatment.  The aim of this form is to ask whether we 
may keep some of the blood taken for use in our research.  
 
In our department we carry out research on kidney disease.  In your particular case, examples of the 
type of research we might plan include testing DNA (gene testing) and analyzing chemicals made by 
the cells in the sample. 
 
By signing this form, you will only be giving us permission to store your tissue for future research of 
this type.   Any use that we may want to make of it in the future will have first to be approved by our 
local Research Ethics Committee, which is an independent panel of experts who assess all research 
projects for safety, ethical acceptability and who protect patients’ interests. Most of the work that 
we envisage will have no direct implications for your personal health. This may be because the tissue 
cannot be identified as yours, or it may simply be because of the type of research involved.  
 
However, in some circumstances we may wish to use tissue which we can link back to you and your 
clinical record. Such research may have direct consequences for you or for your family. If it does, we 
would first ask the Research Ethics Committee and having obtained their approval for the research; 
we would always come back to you to explain the implications, and would then ask your consent to 
proceed. You would of course have the opportunity to refuse permission at that stage. If we do not 
believe our research will have implications for you or your relatives, and the Research Ethics 
Committee approves the research without your further consent, then we will not ask your 
permission.  
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Further details of the type of research we do are on the other side of this page, and will be explained 
to you by the doctor signing the form.  
 
The information obtained from our research could be published in scientific journals and discussed at scientific 
and medical conferences.  It would be completely anonymous.  If we decided that it would be helpful to publish 
or discuss information about your case alone, it would still be anonymous but we would not go ahead without 
obtaining your consent again.  
 
There is always a possibility that tissue which cannot be linked back to you may be used in the commercial 
development of medical technology. We would only ask for your consent to such development in relation to 
your tissue if for any reason it could be linked to you. 
 
 
You do not have to agree to the storage of your tissue.  You are free to decide not to participate. 
 
I confirm that I have explained the nature of the tissue, organs or body parts that it is intended to remove.  I have 
explained that they may be stored for use at a later date, in research as well as for diagnosis.  I have explained 
this in terms which, in my judgement, are suited to the understanding of the patient and/or parent/guardian if the 
patient is a child. 
 
Signature …………………………………………………………………… Date ……………………………. 
 








When you receive a kidney transplant you will be on drugs to prevent rejection of your transplant. 
Mycophenolate mofetil and Myofortic are immunosuppressants which inhibit an enzyme involved in 
causing rejection.  As the activity of the enzyme varies from person-to-person, the dose of the drugs 
needed to achieve maximum benefit also varies.  This study aims to characterize whether your enzyme has 
high, medium or low activity.  By studying your gene sequence, we hope to understand the factors that 
determine the activity of your enzyme.  In the long term we hope this will lead to personalized dosing 
regimens for these drugs.  This will aim to minimize side effects and provide optimal immunosuppression 




TO BE COMPLETED BY THE PATIENT/PARENT/GUARDIAN: 
 
 
Please read this form carefully.  You will be given a copy. 
 
 If there is anything that you do not understand about the explanation and information you have 
been given, or if you want more information, you should ask the doctor before you sign the form. 
 
If you understand the explanation and agree to the proposed plan, please print your name and sign 
in the space indicated below. Please note that you will also be asked to sign a separate consent form 
for the operation or investigation itself.  
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1. I understand that I am consenting for my tissue to be stored for research of a particular kind. 
2. I understand that any further use of my tissue in the future for research of this kind will be 
approved by the local Research Ethics Committee 
3. I understand that if our research is thought likely to have any implications for me or my family, you will 
explain them to me, and ask my specific consent before proceeding with it. 
4. I understand that if it is believed that our research will have no such implications, and if the Research Ethics 
Committee has approved the research, I will not be asked for further permission. 
5. I understand that I will be asked to give consent for the commercial use of any  tissue that can be linked 
back to me. 
 
 
Signature ....................................................................................... Date  
 
Name (please PRINT) ...................................................................  Relationship: 
Patient/Parent/Guardian/Other* 
          *(Please delete as necessary) 
 
 
This form should be witnessed by another person independent from the doctors looking after the 
patient.  This could for example be a relative or member of the nursing staff. 
 
Witness signature ............................................................................ Date: 
 
Name (please PRINT) ..................................................................... Relationship:  
 
 
Where relevant, a translator should sign below to confirm that they have interpreted the 




Translator signature .......................................................................... Date:  
 

















Telephone number:  
 276 
8.2 Appendix 2 
 




Standard Criteria Donor (SCD) 
Donor age<55 years or donor age 55-59 years but no co-morbidity (see extended criteria donor) 
 
Extended Criteria Donor (ECD) 
Donor age >60 years or cold ischaemia time >24 hours and non-heart beating donor or donor age 
55-59 with two of the following: 
1. Cerebrovascular accident 
2. Acute kidney Injury (creatinine> 150 µmol/L) 
3. Hypertension 






All patients will receive standard antibiotic prophylaxis as follows: 
Co-amoxiclav: 1.2 g at induction then at 2 and 6 hours post-transplant. 
Penicillin allergic patients will receive 1g vancomycin over 60 min and to check concentrations and 
ensure cover for 3 days and ciprofloxacin 500 mg orally and repeat dose after 12 hours. 
Standard Risk 
SCD and no HLA antibodies on current or historical sera. 
Induction 
1. Basiliximab 20 mg at days 0 and 4. 
2.  Methylprednisolone 500 mg at day 0. 
Maintenance 
1. Ciclosporin 10mg/kg in two divided doses (aim ciclosporin concentrations 150-250 ng/mL 
first 3 months and 100-175 ng/mL thereafter). 
2. MMF 1 g twice daily. Patients of Black ethnicity to receive 1.5 g twice daily.  
3. Prednisolone 20 mg daily as a starting dose. 
High Risk 
ECD or anti-HLA antibodies or loss of previous graft. 
Induction 
1. ATG on days 0 (0.25mg/kg) and 4 (1.5 mg/kg) 
2. Methylprednisolone 500mg at day 0. 
Maintenance 
1. Ciclosporin 10mg/kg in two divided doses (aim ciclosporin concentrations 150-250 ng/mL 
first 3 months and 100-175 ng/mL thereafter). 
2. MMF 1 g twice daily. Patients of Black ethnicity to receive 1.5 g twice daily.  
3. Prednisolone 20 mg daily as a starting dose. 
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8.3 Appendix 3 
8.3.1 IMPDH I DNA Sequence 
 
Chromosome 3, NC_000003.11 (49061758..49066875, complement) 



























































































































































































8.3.2 IMPDH II DNA Sequence 
 
Chromosome 7, NC_000007.13 (128032331..128050036, complement) 





























































































8.4 Appendix 4 
8.4.1 IMPDH I Amino Acid Sequence 
NCBI Reference Sequence: NP_001136045.1 
 
1 madylisggt gyvpedglta qqlfasadgl tyndflilpg fidfiadevd ltsaltrkit 
61 lktplisspm dtvteadmai amalmggigf ihhnctpefq anevrkvkkf eqgfitdpvv 
121 lspshtvgdv leakmrhgfs gipitetgtm gsklvgivts rdidflaekd httllsevmt 
181 prielvvapa gvtlkeanei lqrskkgklp ivndcdelva iiartdlkkn rdyplaskds 
241 qkqllcgaav gtreddkyrl dlltqagvdv ivldssqgns vyqiamvhyi kqkyphlqvi 
301 ggnvvtaaqa knlidagvdg lrvgmgcgsi citqevmacg rpqgtavykv aeyarrfgvp 
361 iiadggiqtv ghvvkalalg astvmmgsll aatteapgey ffsdgvrlkk yrgmgsldam 
421 ekssssqkry fsegdkvkia qgvsgsiqdk gsiqkfvpyl iagiqhgcqd igarslsvlr 
481 smmysgelkf ekrtmsaqie ggvhglhsye krly 
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8.4.2 IMPDH II Amino Acid Sequence 
NCBI Reference Sequence: NP_000875.2 
 
1  madylisggt syvpddglta qqlfncgdgl tyndflilpg yidftadqvd ltsaltkkit 
61  lktplvsspm dtvteagmai amaltggigf ihhnctpefq anevrkvkky eqgfitdpvv 
121  lspkdrvrdv feakarhgfc gipitdtgrm gsrlvgiiss rdidflkeee hdcfleeimt 
181  kredlvvapa gitlkeanei lqrskkgklp ivneddelva iiartdlkkn rdyplaskda 
241  kkqllcgaai gtheddkyrl dllaqagvdv vvldssqgns ifqinmikyi kdkypnlqvi 
301  ggnvvtaaqa knlidagvda lrvgmgsgsi citqevlacg rpqatavykv seyarrfgvp 
361  viadggiqnv ghiakalalg astvmmgsll aatteapgey ffsdgirlkk yrgmgsldam 
421  dkhlssqnry fseadkikva qgvsgavqdk gsihkfvpyl iagiqhscqd igaksltqvr 
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